Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
30900.0 | 2023-07-20 00:00:00 UTC | Abbott (ABT) Q2 Earnings and Revenues Surpass Estimates | ABT | https://www.nasdaq.com/articles/abbott-abt-q2-earnings-and-revenues-surpass-estimates | nan | nan | Abbott (ABT) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.43 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 3.85%. A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $0.98 per share when it actually produced earnings of $1.03, delivering a surprise of 5.10%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $9.98 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.84%. This compares to year-ago revenues of $11.26 billion. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Abbott shares have lost about 2.3% since the beginning of the year versus the S&P 500's gain of 18.9%.
What's Next for Abbott?
While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Abbott: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.11 on $9.77 billion in revenues for the coming quarter and $4.39 on $39.5 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the top 44% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, ICU Medical (ICUI), has yet to report results for the quarter ended June 2023.
This medical device maker is expected to post quarterly earnings of $1.55 per share in its upcoming report, which represents a year-over-year change of +13.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
ICU Medical's revenues are expected to be $562.9 million, up 0.3% from the year-ago quarter.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
ICU Medical, Inc. (ICUI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.04 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ICU Medical, Inc. (ICUI) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ICU Medical, Inc. (ICUI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.04 per share. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $9.98 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.84%. | Abbott (ABT) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.04 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ICU Medical, Inc. (ICUI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott, which belongs to the Zacks Medical - Products industry, posted revenues of $9.98 billion for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 2.84%. | Abbott (ABT) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.04 per share. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report ICU Medical, Inc. (ICUI) : Free Stock Analysis Report To read this article on Zacks.com click here. While Abbott has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? |
30901.0 | 2023-07-20 00:00:00 UTC | Abbott (ABT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates | ABT | https://www.nasdaq.com/articles/abbott-abt-q2-earnings%3A-how-key-metrics-compare-to-wall-street-estimates | nan | nan | Abbott (ABT) reported $9.98 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 11.4%. EPS of $1.08 for the same period compares to $1.43 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $9.7 billion, representing a surprise of +2.84%. The company delivered an EPS surprise of +3.85%, with the consensus EPS estimate being $1.04.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net sales- Diagnostics- U.S. $961 million versus $1.07 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -61.1% change.
Net sales- Diagnostics- International: $1.36 billion versus $1.46 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -26.8% change.
Net sales- Nutrition- International: $1.20 billion compared to the $1.15 billion average estimate based on four analysts. The reported number represents a change of +0.3% year over year.
Net sales- Nutrition- U.S. $881 million versus $820.16 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +15.8% change.
Net sales- Medical Devices- Rhythm Management- Total: $583 million versus $624.97 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.4% change.
Net sales- Medical Devices- Diabetes Care: $1.42 billion versus the four-analyst average estimate of $1.27 billion. The reported number represents a year-over-year change of +19.5%.
Net sales- Established Pharmaceuticals: $1.29 billion versus the four-analyst average estimate of $1.25 billion. The reported number represents a year-over-year change of +5.2%.
Net sales- Diagnostics: $2.32 billion versus $2.52 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -46.4% change.
Net sales- Nutrition: $2.08 billion versus $1.98 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.3% change.
Net sales- Medical Devices- Vascular- Total: $715 million compared to the $643.75 million average estimate based on four analysts. The reported number represents a change of +9.5% year over year.
Net sales- Medical Devices- Neuromodulation- Total: $227 million compared to the $195.07 million average estimate based on four analysts. The reported number represents a change of +15.2% year over year.
Net sales- Medical Devices- Structural Heart- Total: $498 million compared to the $470.75 million average estimate based on four analysts. The reported number represents a change of +13.2% year over year.
View all Key Company Metrics for Abbott here>>>
Shares of Abbott have returned +1% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) reported $9.98 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 11.4%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. | Abbott (ABT) reported $9.98 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 11.4%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales- Diagnostics- U.S. $961 million versus $1.07 billion estimated by four analysts on average. | Abbott (ABT) reported $9.98 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 11.4%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net sales- Diagnostics- U.S. $961 million versus $1.07 billion estimated by four analysts on average. | Abbott (ABT) reported $9.98 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 11.4%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The reported revenue compares to the Zacks Consensus Estimate of $9.7 billion, representing a surprise of +2.84%. |
30902.0 | 2023-07-20 00:00:00 UTC | Abbott beats quarterly profit estimates on demand for medical devices | ABT | https://www.nasdaq.com/articles/abbott-beats-quarterly-profit-estimates-on-demand-for-medical-devices-0 | nan | nan | Adds diagnostic sales in paragraphs 4, 5, forecast in paragraph 7
July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices.
Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S., as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease.
Rival J&J's medical device segment also topped estimates earlier in the day, helped by a recovery in demand for medical procedures which were delayed during the pandemic.
Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion.
Abbott's diagnostic sales came in at $2.3 billion in the quarter, in line with analysts' average estimates.
The company saw a further decline in COVID-19 test kits sales after U.S. government ended the COVID-19 Public Health Emergency on May 11.
The company cut its annual COVID-related sales forecast to $1.3 billion, from $1.5 billion previously.
However, the medical device maker retained its annual profit of $4.30 to $4.50 per share, indicating an increase in its outlook for its non-COVID businesses.
Excluding items, Abbott earned $1.08 per share in second quarter, above Refinitiv IBES estimates of $1.05 per share.
(Reporting by Khushi Mandowara and Pratik Jain in Bengaluru; Editing by Pooja Desai)
((Khushi.Mandowara@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds diagnostic sales in paragraphs 4, 5, forecast in paragraph 7 July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S., as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease. The company saw a further decline in COVID-19 test kits sales after U.S. government ended the COVID-19 Public Health Emergency on May 11. | Adds diagnostic sales in paragraphs 4, 5, forecast in paragraph 7 July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion. The company cut its annual COVID-related sales forecast to $1.3 billion, from $1.5 billion previously. | Adds diagnostic sales in paragraphs 4, 5, forecast in paragraph 7 July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Rival J&J's medical device segment also topped estimates earlier in the day, helped by a recovery in demand for medical procedures which were delayed during the pandemic. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion. | Adds diagnostic sales in paragraphs 4, 5, forecast in paragraph 7 July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S., as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease. Abbott's diagnostic sales came in at $2.3 billion in the quarter, in line with analysts' average estimates. |
30903.0 | 2023-07-20 00:00:00 UTC | Abbott beats quarterly profit estimates on demand for medical devices | ABT | https://www.nasdaq.com/articles/abbott-beats-quarterly-profit-estimates-on-demand-for-medical-devices | nan | nan | July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices.
Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S. as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease.
Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion.
The company cut its annual COVID-related sales forecast to $1.3 billion, from $1.5 billion previously.
Excluding items, Abbott earned $1.08 per share in second quarter, above Refinitiv IBES estimates of $1.05 per share.
(Reporting by Khushi Mandowara and Pratik Jain in Bengaluru; Editing by Pooja Desai)
((Khushi.Mandowara@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S. as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease. (Reporting by Khushi Mandowara and Pratik Jain in Bengaluru; Editing by Pooja Desai) ((Khushi.Mandowara@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S. as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion. | July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S. as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion. | July 20 (Reuters) - Abbott Laboratories ABT.N on Thursday reported second-quarter profit above expectations, due to recovery in surgical procedure volumes and demand for its diabetes care devices. Demand for medical devices is expected to rise this year, tracking a recovery in non-urgent surgical procedures across the U.S. as older adults in particular get more comfortable visiting hospitals and staffing shortages at those facilities ease. Abbott clocked quarterly sales for its medical devices at $4.3 billion, with $1.3 billion coming from continuous-glucose-monitoring device Freestyle Libre, beating analysts' estimates of $4.10 billion. |
30904.0 | 2023-07-20 00:00:00 UTC | Abbott Laboratories Q2 Profit Decreases, but beats estimates | ABT | https://www.nasdaq.com/articles/abbott-laboratories-q2-profit-decreases-but-beats-estimates | nan | nan | (RTTNews) - Abbott Laboratories (ABT) released earnings for second quarter that decreased from last year but beat the Street estimates.
The company's bottom line came in at $1.38 billion, or $0.78 per share. This compares with $2.02 billion, or $1.14 per share, in last year's second quarter.
Excluding items, Abbott Laboratories reported adjusted earnings of $1.89 billion or $1.08 per share for the period.
Analysts on average had expected the company to earn $1.05 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter fell 11.4% to $9.98 billion from $11.26 billion last year.
Abbott Laboratories earnings at a glance (GAAP) :
-Earnings (Q2): $1.38 Bln. vs. $2.02 Bln. last year. -EPS (Q2): $0.78 vs. $1.14 last year. -Analyst Estimates: $1.05 -Revenue (Q2): $9.98 Bln vs. $11.26 Bln last year.
-Guidance: Full year EPS guidance: $4.30 to $4.50
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) released earnings for second quarter that decreased from last year but beat the Street estimates. Excluding items, Abbott Laboratories reported adjusted earnings of $1.89 billion or $1.08 per share for the period. Analysts on average had expected the company to earn $1.05 per share, according to figures compiled by Thomson Reuters. | (RTTNews) - Abbott Laboratories (ABT) released earnings for second quarter that decreased from last year but beat the Street estimates. Excluding items, Abbott Laboratories reported adjusted earnings of $1.89 billion or $1.08 per share for the period. Abbott Laboratories earnings at a glance (GAAP) : -Earnings (Q2): $1.38 Bln. | (RTTNews) - Abbott Laboratories (ABT) released earnings for second quarter that decreased from last year but beat the Street estimates. The company's revenue for the quarter fell 11.4% to $9.98 billion from $11.26 billion last year. -Analyst Estimates: $1.05 -Revenue (Q2): $9.98 Bln vs. $11.26 Bln last year. | (RTTNews) - Abbott Laboratories (ABT) released earnings for second quarter that decreased from last year but beat the Street estimates. This compares with $2.02 billion, or $1.14 per share, in last year's second quarter. Excluding items, Abbott Laboratories reported adjusted earnings of $1.89 billion or $1.08 per share for the period. |
30905.0 | 2023-07-19 00:00:00 UTC | Pre-Market Earnings Report for July 20, 2023 : JNJ, ABT, PM, TSM, MMC, BX, FCX, TFC, DHI, TRV, NEM, GPC | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-for-july-20-2023-%3A-jnj-abt-pm-tsm-mmc-bx-fcx-tfc-dhi-trv-nem | nan | nan | The following companies are expected to report earnings prior to market open on 07/20/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
Johnson & Johnson (JNJ)is reporting for the quarter ending June 30, 2023. The large cap pharmaceutical company's consensus earnings per share forecast from the 7 analysts that follow the stock is $2.61. This value represents a 0.77% increase compared to the same quarter last year. In the past year JNJ has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 6.77%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for JNJ is 14.94 vs. an industry ratio of 21.10.
Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2023. The medical products company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.04. This value represents a 27.27% decrease compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 5.1%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 24.36 vs. an industry ratio of 5.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Philip Morris International Inc (PM)is reporting for the quarter ending June 30, 2023. The tobacco company's consensus earnings per share forecast from the 8 analysts that follow the stock is $1.48. This value represents a no change for the same quarter last year. In the past year PM has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 3.76%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for PM is 15.89 vs. an industry ratio of 8.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Taiwan Semiconductor Manufacturing Company Ltd. (TSM)is reporting for the quarter ending June 30, 2023. The semi fab foundry company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.07. This value represents a 30.97% decrease compared to the same quarter last year. In the past year TSM has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 8.26%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for TSM is 19.72 vs. an industry ratio of 19.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Marsh & McLennan Companies, Inc. (MMC)is reporting for the quarter ending June 30, 2023. The insurance brokers company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.12. This value represents a 12.17% increase compared to the same quarter last year. In the past year MMC has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 3.27%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for MMC is 24.69 vs. an industry ratio of 21.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Blackstone Inc. (BX)is reporting for the quarter ending June 30, 2023. The financial services company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.92. This value represents a 38.26% decrease compared to the same quarter last year. In the past year BX has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for BX is 25.51 vs. an industry ratio of 13.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Freeport-McMoran, Inc. (FCX)is reporting for the quarter ending June 30, 2023. The mining company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.28. This value represents a 51.72% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for FCX is 26.24 vs. an industry ratio of 95.80.
Truist Financial Corporation (TFC)is reporting for the quarter ending June 30, 2023. The bank company's consensus earnings per share forecast from the 9 analysts that follow the stock is $0.98. This value represents a 18.33% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for TFC is 8.67 vs. an industry ratio of 8.90.
D.R. Horton, Inc. (DHI)is reporting for the quarter ending June 30, 2023. The building (residential/commercial) company's consensus earnings per share forecast from the 16 analysts that follow the stock is $2.81. This value represents a 39.83% decrease compared to the same quarter last year. DHI missed the consensus earnings per share in the 3rd calendar quarter of 2022 by -7.71%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DHI is 11.44 vs. an industry ratio of 9.60, implying that they will have a higher earnings growth than their competitors in the same industry.
The Travelers Companies, Inc. (TRV)is reporting for the quarter ending June 30, 2023. The insurance (property & casualty) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.27. This value represents a 11.67% decrease compared to the same quarter last year. In the past year TRV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for TRV is 12.11 vs. an industry ratio of 17.40.
Newmont Corporation (NEM)is reporting for the quarter ending June 30, 2023. The mining company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.38. This value represents a 17.39% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NEM is 19.73 vs. an industry ratio of -17.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Genuine Parts Company (GPC)is reporting for the quarter ending June 30, 2023. The auto (truck) company's consensus earnings per share forecast from the 6 analysts that follow the stock is $2.31. This value represents a 5.00% increase compared to the same quarter last year. In the past year GPC has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 5.94%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for GPC is 18.40 vs. an industry ratio of 18.30, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2023. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 24.36 vs. an industry ratio of 5.10, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 24.36 vs. an industry ratio of 5.10, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2023. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 24.36 vs. an industry ratio of 5.10, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2023. In the past year ABT has beat the expectations every quarter. | Abbott Laboratories (ABT)is reporting for the quarter ending June 30, 2023. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABT is 24.36 vs. an industry ratio of 5.10, implying that they will have a higher earnings growth than their competitors in the same industry. |
30906.0 | 2023-07-19 00:00:00 UTC | 5 Big Cap Earnings Charts to Watch This Week | ABT | https://www.nasdaq.com/articles/5-big-cap-earnings-charts-to-watch-this-week | nan | nan | Second quarter earnings season heads into its second week. In addition to regional banks, we will get some of the big growth stocks like Netflix and Tesla along with dozens of large cap companies in a variety of industries including energy, big pharma, the semiconductors, paint, homebuilders, railroads and car parts.
These five companies represent a cross selection of several of those industries. Most have solid earnings surprise track records but will that even matter this quarter?
Guidance will be important, once again. Is the economy still slowing, or isn’t it?
Investors will be looking for clues about a soft landing.
Several of these stocks are up big this year but many are not cheap. Valuation could be an issue, especially for the “magnificent 7” stocks.
5 Big Cap Earnings Charts to Watch This Week
1. Netflix (NFLX) has beat 3 out of the last 4 quarters. Wall Street has embraced the streaming giant once again as shares of Netflix are up 53% year-to-date. Over the last year, shares jumped 138%. Netflix isn’t cheap. It trades with a forward P/E of 39. Netflix will set the tone for big cap growth stocks this earnings season.
2. Tesla (TSLA) has beat 9 quarters in a row. That’s impressive during a pandemic which had global supply chain problems. Shares of Tesla have rebounded in 2023, gaining 134% year-to-date. Tesla is expensive with a forward P/E of 80 but that has never stopped investors from diving in before.
3. Taiwan Semiconductor (TSM) has beat 10 quarters in a row. Impressive. Shares of Taiwan Semiconductor have jumped 38.6% year-to-date. It’s fairly cheap, for a tech stock. Taiwan Semiconductor has a forward P/E of 20. Should Taiwan Semiconductor be on your short list?
4. Halliburton (HAL) hasn’t missed since 2018. That’s an amazing track record as the energy industry struggled at the beginning of the pandemic, in 2020. Shares of Halliburton are down 5.4% year-to-date but are up 33.6% over the last year. Halliburton is cheap, with a forward P/E of 12.
5. Abbott Laboratories (ABT) has beat 8 quarters in a row. Shares haven’t done much this year, falling 2%. Over the last year, Abbott Laboratories shares are down but only 1.1%. It’s treading water. Abbott Laboratories isn’t cheap. It has a forward P/E of 25. Is it time for Abbott Laboratories to make a move?
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Halliburton Company (HAL) : Free Stock Analysis Report
Netflix, Inc. (NFLX) : Free Stock Analysis Report
Taiwan Semiconductor Manufacturing Company Ltd. (TSM) : Free Stock Analysis Report
Tesla, Inc. (TSLA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) has beat 8 quarters in a row. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Halliburton Company (HAL) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report Taiwan Semiconductor Manufacturing Company Ltd. (TSM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. In addition to regional banks, we will get some of the big growth stocks like Netflix and Tesla along with dozens of large cap companies in a variety of industries including energy, big pharma, the semiconductors, paint, homebuilders, railroads and car parts. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Halliburton Company (HAL) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report Taiwan Semiconductor Manufacturing Company Ltd. (TSM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories (ABT) has beat 8 quarters in a row. Netflix will set the tone for big cap growth stocks this earnings season. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Halliburton Company (HAL) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report Taiwan Semiconductor Manufacturing Company Ltd. (TSM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories (ABT) has beat 8 quarters in a row. In addition to regional banks, we will get some of the big growth stocks like Netflix and Tesla along with dozens of large cap companies in a variety of industries including energy, big pharma, the semiconductors, paint, homebuilders, railroads and car parts. | Abbott Laboratories (ABT) has beat 8 quarters in a row. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Halliburton Company (HAL) : Free Stock Analysis Report Netflix, Inc. (NFLX) : Free Stock Analysis Report Taiwan Semiconductor Manufacturing Company Ltd. (TSM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report To read this article on Zacks.com click here. Several of these stocks are up big this year but many are not cheap. |
30907.0 | 2023-07-19 00:00:00 UTC | Validea's Top Health Care Stocks Based On Peter Lynch - 7/19/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-health-care-stocks-based-on-peter-lynch-7-19-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
CIGNA GROUP (CI) is a large-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Cigna Group is a global health services company. The Company's portfolio of offerings solves diverse challenges across the healthcare system. The Company offers a differentiated set of pharmacy, medical, behavioral, dental and supplemental products, and services, primarily through two platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes a range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions, which are provided to health plans, employers, government organizations and health care providers. Cigna Healthcare includes the United States Commercial, United States Government, and International Health operating segments, which provide medical and coordinated solutions to clients and customers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
INVENTORY TO SALES: PASS
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of CIGNA GROUP
CI Guru Analysis
CI Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Peter Lynch is 72% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Integra LifeSciences Holdings Corporation is a medical technology company. The Company operates through two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS segment consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield and Bactiseal. Its product offering includes CereLink in the Unites States and Europe. The Company's TT segment focuses on three areas, which include complex wound surgery, surgical reconstruction and peripheral nerve repair. TT's regenerative platform includes multiple brands, such as Integra Dermal Matrices, AmnioExcel, SurgiMend, MicroMatrix and NeuraGen. The Company's manufacturing and research facilities are located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of INTEGRA LIFESCIENCES HOLDINGS CORP
IART Guru Analysis
IART Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. | Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. Detailed Analysis of INTEGRA LIFESCIENCES HOLDINGS CORP IART Guru Analysis IART Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. Evernorth Health Services includes a range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions, which are provided to health plans, employers, government organizations and health care providers. | Detailed Analysis of CIGNA GROUP CI Guru Analysis CI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. |
30908.0 | 2023-07-18 00:00:00 UTC | XLV, ABT, DHR, BMY: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/xlv-abt-dhr-bmy%3A-large-outflows-detected-at-etf | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $753.8 million dollar outflow -- that's a 1.8% decrease week over week (from 310,820,000 to 305,070,000). Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Danaher Corp (Symbol: DHR) is up about 1%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.10. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
ETFs With Stocks That Insiders Are Buying
ETFs Holding ANSS
BKEP market cap history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Danaher Corp (Symbol: DHR) is up about 1%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $753.8 million dollar outflow -- that's a 1.8% decrease week over week (from 310,820,000 to 305,070,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Danaher Corp (Symbol: DHR) is up about 1%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.10. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Danaher Corp (Symbol: DHR) is up about 1%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $753.8 million dollar outflow -- that's a 1.8% decrease week over week (from 310,820,000 to 305,070,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $132.10. | Among the largest underlying components of XLV, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.3%, Danaher Corp (Symbol: DHR) is up about 1%, and Bristol Myers Squibb Co. (Symbol: BMY) is up by about 0.8%. Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
30909.0 | 2023-07-18 00:00:00 UTC | Why Abbott (ABT) Might Surprise This Earnings Season | ABT | https://www.nasdaq.com/articles/why-abbott-abt-might-surprise-this-earnings-season | nan | nan | Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Abbott is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABT in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $1.05 per share for ABT, compared to a broader Zacks Consensus Estimate of $1.04 per share. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.64% heading into earnings season.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that ABT has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for Abbott, and that a beat might be in the cards for the upcoming report.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT may be one such company. In fact, the Most Accurate Estimate for the current quarter is currently at $1.05 per share for ABT, compared to a broader Zacks Consensus Estimate of $1.04 per share. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT may be one such company. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. | This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +0.64% heading into earnings season. Given that ABT has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT may be one such company. | Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT may be one such company. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABT in this report. Given that ABT has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. |
30910.0 | 2023-07-18 00:00:00 UTC | Here's Why You Should Add BD (BDX) Stock in Your Portfolio | ABT | https://www.nasdaq.com/articles/heres-why-you-should-add-bd-bdx-stock-in-your-portfolio | nan | nan | Becton, Dickinson and Company BDX, popularly known as BD, has been gaining from its series of product launches over the past few months. The optimism led by a solid second-quarter fiscal 2023 performance and a few regulatory approvals are expected to contribute further. Forex woes and stiff competition persist.
Over the past year, this Zacks Rank #2 (Buy) stock has gained 7.2% compared with the 19.4% rise of the industry and 14.9% growth of the S&P 500.
The renowned medical technology company has a market capitalization of $72.89 billion. It projects 10.1% growth for the next five years and expects to maintain its strong performance. BD has delivered an earnings surprise of 5.8% for the past four quarters, on average.
Image Source: Zacks Investment Research
Let’s delve deeper.
Regulatory Approvals: BD has been progressing impressively on the regulatory front, raising our optimism. In May, BD received the FDA’s 510(k) clearance for the new BD Kiestra Methicillin-resistant Staphylococcus aureus imaging application.
At the time of its second-quarter fiscal 2023 earnings release in May, BD confirmed that its BD Life Sciences segment’s Integrated Diagnostic Solutions business unit filed for US regulatory clearance of BD MiniDraw.
Product Launches: We are upbeat about BD’s slew of product launches in recent times. In June, the company announced the worldwide commercial launch of a new automated instrument, BD FACSDuet Premium Sample Preparation System.
In May, BD announced expanded customer availability of an all-in-one prefilled flush syringe with an integrated disinfection unit designed to reinforce compliance with infection prevention guidelines and simplify nursing workflow.
Strong Q2 Results: BD’s solid second-quarter fiscal 2023 results buoy our optimism. The company registered solid top-line and bottom-line results, along with improvements in the overall base revenues. Robust performances by the majority of its segments and both geographic regions were seen. Strength in BD’s segment’s business units during the reported quarter was also witnessed. The expansion of both margins bodes well.
Downsides
Stiff Competition: BD, being a global company, faces significant competition from a wide range of companies, including large medical device companies with multiple product lines. Some of these companies may have greater resources and may be more specialized than BD with respect to particular markets or product lines. Non-traditional entrants, such as technology companies, are also entering the healthcare industry with resources.
Forex Woes: BD generates a substantial amount of its revenues from international operations. The revenues BD report with respect to its operations outside the United States may be adversely affected by fluctuations in foreign currency exchange rates. BD cannot predict with any certainty changes in foreign currency exchange rates or the degree to which it can mitigate such risks.
Estimate Trend
BD is witnessing a positive estimate revision trend for fiscal 2023. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 0.4% north to $12.19.
The Zacks Consensus Estimate for the company’s third-quarter fiscal 2023 revenues is pegged at $4.83 billion, suggesting a 3.9% improvement from the year-ago quarter’s reported number.
Other Key Picks
A few other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, HealthEquity, Inc. HQY and Boston Scientific Corporation BSX.
Abbott, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 5.1%. ABT’s earnings surpassed estimates in all the trailing four quarters, with an average of 19.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Abbott has lost 2.7% compared with the industry’s 22.8% decline over the past year.
HealthEquity, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 22%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 9.1%.
HealthEquity has gained 4.3% against the industry’s 15.7% decline over the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.5%. BSX’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.9%.
Boston Scientific has gained 39.4% against the industry’s 22.8% decline over the past year.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Becton, Dickinson and Company (BDX) : Free Stock Analysis Report
HealthEquity, Inc. (HQY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other Key Picks A few other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, HealthEquity, Inc. HQY and Boston Scientific Corporation BSX. ABT’s earnings surpassed estimates in all the trailing four quarters, with an average of 19.3%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. | Other Key Picks A few other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, HealthEquity, Inc. HQY and Boston Scientific Corporation BSX. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. ABT’s earnings surpassed estimates in all the trailing four quarters, with an average of 19.3%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Other Key Picks A few other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, HealthEquity, Inc. HQY and Boston Scientific Corporation BSX. ABT’s earnings surpassed estimates in all the trailing four quarters, with an average of 19.3%. | Other Key Picks A few other top-ranked stocks in the broader medical space are Abbott Laboratories ABT, HealthEquity, Inc. HQY and Boston Scientific Corporation BSX. ABT’s earnings surpassed estimates in all the trailing four quarters, with an average of 19.3%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30911.0 | 2023-07-18 00:00:00 UTC | 2 Medical Stocks to Buy as Earnings Approach | ABT | https://www.nasdaq.com/articles/2-medical-stocks-to-buy-as-earnings-approach | nan | nan | Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week’s earnings lineup.
Let’s see if now is a good time to buy either of these renowned medical product producers ahead of their second-quarter results on Thursday, July 20.
Abbott Laboratories Q2 Preview
Multinational healthcare company Abbott Laboratories’ Q2 results are much anticipated as a provider of breakthrough medical products for diagnostics, medical devices, nutrition, and branded generic pharmaceuticals.
Notably, Abbott Laboratories is expected to see a dip in its top and bottom line with the company up against a tough-to-compete against prior-year quarter. Still, the Zacks Expected Surprise Prediction (ESP) indicates Abbott Laboratories could top earnings expectations.
According to Zacks estimates Abbott Laboratories' Q2 sales are projected at $9.70 billion, down -14% from a year ago. Earnings are forecasted to decline -27% at $1.04 per share compared to EPS of $1.43 in the prior-year quarter. With that being said, Abbott Laboratories is expected to post an earnings surprise with the Most Accurate Estimate having Q2 EPS at $1.05 per share and slightly above the Zacks Consensus.
Plus, Abbott Laboratories has surpassed earnings estimates for eight consecutive quarters dating back to July of 2021.
Image Source: Zacks Investment Research
Intuitive Surgical Q2 Preview
Anticipation is high for Intuitive Surgical’s Q2 results as well with the company being a pioneer in robotic-assisted surgery and prospects increasing in regard to the assistance of artificial intelligence (AI).
To that point, Intuitive Surgical is expecting solid top and bottom line growth for the quarter. Earnings are forecasted to jump 16% at $1.32 per share with sales expected at $1.73 billion, up 14% from Q2 2022.
The Zacks ESP does indicate Intuitive Surgical could miss earnings expectations with the Most Accurate Estimate having Q2 EPS at $1.30 and -1% below the Zacks Consensus. With that being said, Intuitive Surgical most recently surpassed Q1 earnings estimates by 3% in April and investors are hoping the company can build on this.
Image Source: Zacks Investment Research
EPS Outlook
Following a very tough to compete against year Abbott Laboratories earnings are now forecasted to decline -18% in fiscal 2023 at $4.39 per share compared to EPS of $5.34 in 2022. However, FY24 earnings are expected to rebound and rise 4% at $4.54 per share which would still represent 24% growth over the last five years with 2020 earnings at $3.65 per share.
Image Source: Zacks Investment Research
Turning to Intuitive Surgical, annual earnings are anticipated to rise 17% this year at $5.47 per share compared to EPS of $4.68 in 2022. Even better, FY24 earnings are expected to jump another 16% at $6.35 per share.
More impressive, fiscal 2024 projections would represent 115% EPS growth over the last five years with 2020 earnings at $2.94 per share.
Image Source: Zacks Investment Research
Takeaway
Abbott Laboratories and Intuitive Surgical stock currently sport a Zacks Rank #2 (Buy). While the expansive growth of these medical product innovators has somewhat slowed in recent years their bottom-line expansion is still attractive.
Furthermore, annual earnings estimate revisions have remained higher over the last 60 days which is a good sign for Abbott Laboratories and Intuitive Surgical stock leading up to their second quarter reports. It would be no surprise if both companies were able to offer favorable guidance which could be a strong catalyst going forward.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week’s earnings lineup. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Turning to Intuitive Surgical, annual earnings are anticipated to rise 17% this year at $5.47 per share compared to EPS of $4.68 in 2022. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week’s earnings lineup. Image Source: Zacks Investment Research Intuitive Surgical Q2 Preview Anticipation is high for Intuitive Surgical’s Q2 results as well with the company being a pioneer in robotic-assisted surgery and prospects increasing in regard to the assistance of artificial intelligence (AI). | Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week’s earnings lineup. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research EPS Outlook Following a very tough to compete against year Abbott Laboratories earnings are now forecasted to decline -18% in fiscal 2023 at $4.39 per share compared to EPS of $5.34 in 2022. | Among the broader healthcare space, Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) are two medical stocks that will highlight this week’s earnings lineup. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report To read this article on Zacks.com click here. Still, the Zacks Expected Surprise Prediction (ESP) indicates Abbott Laboratories could top earnings expectations. |
30912.0 | 2023-07-17 00:00:00 UTC | See Which Of The Latest 13F Filers Holds Abbott Laboratories | ABT | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbott-laboratories-5 | nan | nan | At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 06/30/2023 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 10 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their long positions with the SEC, but are not required to disclose their short positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story because the bearish/short side of the position is not seen.
Having given that caveat, we believe that looking at groups of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers:
FUND NEW POSITION? CHANGE IN SHARE COUNT CHANGE IN MARKET VALUE ($ IN 1000'S)
Investment Advisory Group LLC Existing -82 +$14
Genesee Capital Advisors LLC Existing -273 +$85
Elk River Wealth Management LLC Existing UNCH +$46
Ergawealth Advisors Inc. Existing UNCH +$32
Wedge Capital Management L L P NC Existing UNCH +$24
Clarus Group Inc. Existing +243 +$61
Carl P. Sherr & Co. LLC Existing UNCH +$16
Naples Global Advisors LLC Existing -185 +$154
Procyon Advisors LLC Existing +4,497 +$608
Heritage Investment Group Inc. Existing UNCH +$22
Aggregate Change: +4,200 +$1,062
In terms of shares owned, we count 2 of the above funds having increased existing ABT positions from 03/31/2023 to 06/30/2023, with 3 having decreased their positions.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABT share count in the aggregate among all of the funds which held ABT at the 06/30/2023 reporting period (out of the 678 we looked at in total). We then compared that number to the sum total of ABT shares those same funds held back at the 03/31/2023 period, to see how the aggregate share count held by hedge funds has moved for ABT. We found that between these two periods, funds reduced their holdings by 155,358 shares in the aggregate, from 11,807,044 down to 11,651,686 for a share count decline of approximately -1.32%. The overall top three funds holding ABT on 06/30/2023 were:
» FUND SHARES OF ABT HELD
1. Bartlett & Co. LLC 1,071,357
2. Nordea Investment Management AB 774,267
3. Gateway Investment Advisers LLC 563,786
4-10 Find out the full Top 10 Hedge Funds Holding ABT »
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT).
10 S&P 500 Components Hedge Funds Are Buying »
Also see:
Office Supplies Dividend Stocks
MLKN Earnings History
Institutional Holders of DFH
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 06/30/2023 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 10 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Abbott Laboratories (Symbol: ABT). Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: | At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 06/30/2023 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 10 of these funds. Below, let's take a look at the change in ABT positions, for this latest batch of 13F filers: Existing UNCH +$22 Aggregate Change: +4,200 +$1,062 In terms of shares owned, we count 2 of the above funds having increased existing ABT positions from 03/31/2023 to 06/30/2023, with 3 having decreased their positions. | We then compared that number to the sum total of ABT shares those same funds held back at the 03/31/2023 period, to see how the aggregate share count held by hedge funds has moved for ABT. Gateway Investment Advisers LLC 563,786 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 06/30/2023 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 10 of these funds. | Existing UNCH +$22 Aggregate Change: +4,200 +$1,062 In terms of shares owned, we count 2 of the above funds having increased existing ABT positions from 03/31/2023 to 06/30/2023, with 3 having decreased their positions. Gateway Investment Advisers LLC 563,786 4-10 Find out the full Top 10 Hedge Funds Holding ABT » We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. At Holdings Channel, we have reviewed the latest batch of the 21 most recent 13F filings for the 06/30/2023 reporting period, and noticed that Abbott Laboratories (Symbol: ABT) was held by 10 of these funds. |
30913.0 | 2023-07-16 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-27 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
Excess Returns Investing Podcast
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. |
30914.0 | 2023-07-14 00:00:00 UTC | Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-is-a-trending-stock%3A-facts-to-know-before-betting-on-it-0 | nan | nan | Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this maker of infant formula, medical devices and drugs have returned +2.6%, compared to the Zacks S&P 500 composite's +3.4% change. During this period, the Zacks Medical - Products industry, which Abbott falls in, has gained 3%. The key question now is: What could be the stock's future direction?
While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.
Revisions to Earnings Estimates
Rather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.
Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.
Abbott is expected to post earnings of $1.04 per share for the current quarter, representing a year-over-year change of -27.3%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.
For the current fiscal year, the consensus earnings estimate of $4.39 points to a change of -17.8% from the prior year. Over the last 30 days, this estimate has remained unchanged.
For the next fiscal year, the consensus earnings estimate of $4.54 indicates a change of +3.5% from what Abbott is expected to report a year ago. Over the past month, the estimate has remained unchanged.
With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Abbott.
The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:
12 Month EPS
Projected Revenue Growth
While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.
In the case of Abbott, the consensus sales estimate of $9.67 billion for the current quarter points to a year-over-year change of -14.1%. The $39.39 billion and $41.07 billion estimates for the current and next fiscal years indicate changes of -9.8% and +4.3%, respectively.
Last Reported Results and Surprise History
Abbott reported revenues of $9.75 billion in the last reported quarter, representing a year-over-year change of -18.1%. EPS of $1.03 for the same period compares with $1.73 a year ago.
Compared to the Zacks Consensus Estimate of $9.65 billion, the reported revenues represent a surprise of +1.01%. The EPS surprise was +5.1%.
The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.
Valuation
Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.
Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.
As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.
Abbott is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.
Conclusion
The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Abbott. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Over the past month, shares of this maker of infant formula, medical devices and drugs have returned +2.6%, compared to the Zacks S&P 500 composite's +3.4% change. | Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. For the next fiscal year, the consensus earnings estimate of $4.54 indicates a change of +3.5% from what Abbott is expected to report a year ago. | Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. | Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. When earnings estimates for a company go up, the fair value for its stock goes up as well. |
30915.0 | 2023-07-14 00:00:00 UTC | Here's What To Expect From Intuitive Surgical's Q2 | ABT | https://www.nasdaq.com/articles/heres-what-to-expect-from-intuitive-surgicals-q2 | nan | nan | Intuitive Surgical (NASDAQ: ISRG) will report its Q2 2023 results on Thursday, July 20. We expect the company’s revenues to come in at $1.7 billion, aligning with the consensus estimate. This would mark year-over-year growth of about 12%. Earnings are likely to come in at about $1.32 on a per-share and adjusted basis, in line with the consensus estimate. See our interactive dashboard analysis on Intuitive Surgical Earnings Preview for more details on how the company’s revenues and earnings will likely trend for the quarter. So, what are some of the trends that are likely to drive Intuitive Surgical’s results?
The company will likely continue to benefit from a rise in total procedure volume. The company continues to expand its installed base, which results in the growth of recurring revenues, such as consumables. Intuitive Surgical’s revenue of $1.7 billion in Q1’23 reflected a 14% y-o-y rise, with instruments and accessories seeing 22% growth, services up 14%, and the systems segment seeing no growth. Overall procedure volume was up a solid 26%, and the company’s installed base grew 12% to 7,779 systems.
Intuitive Surgical reported a 6% rise in adjusted net income to $437 million in Q1, as the 14% sales growth was partly offset by over 400 bps fall in operating margin. This can primarily be attributed to higher fixed and component costs. With elevated inflation, the costs may remain high for the company in the near term. Our Intuitive Surgical Operating Income Comparison dashboard has more details.
Not only do we expect Intuitive Surgical to post an in-line Q2, we believe its stock is fully valued. We estimate Intuitive Surgical’s Valuation to be around $313 per share, which is 8% below the current market price of $339. This represents a 57x P/E multiple based on our forward adjusted earnings expectation of $5.48. ISRG stock enjoys a higher valuation multiple, given the substantial revenue and earnings growth over the past years.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year
While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Returns Jul 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
ISRG Return -1% 28% 381%
S&P 500 Return 0% 16% 98%
Trefis Multi-Strategy Portfolio 3% 22% 291%
[1] Month-to-date and year-to-date as of 7/12/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company continues to expand its installed base, which results in the growth of recurring revenues, such as consumables. Intuitive Surgical reported a 6% rise in adjusted net income to $437 million in Q1, as the 14% sales growth was partly offset by over 400 bps fall in operating margin. ISRG stock enjoys a higher valuation multiple, given the substantial revenue and earnings growth over the past years. | Our Intuitive Surgical Operating Income Comparison dashboard has more details. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. Total [2] ISRG Return -1% 28% 381% S&P 500 Return 0% 16% 98% Trefis Multi-Strategy Portfolio 3% 22% 291% [1] Month-to-date and year-to-date as of 7/12/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | See our interactive dashboard analysis on Intuitive Surgical Earnings Preview for more details on how the company’s revenues and earnings will likely trend for the quarter. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. Total [2] ISRG Return -1% 28% 381% S&P 500 Return 0% 16% 98% Trefis Multi-Strategy Portfolio 3% 22% 291% [1] Month-to-date and year-to-date as of 7/12/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company continues to expand its installed base, which results in the growth of recurring revenues, such as consumables. ISRG stock enjoys a higher valuation multiple, given the substantial revenue and earnings growth over the past years. Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year While ISRG stock looks appropriately priced, it is helpful to see how Intuitive Surgical’s Peers fare on metrics that matter. |
30916.0 | 2023-07-13 00:00:00 UTC | Abbott (ABT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? | ABT | https://www.nasdaq.com/articles/abbott-abt-expected-to-beat-earnings-estimates%3A-can-the-stock-move-higher-0 | nan | nan | Abbott (ABT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The earnings report, which is expected to be released on July 20, 2023, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on theearnings call it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This maker of infant formula, medical devices and drugs is expected to post quarterly earnings of $1.04 per share in its upcoming report, which represents a year-over-year change of -27.3%.
Revenues are expected to be $9.67 billion, down 14.1% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Abbott?
For Abbott, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.86%.
On the other hand, the stock currently carries a Zacks Rank of #2.
So, this combination indicates that Abbott will most likely beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Abbott would post earnings of $0.98 per share when it actually produced earnings of $1.03, delivering a surprise of +5.10%.
Over the last four quarters, the company has beaten consensus EPS estimates four times.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Abbott appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Just Released: Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023?
From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don’t miss your chance to still be among the first to get in on these just-released stocks.
See New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. | Abbott (ABT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). | Abbott (ABT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. | Abbott (ABT) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. The earnings report, which is expected to be released on July 20, 2023, might help the stock move higher if these key numbers are better than expectations. |
30917.0 | 2023-07-13 00:00:00 UTC | 5 Stocks to Buy Ahead of Q2 Earnings Next Week | ABT | https://www.nasdaq.com/articles/5-stocks-to-buy-ahead-of-q2-earnings-next-week | nan | nan | The first-quarter 2023 earnings season is set to kick off this week. Market participants will try to analyze this reporting cycle against the backdrop of the Fed’s interest rate hike policies. Therefore, this season, management guidance and the near-term business outlook will get more importance than actual results. In addition to earnings and revenues, margins will get more attention from financial researchers.
At present, our estimate has shown that total earnings of the S&P 500 Index likely to drop 9.8% year-over-year on 0.4% lower revenues. The second-quarter earnings decline would follow the 3.4% decline in the first quarter and a 5.4% drop in fourth-quarter 2022.
Despite a tepid outlook, a handful of stocks with a favorable Zacks Rank are set to b eat on second quarter earnings next week. The combination of a possible earnings beat with a favorable Zacks Rank should drive their stocks in the near future.
Our Picks
We have narrowed our search to five companies that are set to declare second-quarter earnings results next week. Each of our picks carries a Zacks Rank #2 (Buy) and has a positive Earnings ESP. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that for stocks with the combination of a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, the chance of an earnings beat is as high as 70%. These stocks are anticipated to appreciate after their earnings releases. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The chart below shows the price performance of our five picks in the last quarter.
Image Source: Zacks Investment Research
Genuine Parts Co.‘s GPC strategic buyouts to improve product offerings and expand geographical footprint are boosting its prospects. The KDG acquisition has strengthened the market-leading position of GPC in the North American industrial platform.
GPC’s dividend aristocrat status is commendable. The upbeat 2023 sales view further sparks optimism. GPC projects 2023 revenues from both the Automotive and Industrial segments to increase by 4-6%.
Genuine Parts has an Earnings ESP of +0.79%. It has an expected earnings growth rate of 8.9% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last 30 days.
GPC recorded earnings surprises in the last four reported quarters, with an average beat of 8.2%. The company is set to release earnings results on Jul 20, before the opening bell.
Abbott Laboratories ABT exited the first quarter of 2023 with better-than-expected earnings and revenues. The Medical Device segment of ABT registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. The Diabetes Care business continued to benefit from the growing sales of its sensor-based continuous glucose monitoring system, FreeStyle Libre.
Abbott has an Earnings ESP of +0.85%. The Zacks Consensus Estimate for current-year earnings has improved 0.2% over the last 60 days. ABT recorded earnings surprises in the last four reported quarters, with an average beat of 19.3%. The company is set to release earnings results on Jul 20, before the opening bell.
AutoNation Inc.‘s AN diversified product mix and multiple streams of income reduce its risk profile and augur well for earnings and sales growth. Enhanced digital solutions have helped AN to further boost profitability and market presence. Buyouts of 11 dealerships from Priority 1 Automotive and Peacock Automotive are boosting AN’s growth prospects.
AutoNation has an Earnings ESP of +9.85%. The Zacks Consensus Estimate for current-year earnings has improved 0.2% over the last seven days. AN recorded earnings surprises in three out of the last four reported quarters, with an average beat of 5%. The company is set to release earnings results on Jul 21, before the opening bell.
Snap-on Inc. SNA has been benefiting from positive business momentum and gains from its Value Creation plan. SNA is on track with its Rapid Continuous Improvement process and other cost-reduction initiatives. Cost-reduction plans, including the RCI program, designed to enhance organizational effectiveness and minimize costs, bode well. Higher sales volume and gains from RCI initiatives have led to the margin expansion of SNA.
Snap-on has an Earnings ESP of +0.59%. It has an expected earnings growth rate of 6% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 3.5% over the last 90 days.
SNA recorded earnings surprises in the last four reported quarters, with an average beat of 9.6%. The company is set to release earnings results on Jul 20, before the opening bell.
PPG Industries Inc. PPG is executing a cost cutting and restructuring strategy. Cost savings from restructuring are likely to support its margins. PPG is also taking steps to expand business inorganically. Acquisitions including Tikkurila, Worwag and Cetelon are expected to contribute to PPG’s sales this year.
PPG Industries has an Earnings ESP of +2.57%. It has an expected earnings growth rate of 20.7% for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.7% over the last seven days.
PPG recorded earnings surprises in three out of the last four reported quarters, with an average beat of 6.6%. The company is set to release earnings results on Jul 20, after the closing bell.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
Just Released: Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for 2023?
From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%. Our Director of Research has now combed through 4,000 companies covered by the Zacks Rank and handpicked the best 10 tickers to buy and hold in 2023. Don’t miss your chance to still be among the first to get in on these just-released stocks.
See New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Genuine Parts Company (GPC) : Free Stock Analysis Report
Snap-On Incorporated (SNA) : Free Stock Analysis Report
PPG Industries, Inc. (PPG) : Free Stock Analysis Report
AutoNation, Inc. (AN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT exited the first quarter of 2023 with better-than-expected earnings and revenues. The Medical Device segment of ABT registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. ABT recorded earnings surprises in the last four reported quarters, with an average beat of 19.3%. | The Medical Device segment of ABT registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Genuine Parts Company (GPC) : Free Stock Analysis Report Snap-On Incorporated (SNA) : Free Stock Analysis Report PPG Industries, Inc. (PPG) : Free Stock Analysis Report AutoNation, Inc. (AN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT exited the first quarter of 2023 with better-than-expected earnings and revenues. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Genuine Parts Company (GPC) : Free Stock Analysis Report Snap-On Incorporated (SNA) : Free Stock Analysis Report PPG Industries, Inc. (PPG) : Free Stock Analysis Report AutoNation, Inc. (AN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT exited the first quarter of 2023 with better-than-expected earnings and revenues. The Medical Device segment of ABT registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. | Abbott Laboratories ABT exited the first quarter of 2023 with better-than-expected earnings and revenues. The Medical Device segment of ABT registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. ABT recorded earnings surprises in the last four reported quarters, with an average beat of 19.3%. |
30918.0 | 2023-07-13 00:00:00 UTC | September 1st Options Now Available For Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/september-1st-options-now-available-for-abbott-laboratories-abt | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the September 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new September 1st contracts and identified one put and one call contract of particular interest.
The put contract at the $103.00 strike price has a current bid of $1.32. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $103.00, but will also collect the premium, putting the cost basis of the shares at $101.68 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $106.71/share today.
Because the $103.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 1.28% return on the cash commitment, or 9.36% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $103.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $1.73. If an investor was to purchase shares of ABT stock at the current price level of $106.71/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $110.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.70% if the stock gets called away at the September 1st expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red:
Considering the fact that the $110.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 1.62% boost of extra return to the investor, or 11.83% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $106.71) to be 23%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
Also see:
Cheap Healthcare Stocks
HAO YTD Return
UFAB Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the September 1st expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the September 1st expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the September 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new September 1st contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options begin trading today, for the September 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new September 1st contracts and identified one put and one call contract of particular interest. |
30919.0 | 2023-07-12 00:00:00 UTC | What's in Store for Abbott Laboratories (ABT) in Q2 Earnings? | ABT | https://www.nasdaq.com/articles/whats-in-store-for-abbott-laboratories-abt-in-q2-earnings-0 | nan | nan | Abbott Laboratories ABT is slated to report second-quarter 2023 results on July 20 before market open.
In the last reported quarter, the company delivered an earnings surprise of 5.1%. In the trailing four quarters, its earnings exceeded the Zacks Consensus Estimate on all the occasions, the average beat being 19.28%.
Let's see how things have shaped up prior to this announcement.
Factors at Play
Within Established Pharmaceuticals Division (EPD), the company has been witnessing solid growth banking on the successful execution of its Branded Generic operating model. The second-quarter performance is likely to have been driven by growing customer demand for core therapeutic lines, including cardiometabolic, respiratory and central nervous system/pain management. Our model projects the EPD business to report $1.82 billion revenues for the second quarter, suggesting a 3.4% decline year over year.
In Diagnostics, we expect the company to report a year-over-year decline in COVID test sales due to lower demand for laboratory-based tests. Excluding COVID testing revenues, sales of routine diagnostic tests are expected to have improved on the continuous rollout of Alinity — Abbott’s suite of diagnostic instruments — and expanding menus across testing platforms of immunoassay, clinical chemistry and molecular testing. In April 2023, Abbott partnered with the Climate Amplified Disease and Epidemics consortium — a group of more than 100 global scientists in public health agencies, academia and industry focused on using data science technology and diagnostic testing to assess and potentially mitigate the impact climate change has on disease outbreaks. We believe this development to have contributed to the company’s second-quarter performance. Our model projects the Diagnostics business to report $3.18 billion revenues in Q2, indicating a 26.4% fall year over year.
Abbott’s another consumer-facing business Diabetes Care, has been catching up, backed by new product instructions. The full launch of Libre 3 in the United States, which automatically delivers minute glucose readings with accuracy, courtesy of the world’s smallest and thinnest wearable sensor is likely to have contributed to second-quarter performance on strong consumer adoption. In April 2023, Abbott’s FreeStyle Libre 3 reader, featuring the world's smallest, thinnest and most discreet glucose sensor, received FDA clearance. In the same month, the Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14-day system for insulin-using1 Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections. These developments are likely to have contributed to company’s top line during the reported quarter backed by strong market adoption. Our model expects the Diabetes business to report $1.03 billion revenues in Q2, calling for a 14% decline year over year.
Within Structural Heart, the recent FDA approval for company's TactiFlex Ablation Catheter, Sensor Enabled — the world's first ablation catheter with a flexible tip and contact force technology and Assert-IQ insertable cardiac monitor (ICM) to help doctors monitor people's heart rhythms are expected have contributed to the second-quarter performance on the back on strong market adoption. Our model project EPD business to report $420 million revenues in Q2, indicating a 4.5% decline year over year.
Within Nutrition, total worldwide Nutrition and Pediatric Nutrition sales are expected to have declined in the quarter to be reported, thanks to the voluntary recall and manufacturing shutdown of certain infant formula products manufactured at one of Abbott's U.S. plants since last February. These include the company’s market-leading Similac and Elecare. However, the segment is likely to have benefitted from strong performance of its market leading Ensure brand. Our model expects Nutrition business to report $1.75 billion revenues in the quarter to be reported, suggesting a 10.6% decline year over year.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories price-eps-surprise | Abbott Laboratories Quote
In April 2023, Abbott acquired Cardiovascular Systems — a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The addition of CSI to ABT's vascular portfolio is a part of a larger investment that will improve the company's capacity to treat patients with peripheral and coronary artery disease. We believe this strategic move to have contributed positively to the company’s top line during the second quarter.
However, Persistent healthcare staffing challenges and diminishing demand for COVID-testing products are expected to have dented Abbott’s overall second-quarter performance. The decline in U.S. infant formula sales due to manufacturing disruptions and stubborn inflationary pressure, record strengthening of the U.S. dollar and supply chain issues in certain areas of business are expected to have weighed heavily on the company through the second quarter.
Estimates
For second-quarter 2023, the Zacks Consensus Estimate for total revenues is pegged at $9.67 billion, indicating a 14.1% decline from the prior-year comparable quarter’s reported figure. The consensus mark for earnings is pegged at $1,04 per share, suggesting a 27.3% decline year on year.
Earnings Whispers
Our proven model predicts an earnings beat for Abbott this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Abbott has an Earnings ESP of +0.86%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: It currently carries a Zacks Rank #2.
Other Stocks Worth Considering
Here are some medical stocks worth considering as these have the right combination of elements to post an earnings beat this quarter.
HealthEquity HQY has an Earnings ESP of +0.98% and a Zacks Rank of #1. The company will release third-quarter 2023 results on Sep 5. You can see the complete list of today’s Zacks #1 Rank stocks here.
HealthEquity has a 2024 expected earnings growth rate of 22%. HQY’s earnings yield of 2.76% compares favorably with the industry’s (4.23%).
Exact Sciences Corporation EXAS has an Earnings ESP of +2.26% and a Zacks Rank of #2. Exact Sciences is expected to release second-quarter fiscal 2023 results on Aug 1.
Exact Sciences’ Price/Sales ratio of 7.8% compares favorably with the industry’s 7.4%. EXAS has projected sale growth of 15.8% compared with the industry’s 0.9%.
Neogen Corporation NEOG currently has an Earnings ESP of +33.33% and a Zacks Rank of #1. NEOG is expected to release third-quarter 2023 results on July 25.
NEOG’s earnings yield of 1.44% compares favorably with the industry’s (3.1%). NEOG’s current ratio of 5.2% compares favorably with the industry’s 2.2%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
Yes, I Want to Help Protect My Portfolio Against Inflation >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Neogen Corporation (NEOG) : Free Stock Analysis Report
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
HealthEquity, Inc. (HQY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The addition of CSI to ABT's vascular portfolio is a part of a larger investment that will improve the company's capacity to treat patients with peripheral and coronary artery disease. Abbott Laboratories ABT is slated to report second-quarter 2023 results on July 20 before market open. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report second-quarter 2023 results on July 20 before market open. The addition of CSI to ABT's vascular portfolio is a part of a larger investment that will improve the company's capacity to treat patients with peripheral and coronary artery disease. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is slated to report second-quarter 2023 results on July 20 before market open. The addition of CSI to ABT's vascular portfolio is a part of a larger investment that will improve the company's capacity to treat patients with peripheral and coronary artery disease. | Abbott Laboratories ABT is slated to report second-quarter 2023 results on July 20 before market open. The addition of CSI to ABT's vascular portfolio is a part of a larger investment that will improve the company's capacity to treat patients with peripheral and coronary artery disease. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Neogen Corporation (NEOG) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30920.0 | 2023-07-12 00:00:00 UTC | ABT vs. LMAT: Which Stock Should Value Investors Buy Now? | ABT | https://www.nasdaq.com/articles/abt-vs.-lmat%3A-which-stock-should-value-investors-buy-now | nan | nan | Investors interested in Medical - Products stocks are likely familiar with Abbott (ABT) and LeMaitre Vascular (LMAT). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, Abbott is sporting a Zacks Rank of #2 (Buy), while LeMaitre Vascular has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that ABT has an improving earnings outlook. However, value investors will care about much more than just this.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
ABT currently has a forward P/E ratio of 24.51, while LMAT has a forward P/E of 52.93. We also note that ABT has a PEG ratio of 4.82. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. LMAT currently has a PEG ratio of 5.29.
Another notable valuation metric for ABT is its P/B ratio of 5.02. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, LMAT has a P/B of 5.14.
These are just a few of the metrics contributing to ABT's Value grade of B and LMAT's Value grade of D.
ABT sticks out from LMAT in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABT is the better option right now.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
Yes, I Want to Help Protect My Portfolio Against Inflation >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
LeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors interested in Medical - Products stocks are likely familiar with Abbott (ABT) and LeMaitre Vascular (LMAT). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that ABT has an improving earnings outlook. ABT currently has a forward P/E ratio of 24.51, while LMAT has a forward P/E of 52.93. | These are just a few of the metrics contributing to ABT's Value grade of B and LMAT's Value grade of D. ABT sticks out from LMAT in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABT is the better option right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in Medical - Products stocks are likely familiar with Abbott (ABT) and LeMaitre Vascular (LMAT). | The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that ABT has an improving earnings outlook. These are just a few of the metrics contributing to ABT's Value grade of B and LMAT's Value grade of D. ABT sticks out from LMAT in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABT is the better option right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report LeMaitre Vascular, Inc. (LMAT) : Free Stock Analysis Report To read this article on Zacks.com click here. | These are just a few of the metrics contributing to ABT's Value grade of B and LMAT's Value grade of D. ABT sticks out from LMAT in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABT is the better option right now. Investors interested in Medical - Products stocks are likely familiar with Abbott (ABT) and LeMaitre Vascular (LMAT). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that ABT has an improving earnings outlook. |
30921.0 | 2023-07-12 00:00:00 UTC | Validea's Top Health Care Stocks Based On Peter Lynch - 7/12/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-health-care-stocks-based-on-peter-lynch-7-12-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
APOLLO MEDICAL HOLDINGS INC (AMEH) is a small-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Peter Lynch is 72% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Apollo Medical Holdings, Inc. is a healthcare company. The Company provides care coordination services to each constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists. The Company operates an integrated healthcare delivery platform that enables providers to participate successfully in value-based care arrangements. To implement a patient-centered, physician-centric experience, the Company also have other integrated and synergistic operations, including management service organizations (MSOs) that provide management and other services to its affiliated independent practice associations (IPAs), outpatient clinics, and hospitalists that coordinate the care of patients in hospitals.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: FAIL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of APOLLO MEDICAL HOLDINGS INC
AMEH Guru Analysis
AMEH Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis APOLLO MEDICAL HOLDINGS INC (AMEH) is a small-cap growth stock in the Healthcare Facilities industry. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. | Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis APOLLO MEDICAL HOLDINGS INC (AMEH) is a small-cap growth stock in the Healthcare Facilities industry. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis APOLLO MEDICAL HOLDINGS INC (AMEH) is a small-cap growth stock in the Healthcare Facilities industry. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis APOLLO MEDICAL HOLDINGS INC (AMEH) is a small-cap growth stock in the Healthcare Facilities industry. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. |
30922.0 | 2023-07-11 00:00:00 UTC | Abbott (ABT) Gains But Lags Market: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-but-lags-market%3A-what-you-should-know-17 | nan | nan | In the latest trading session, Abbott (ABT) closed at $107.50, marking a +0.45% move from the previous day. This move lagged the S&P 500's daily gain of 0.67%. Elsewhere, the Dow gained 0.93%, while the tech-heavy Nasdaq added 9.29%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had gained 5.54% over the past month. This has outpaced the Medical sector's loss of 1.19% and the S&P 500's gain of 2.65% in that time.
Wall Street will be looking for positivity from Abbott as it approaches its next earnings report date. This is expected to be July 20, 2023. The company is expected to report EPS of $1.04, down 27.27% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $9.67 billion, down 14.08% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.39 per share and revenue of $39.39 billion, which would represent changes of -17.79% and -9.78%, respectively, from the prior year.
Any recent changes to analyst estimates for Abbott should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Abbott is holding a Zacks Rank of #2 (Buy) right now.
Looking at its valuation, Abbott is holding a Forward P/E ratio of 24.4. For comparison, its industry has an average Forward P/E of 23.25, which means Abbott is trading at a premium to the group.
Investors should also note that ABT has a PEG ratio of 4.79 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.61 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 81, putting it in the top 33% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In the latest trading session, Abbott (ABT) closed at $107.50, marking a +0.45% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.79 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | In the latest trading session, Abbott (ABT) closed at $107.50, marking a +0.45% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.79 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, Abbott (ABT) closed at $107.50, marking a +0.45% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.79 right now. | In the latest trading session, Abbott (ABT) closed at $107.50, marking a +0.45% move from the previous day. Investors should also note that ABT has a PEG ratio of 4.79 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30923.0 | 2023-07-11 00:00:00 UTC | Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories | ABT | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-buckle-abbvie-and-abbott-laboratories | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. will pay its quarterly dividend of $0.35 on 7/28/23, AbbVie Inc will pay its quarterly dividend of $1.48 on 8/15/23, and Abbott Laboratories will pay its quarterly dividend of $0.51 on 8/15/23. As a percentage of BKE's recent stock price of $35.36, this dividend works out to approximately 0.99%, so look for shares of Buckle, Inc. to trade 0.99% lower — all else being equal — when BKE shares open for trading on 7/13/23. Similarly, investors should look for ABBV to open 1.10% lower in price and for ABT to open 0.48% lower, all else being equal.
Below are dividend history charts for BKE, ABBV, and ABT, showing historical dividends prior to the most recent ones declared.
Buckle, Inc. (Symbol: BKE):
AbbVie Inc (Symbol: ABBV):
Abbott Laboratories (Symbol: ABT):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 3.96% for Buckle, Inc., 4.39% for AbbVie Inc, and 1.90% for Abbott Laboratories.
Free Report: Top 8%+ Dividends (paid monthly)
In Tuesday trading, Buckle, Inc. shares are currently up about 1.8%, AbbVie Inc shares are up about 0.2%, and Abbott Laboratories shares are up about 0.3% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
Preferred Stock Channel
SNY shares outstanding history
EGLX Average Annual Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABBV to open 1.10% lower in price and for ABT to open 0.48% lower, all else being equal. Below are dividend history charts for BKE, ABBV, and ABT, showing historical dividends prior to the most recent ones declared. | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. (Symbol: BKE): AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 1.10% lower in price and for ABT to open 0.48% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Buckle, Inc. (Symbol: BKE): AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: ABT): In general, dividends are not always predictable, following the ups and downs of company profits over time. Similarly, investors should look for ABBV to open 1.10% lower in price and for ABT to open 0.48% lower, all else being equal. | Looking at the universe of stocks we cover at Dividend Channel, on 7/13/23, Buckle, Inc. (Symbol: BKE), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT) will all trade ex-dividend for their respective upcoming dividends. Similarly, investors should look for ABBV to open 1.10% lower in price and for ABT to open 0.48% lower, all else being equal. Below are dividend history charts for BKE, ABBV, and ABT, showing historical dividends prior to the most recent ones declared. |
30924.0 | 2023-07-11 00:00:00 UTC | AngioDynamics (ANGO) to Report Q4 Earnings: What's in the Cards? | ABT | https://www.nasdaq.com/articles/angiodynamics-ango-to-report-q4-earnings%3A-whats-in-the-cards | nan | nan | AngioDynamics, Inc. ANGO is scheduled to release fourth-quarter fiscal 2023 results on Jul 12, before the opening bell.
In the last reported quarter, the company reported a loss of 3 cents per share compared with the Zacks Consensus Estimate of a loss of a penny. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on one occasion, lagged twice and broke even once, delivering a negative earnings surprise of 50%, on average.
Let’s see how things have shaped up prior to this announcement.
Factors at Play
Med Tech Business
In June, AngioDynamics completed the sale of its Dialysis product portfolio and BioSentry Tract Sealant System Biopsy product to Merit Medical Systems, Inc. The transaction consists of AngioDynamics’ DuraFlow, DuraMax, Evenmore, Schon XL, Trio-CT and Vaxel Plus Hemodialysis Catheter brands and BioSentry Tract Sealant System Biopsy brand. AngioDynamics’ management intends to use the net proceeds to eliminate its existing debt and support further strategic investments in growth and profitability.
AngioDynamics’ management believes that this divestiture is likely to support its focus on the high-growth Med Tech platforms and better position the company to focus on driving growth in the NanoKnife, Mechanical Thrombectomy and Auryon businesses. This raises our optimism about the company.
However, AngioDynamics’ net sales for its fiscal 2023 will be inclusive of the Dialysis Product Portfolio and BioSentry product and are expected to be in the range of $338 million to $339 million.
On the third quarter of fiscal 2023earnings callin March, AngioDynamics confirmed that the uptick in its Med Tech net sales was driven by robust Auryon and NanoKnife sales. The company also witnessed strong NanoKnife disposable sales and AlphaVac sales. We expect the momentum for the above-mentioned products to be robust in the fiscal fourth quarter as well on the back of continued strong demand.
AngioDynamics, Inc. Price and EPS Surprise
AngioDynamics, Inc. price-eps-surprise | AngioDynamics, Inc. Quote
However, sustained lower sales of AngioVac are likely to have continued in the fiscal fourth quarter due to its nature. It is AngioDynamics’ most sensitive product and is impacted by hospital staffing challenges due to the complex nature of the procedure, requiring numerous support specialties, including perfusionists, and usually requiring an ICU bed. This is likely to have weighed on the company’s segmental performance.
We estimate the fiscal fourth-quarter Med Tech revenues to be $26.9 million, suggesting an uptick of 19.1% from the year-ago quarter’s reported figure.
Med Device Business
On the fiscal third-quarterearnings call AngioDynamics confirmed that the Med Device segment’s strong year-over-year growth was driven by strength in the company’s angiographic products, ports, dialysis and microwave. The growth in the fiscal third quarter was also positively impacted by a less challenging comp due to the headwinds faced due to a tight labor market and supply chain disruptions in the year-ago period.
We expect the demand for the segment’s products to have continued in the fiscal fourth quarter, thereby driving the segmental revenues. However, continued higher inflationary pressures are likely to have dented the company’s segmental and overall revenues.
We estimate the fiscal fourth-quarter Med Device revenues to be $63.6 million, suggesting a decline of 1.3% from the year-ago quarter’s reported figure.
The Estimate Picture
For fourth-quarter fiscal 2023, the Zacks Consensus Estimate of $90.7 million for total revenues calls for an uptick of 4.3% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at 3 cents, implying a surge of 200% from the prior-year quarter’s reported number.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP has higher chances of beating estimates. This is not the case here, as you can see below.
Earnings ESP: AngioDynamics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Abbott Laboratories ABT has an Earnings ESP of +0.86% and a Zacks Rank of 2. ABT has an estimated long-term growth rate of 5.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 19.3%.
McKesson Corporation MCK has an Earnings ESP of +0.20% and is a Zacks #2 Rank stock. MCK has an estimated long-term growth rate of 10.8%.
McKesson’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 4.5%.
HealthEquity, Inc. HQY has an Earnings ESP of +0.98% and sports a Zacks Rank of 1 at present. HQY has an estimated long-term growth rate of 22%.
HealthEquity’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 9.1%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report
McKesson Corporation (MCK) : Free Stock Analysis Report
HealthEquity, Inc. (HQY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT has an Earnings ESP of +0.86% and a Zacks Rank of 2. ABT has an estimated long-term growth rate of 5.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.86% and a Zacks Rank of 2. ABT has an estimated long-term growth rate of 5.1%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT has an Earnings ESP of +0.86% and a Zacks Rank of 2. ABT has an estimated long-term growth rate of 5.1%. | Abbott Laboratories ABT has an Earnings ESP of +0.86% and a Zacks Rank of 2. ABT has an estimated long-term growth rate of 5.1%. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30925.0 | 2023-07-11 00:00:00 UTC | September 15th Options Now Available For Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/september-15th-options-now-available-for-abbott-laboratories-abt | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new September 15th contracts and identified one put and one call contract of particular interest.
The put contract at the $105.00 strike price has a current bid of $2.21. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $105.00, but will also collect the premium, putting the cost basis of the shares at $102.79 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $107.35/share today.
Because the $105.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 2.10% return on the cash commitment, or 11.64% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $105.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $110.00 strike price has a current bid of $2.20. If an investor was to purchase shares of ABT stock at the current price level of $107.35/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $110.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.52% if the stock gets called away at the September 15th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red:
Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.05% boost of extra return to the investor, or 11.33% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $107.35) to be 23%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
Also see:
Lennar YTD Return
EFC Dividend Growth Rate
Institutional Holders of SPRB
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the September 15th expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the September 15th expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new September 15th contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $110.00 strike highlighted in red: Considering the fact that the $110.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the September 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new September 15th contracts and identified one put and one call contract of particular interest. |
30926.0 | 2023-07-09 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-26 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
Excess Returns Investing Podcast
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. |
30927.0 | 2023-07-09 00:00:00 UTC | PEP, ABBV, or GM: Which Value Stock Could Offer the Highest Upside? | ABT | https://www.nasdaq.com/articles/pep-abbv-or-gm%3A-which-value-stock-could-offer-the-highest-upside | nan | nan | The fear of the U.S. Federal Reserve resuming interest rate hikes soon has reinforced fears of an impending recession. Investors with a long-term horizon could benefit by looking at attractive value stocks – stocks of companies trading at lower prices than what the fundamentals suggest. Using TipRanks’ Stock Comparison Tool, we placed PepsiCo (NASDAQ:PEP), AbbVie (NYSE:ABBV), and General Motors (NYSE:GM) against each other to find the value stock that has the highest upside potential as per Wall Street analysts.
PepsiCo (NASDAQ:PEP)
PepsiCo’s stock movement has been unimpressive this year despite better-than-anticipated first-quarter earnings. The company’s pricing power and robust presence in the snack food and beverage space helped deliver upbeat Q1 results and increase the full-year outlook.
Ahead of PepsiCo’s Q2 results (scheduled on July 13), Goldman Sachs analyst Bonnie Herzog reaffirmed a Buy rating on PEP with a price target of $208, saying that he sees a “favorable risk-reward.” The analyst expects a “healthy” revenue and earnings beat, given continued momentum in the company’s businesses, particularly for Frito-Lay North America (FLNA) as noted in recent NielsenIQ data.
Furthermore, Herzog highlighted that the trends in the PepsiCo Beverages North America (PBNA) segment appear healthy, with consumer elasticities being resilient despite a tough macro backdrop. Consequently, the analyst raised his Q2 organic sales growth expectation to 11.1% from 9.8%, mainly to reflect FLNA strength, and also increased his EPS estimate.
Overall, Herzog believes that PepsiCo is one of the “best positioned companies” in the global food and beverage space to generate solid growth over the next ten years due to its impressive exposure to the snack food space and developing and emerging markets.
Is PEP Stock a Buy Now?
With six Buys and five Holds, PEP stock scores a Moderate Buy consensus rating. At $195.90, the average price target implies 7% upside. Shares have risen 1.3% so far this year. PEP, a dividend king, offers a dividend yield of 2.8%.
AbbVie (NYSE:ABBV)
Shares of AbbVie have been under pressure due to investors’ concerns about the declining sales of the pharma company’s immunology drug Humira due to competition from Biosimilars. Humira sales declined 25.2% to $3.5 billion in Q1 2023, dragging down overall sales by 9.7% to $12.2 billion.
On Thursday, the company lowered its full-year adjusted EPS outlook, citing $280 million in milestone and in-process research and development expenses during the second quarter. The company now expects full-year adjusted EPS between $10.57 and $10.97 per share. Moreover, the company’s Q2 EPS guidance missed analysts’ expectations.
While near-term pressure seems inevitable, AbbVie is optimistic about the road ahead and expects its newer immunology drugs Skyrizi and Rinvoq to deliver sales of over $17.5 billion in 2025. Moreover, as of late May, the company’s pipeline had more than 50 programs in the mid and late-stage development.
It is worth noting that AbbVie has increased its dividend for 51 consecutive years [including the years it was part of Abbott Laboratories (NYSE:ABT)]. The company offers a dividend yield of 4.4%.
Is ABBV Stock a Buy or Sell?
Wall Street is cautiously optimistic on AbbVie stock, with a Moderate Buy consensus rating based on six Buys and five Holds. The average price target of $169.10 implies nearly 25% upside. The stock has declined 16% year-to-date.
General Motors (NYSE:GM)
Legacy automaker General Motors is rapidly moving ahead with its goal to become an all-electric vehicle (EV) company. According to a report by Motor Intelligence, cited by CNBC, Tesla (NASDAQ:TSLA) continued to be the U.S. EV market leader in the first half of 2023 and sold 336,892 vehicles (up 30% year-over-year). A distant second was Hyundai (including the Kia brand) (HYMTF), which sold 38,457 EVs in the first half. Meanwhile, General Motors stood at the third position, with its EV sales rising 365% to 36,322 units.
As part of its goal to accelerate its presence in the EV space, GM entered into an agreement with Tesla last month, which will give its EV buyers access to the Tesla Supercharger network. While GM is cutting costs in several areas, the company continues to invest in its EV ambitions and aims to manufacture 400,000 EVs in North America through the first half of 2024
On Friday, Morgan Stanley analyst Adam Jonas raised his price target for General Motors to $41 from $38 and reiterated a Buy rating. Ahead of the Q2 results, the analyst expects stronger-than-anticipated price and mix and a surprisingly resilient auto consumer to “create beat-and-raise conditions” for the U.S. automakers.
Is GM Stock a Good Buy Now?
Wall Street has a Moderate Buy consensus rating on General Motors stock based on seven Buys and seven Holds. The average price target of $46.85 implies over 18% upside. Shares have risen 18% year-to-date.
Conclusion
Wall Street is cautiously optimistic about AbbVie, PepsiCo, and General Motors amid the ongoing macro pressures. Analysts see higher upside potential in AbbVie from current levels, with the pullback in the stock offering an attractive buying opportunity for the long term. Several analysts are looking beyond the Humira-related headwinds and believe in the growth potential of the company’s newer drugs and an extensive pipeline. The company also offers an attractive dividend yield.
Disclosure
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It is worth noting that AbbVie has increased its dividend for 51 consecutive years [including the years it was part of Abbott Laboratories (NYSE:ABT)]. Furthermore, Herzog highlighted that the trends in the PepsiCo Beverages North America (PBNA) segment appear healthy, with consumer elasticities being resilient despite a tough macro backdrop. According to a report by Motor Intelligence, cited by CNBC, Tesla (NASDAQ:TSLA) continued to be the U.S. EV market leader in the first half of 2023 and sold 336,892 vehicles (up 30% year-over-year). | It is worth noting that AbbVie has increased its dividend for 51 consecutive years [including the years it was part of Abbott Laboratories (NYSE:ABT)]. Using TipRanks’ Stock Comparison Tool, we placed PepsiCo (NASDAQ:PEP), AbbVie (NYSE:ABBV), and General Motors (NYSE:GM) against each other to find the value stock that has the highest upside potential as per Wall Street analysts. AbbVie (NYSE:ABBV) Shares of AbbVie have been under pressure due to investors’ concerns about the declining sales of the pharma company’s immunology drug Humira due to competition from Biosimilars. | It is worth noting that AbbVie has increased its dividend for 51 consecutive years [including the years it was part of Abbott Laboratories (NYSE:ABT)]. Using TipRanks’ Stock Comparison Tool, we placed PepsiCo (NASDAQ:PEP), AbbVie (NYSE:ABBV), and General Motors (NYSE:GM) against each other to find the value stock that has the highest upside potential as per Wall Street analysts. Ahead of PepsiCo’s Q2 results (scheduled on July 13), Goldman Sachs analyst Bonnie Herzog reaffirmed a Buy rating on PEP with a price target of $208, saying that he sees a “favorable risk-reward.” The analyst expects a “healthy” revenue and earnings beat, given continued momentum in the company’s businesses, particularly for Frito-Lay North America (FLNA) as noted in recent NielsenIQ data. | It is worth noting that AbbVie has increased its dividend for 51 consecutive years [including the years it was part of Abbott Laboratories (NYSE:ABT)]. Ahead of PepsiCo’s Q2 results (scheduled on July 13), Goldman Sachs analyst Bonnie Herzog reaffirmed a Buy rating on PEP with a price target of $208, saying that he sees a “favorable risk-reward.” The analyst expects a “healthy” revenue and earnings beat, given continued momentum in the company’s businesses, particularly for Frito-Lay North America (FLNA) as noted in recent NielsenIQ data. Is PEP Stock a Buy Now? |
30928.0 | 2023-07-09 00:00:00 UTC | Wall St Week Ahead-As earnings loom, investors weigh recession resilience | ABT | https://www.nasdaq.com/articles/wall-st-week-ahead-as-earnings-loom-investors-weigh-recession-resilience-0 | nan | nan | By David Randall
NEW YORK, July 7 (Reuters) - As second-quarter earnings approach, investors are looking at beaten-down sectors which might gain ground regardless of whether the U.S. economy falls into recession this year.
While the benchmark S&P 500 .SPXhas gained nearly 15% year-to-date driven by a handful of megacap growth and technology names, some sectors have lagged, including the S&P 500 healthcare, which is down 4.7%. The financials sector is down 2%, while energy is nearly 9% lower.
These unloved sectors are growing attractive to investors increasingly torn over whether a long-feared U.S. recession will ever materialize.
Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said.
Large asset managers such as BlackRock and Wells Fargo highlighted healthcare as a favored sector in their recent outlooks for the rest of the year.
Some large banks have improved their U.S. economicoutlooks, with Goldman Sachs cutting the chance of a recession within the next 12 months to 25% from 35%. The Commerce Department, meanwhile, increased its estimate for first-quarter Gross Domestic Product growth to an 2% annualized rate from its initial 1.3% estimate.
Quincy Krosby, chief global strategist for LPL Financial noted a "tug of war" in the market over the likelihood of a recession.
"But until we hear from companies that they are cutting their labor force, then we think that we will not have a dire earnings season and some of these lagging sectors will become more favorable," she said.
The U.S. economy added the fewest jobs in 2-1/2 years in June, but persistently strong wage growth pointed to still-tight labor market conditions, , all but ensuring the Federal Reserve will resume raising interest rates later this month.
That will likely continue to weigh on stocks overall as borrowing costs increase. Overall, earnings in the S&P 500 are expected to fall 5.7% in the second quarter, largely due to declining margins, Refintiv data showed.
Despite that dim picture, "cheap" valuations and stable healthcare earnings make the sector increasingly attractive to invest in if the economy does slow in the second half, said Sameer Samana, seniorglobal marketstrategist for Wells Fargo Investment Institute.
The healthcare sector trades at a forward price-to-earnings ratio of 17.6, well below the 20.1 ratio of the broad S&P 500.
"We think the Fed will do whatever it takes to get inflation back down close to 2%, and that's why we think we will see a Fed-induced recession" in the coming months, he said.
HEALTHCARE, FINANCIALS
Medical devices and diagnostics are still benefiting from a backlog of delayed care during the coronavirus pandemic, and demand could continue to grow regardless of the direction of the economy, said Max Wasserman, a portfolio manager at Miramar Capital. He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date.
"As things continue reopening we expect to see more data that confirms that people are coming back into the healthcare system," he said.
Financials will likely continue to benefit from the Fed rate-hiking and the belief that worst of this year's regional banking crisis has passed, said Tom Ognar, a portfolio manager at Allspring Global Investments.
He is focusing on companies such as LPL Financial Holdings Inc LPLA.O and Morgan Stanley MS.N in the wealth management sector that appear to have more secular growth opportunities than the big banks, he said.
Big banks start reporting second-quarter results next week.
"If rates stay higher for longer and the Fed has to battle inflation for longer that will only mean that these companies will earn more for longer and buy back more stock," he said.
A market shift away from the handful of megacap technology and growth stocks that have powered the rally in the S&P 500 is not a given, cautioned John Quealy, chief investment officer at Trillium Asset Management.
"The cash flow profiles of some of those (megacap) companies are tremendously attractive, especially if we fall into a recessionary environment."
Overall, the Russell 1000 Growth Index is up 27.5% year to date, compared with a 2.9% gain in the financials and healthcare-heavy Russell 1000 Value.
Yet a continued rally in megacaps will likely stretch their valuations further, prompting some investors to rotate toward healthcare and financials, LPL Financial's Krosby said.
"Everything is at a discount."
Energy, Materials, Healthcare Earnings Expected to Slide https://tmsnrt.rs/3JM4MOm
(Reporting by David Randall; editing by Megan Davies, Michelle Price and Richard Chang)
((David.Randall@thomsonreuters.com; 646-223-6607; Reuters Messaging: david.randall.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. The U.S. economy added the fewest jobs in 2-1/2 years in June, but persistently strong wage growth pointed to still-tight labor market conditions, , all but ensuring the Federal Reserve will resume raising interest rates later this month. Medical devices and diagnostics are still benefiting from a backlog of delayed care during the coronavirus pandemic, and demand could continue to grow regardless of the direction of the economy, said Max Wasserman, a portfolio manager at Miramar Capital. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said. Despite that dim picture, "cheap" valuations and stable healthcare earnings make the sector increasingly attractive to invest in if the economy does slow in the second half, said Sameer Samana, seniorglobal marketstrategist for Wells Fargo Investment Institute. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said. Despite that dim picture, "cheap" valuations and stable healthcare earnings make the sector increasingly attractive to invest in if the economy does slow in the second half, said Sameer Samana, seniorglobal marketstrategist for Wells Fargo Investment Institute. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said. "We think the Fed will do whatever it takes to get inflation back down close to 2%, and that's why we think we will see a Fed-induced recession" in the coming months, he said. |
30929.0 | 2023-07-07 00:00:00 UTC | Noteworthy ETF Inflows: VTI, MRK, ACN, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vti-mrk-acn-abt | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.3 billion dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 1,394,762,430 to 1,405,309,167). Among the largest underlying components of VTI, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.4%, Accenture plc (Symbol: ACN) is trading flat, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average:
Looking at the chart above, VTI's low point in its 52 week range is $174.84 per share, with $221.42 as the 52 week high point — that compares with a last trade of $218.50. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
PBW Average Annual Return
MNAP Videos
ETFs Holding BG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTI, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.4%, Accenture plc (Symbol: ACN) is trading flat, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of VTI, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.4%, Accenture plc (Symbol: ACN) is trading flat, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $174.84 per share, with $221.42 as the 52 week high point — that compares with a last trade of $218.50. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ». | Among the largest underlying components of VTI, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.4%, Accenture plc (Symbol: ACN) is trading flat, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.3 billion dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 1,394,762,430 to 1,405,309,167). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $174.84 per share, with $221.42 as the 52 week high point — that compares with a last trade of $218.50. | Among the largest underlying components of VTI, in trading today Merck & Co Inc (Symbol: MRK) is down about 1.4%, Accenture plc (Symbol: ACN) is trading flat, and Abbott Laboratories (Symbol: ABT) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $2.3 billion dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 1,394,762,430 to 1,405,309,167). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. |
30930.0 | 2023-07-07 00:00:00 UTC | Wall St Week Ahead-As earnings loom, investors weigh recession resilience | ABT | https://www.nasdaq.com/articles/wall-st-week-ahead-as-earnings-loom-investors-weigh-recession-resilience | nan | nan | By David Randall
NEW YORK, July 7 (Reuters) - As second-quarter earnings approach, investors are looking at beaten-down sectors which might gain ground regardless of whether the U.S. economy falls into recession this year.
While the benchmark S&P 500 .SPXhas gained nearly 15% year-to-date driven by a handful of megacap growth and technology names, some sectors have lagged, including the S&P 500 healthcare, which is down 4.7%. The financials sector is down 2%, while energy is nearly 9% lower.
These unloved sectors are growing attractive to investors increasingly torn over whether a long-feared U.S. recession will ever materialize.
Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said.
Large asset managers such as BlackRock and Wells Fargo highlighted healthcare as a favored sector in their recent outlooks for the rest of the year.
Some large banks have improved their U.S. economicoutlooks, with Goldman Sachs cutting the chance of a recession within the next 12 months to 25% from 35%. The Commerce Department, meanwhile, increased its estimate for first-quarter Gross Domestic Product growth to an 2% annualized rate from its initial 1.3% estimate.
Quincy Krosby, chief global strategist for LPL Financial noted a "tug of war" in the market over the likelihood of a recession.
"But until we hear from companies that they are cutting their labor force, then we think that we will not have a dire earnings season and some of these lagging sectors will become more favorable," she said.
The U.S. economy added the fewest jobs in 2-1/2 years in June, but persistently strong wage growth pointed to still-tight labor market conditions, , all but ensuring the Federal Reserve will resume raising interest rates later this month.
That will likely continue to weigh on stocks overall as borrowing costs increase. Overall, earnings in the S&P 500 are expected to fall 5.7% in the second quarter, largely due to declining margins, Refintiv data showed.
Despite that dim picture, "cheap" valuations and stable healthcare earnings make the sector increasingly attractive to invest in if the economy does slow in the second half, said Sameer Samana, seniorglobal marketstrategist for Wells Fargo Investment Institute.
The healthcare sector trades at a forward price-to-earnings ratio of 17.6, well below the 20.1 ratio of the broad S&P 500.
"We think the Fed will do whatever it takes to get inflation back down close to 2%, and that's why we think we will see a Fed-induced recession" in the coming months, he said.
HEALTHCARE, FINANCIALS
Medical devices and diagnostics are still benefiting from a backlog of delayed care during the coronavirus pandemic, and demand could continue to grow regardless of the direction of the economy, said Max Wasserman, a portfolio manager at Miramar Capital. He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date.
"As things continue reopening we expect to see more data that confirms that people are coming back into the healthcare system," he said.
Financials will likely continue to benefit from the Fed rate-hiking and the belief that worst of this year's regional banking crisis has passed, said Tom Ognar, a portfolio manager at Allspring Global Investments.
He is focusing on companies such as LPL Financial Holdings Inc LPLA.O and Morgan Stanley MS.N in the wealth management sector that appear to have more secular growth opportunities than the big banks, he said.
Big banks start reporting second-quarter results next week.
"If rates stay higher for longer and the Fed has to battle inflation for longer that will only mean that these companies will earn more for longer and buy back more stock," he said.
A market shift away from the handful of megacap technology and growth stocks that have powered the rally in the S&P 500 is not a given, cautioned John Quealy, chief investment officer at Trillium Asset Management.
"The cash flow profiles of some of those (megacap) companies are tremendously attractive, especially if we fall into a recessionary environment."
Overall, the Russell 1000 Growth Index is up 27.5% year to date, compared with a 2.9% gain in the financials and healthcare-heavy Russell 1000 Value.
Yet a continued rally in megacaps will likely stretch their valuations further, prompting some investors to rotate toward healthcare and financials, LPL Financial's Krosby said.
"Everything is at a discount."
Energy, Materials, Healthcare Earnings Expected to Slide https://tmsnrt.rs/3JM4MOm
(Reporting by David Randall; editing by Megan Davies, Michelle Price and Richard Chang)
((David.Randall@thomsonreuters.com; 646-223-6607; Reuters Messaging: david.randall.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. The U.S. economy added the fewest jobs in 2-1/2 years in June, but persistently strong wage growth pointed to still-tight labor market conditions, , all but ensuring the Federal Reserve will resume raising interest rates later this month. Medical devices and diagnostics are still benefiting from a backlog of delayed care during the coronavirus pandemic, and demand could continue to grow regardless of the direction of the economy, said Max Wasserman, a portfolio manager at Miramar Capital. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said. Despite that dim picture, "cheap" valuations and stable healthcare earnings make the sector increasingly attractive to invest in if the economy does slow in the second half, said Sameer Samana, seniorglobal marketstrategist for Wells Fargo Investment Institute. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said. Despite that dim picture, "cheap" valuations and stable healthcare earnings make the sector increasingly attractive to invest in if the economy does slow in the second half, said Sameer Samana, seniorglobal marketstrategist for Wells Fargo Investment Institute. | He is bullish on companies such as Abbott Laboratories ABT.N, which is down nearly 3% year to date. Global fund managers increased their allocations to healthcare and banks by about 5 percentage points in June, while cutting holdings of popular recession plays such as cash and consumer staples companies, BofA Global said. "We think the Fed will do whatever it takes to get inflation back down close to 2%, and that's why we think we will see a Fed-induced recession" in the coming months, he said. |
30931.0 | 2023-07-06 00:00:00 UTC | RDVY's Holdings Could Mean 12% Gain Potential | ABT | https://www.nasdaq.com/articles/rdvys-holdings-could-mean-12-gain-potential | nan | nan | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Rising Dividend Achievers ETF (Symbol: RDVY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $52.79 per unit.
With RDVY trading at a recent price near $46.98 per unit, that means that analysts see 12.37% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of RDVY's underlying holdings with notable upside to their analyst target prices are Mueller Industries Inc (Symbol: MLI), Abbott Laboratories (Symbol: ABT), and Synchrony Financial (Symbol: SYF). Although MLI has traded at a recent price of $85.78/share, the average analyst target is 16.58% higher at $100.00/share. Similarly, ABT has 14.67% upside from the recent share price of $107.37 if the average analyst target price of $123.12/share is reached, and analysts on average are expecting SYF to reach a target price of $37.95/share, which is 12.47% above the recent price of $33.74. Below is a twelve month price history chart comparing the stock performance of MLI, ABT, and SYF:
Combined, MLI, ABT, and SYF represent 6.14% of the First Trust Rising Dividend Achievers ETF. Below is a summary table of the current analyst target prices discussed above:
NAME SYMBOL RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
First Trust Rising Dividend Achievers ETF RDVY $46.98 $52.79 12.37%
Mueller Industries Inc MLI $85.78 $100.00 16.58%
Abbott Laboratories ABT $107.37 $123.12 14.67%
Synchrony Financial SYF $33.74 $37.95 12.47%
Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research.
10 ETFs With Most Upside To Analyst Targets »
Also see:
VNDA Stock Predictions
VKTX Options Chain
BITX Options Chain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | First Trust Rising Dividend Achievers ETF RDVY $46.98 $52.79 12.37% Mueller Industries Inc MLI $85.78 $100.00 16.58% Abbott Laboratories ABT $107.37 $123.12 14.67% Synchrony Financial SYF $33.74 $37.95 12.47% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RDVY's underlying holdings with notable upside to their analyst target prices are Mueller Industries Inc (Symbol: MLI), Abbott Laboratories (Symbol: ABT), and Synchrony Financial (Symbol: SYF). Similarly, ABT has 14.67% upside from the recent share price of $107.37 if the average analyst target price of $123.12/share is reached, and analysts on average are expecting SYF to reach a target price of $37.95/share, which is 12.47% above the recent price of $33.74. | Three of RDVY's underlying holdings with notable upside to their analyst target prices are Mueller Industries Inc (Symbol: MLI), Abbott Laboratories (Symbol: ABT), and Synchrony Financial (Symbol: SYF). Similarly, ABT has 14.67% upside from the recent share price of $107.37 if the average analyst target price of $123.12/share is reached, and analysts on average are expecting SYF to reach a target price of $37.95/share, which is 12.47% above the recent price of $33.74. First Trust Rising Dividend Achievers ETF RDVY $46.98 $52.79 12.37% Mueller Industries Inc MLI $85.78 $100.00 16.58% Abbott Laboratories ABT $107.37 $123.12 14.67% Synchrony Financial SYF $33.74 $37.95 12.47% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? | Similarly, ABT has 14.67% upside from the recent share price of $107.37 if the average analyst target price of $123.12/share is reached, and analysts on average are expecting SYF to reach a target price of $37.95/share, which is 12.47% above the recent price of $33.74. Three of RDVY's underlying holdings with notable upside to their analyst target prices are Mueller Industries Inc (Symbol: MLI), Abbott Laboratories (Symbol: ABT), and Synchrony Financial (Symbol: SYF). Below is a twelve month price history chart comparing the stock performance of MLI, ABT, and SYF: Combined, MLI, ABT, and SYF represent 6.14% of the First Trust Rising Dividend Achievers ETF. | Three of RDVY's underlying holdings with notable upside to their analyst target prices are Mueller Industries Inc (Symbol: MLI), Abbott Laboratories (Symbol: ABT), and Synchrony Financial (Symbol: SYF). Similarly, ABT has 14.67% upside from the recent share price of $107.37 if the average analyst target price of $123.12/share is reached, and analysts on average are expecting SYF to reach a target price of $37.95/share, which is 12.47% above the recent price of $33.74. Below is a twelve month price history chart comparing the stock performance of MLI, ABT, and SYF: Combined, MLI, ABT, and SYF represent 6.14% of the First Trust Rising Dividend Achievers ETF. |
30932.0 | 2023-07-06 00:00:00 UTC | Abbott (ABT) Gets FDA Approval for AVEIR DR Leadless Pacemaker | ABT | https://www.nasdaq.com/articles/abbott-abt-gets-fda-approval-for-aveir-dr-leadless-pacemaker | nan | nan | Abbott ABT recently received FDA approval for its pioneering AVEIR dual chamber (DR) leadless pacemaker system. The approval comes following the recent late-breaking clinical trial data showing that the system is safe and effective for treating abnormal heart rhythms.
The latest development significantly increases access to leadless pacing for millions of people across the United States.
Significance of AVEIR DR Devices
The AVEIR DR leadless pacing system is made up of two devices — the previously approved AVEIR VR single-chamber device, which paces the right ventricle, and the recently approved AVEIR AR single-chamber device, which paces the right atrium. Smaller than the AAA battery, each AVEIR pacemaker is implanted via a minimally invasive procedure.
AVEIR DR devices provide synchronized or coordinated cardiac pacing between two leadless pacemakers based on the person's clinical needs using Abbott's novel i2i (implant-to-implant) technology. The breakthrough technology utilizes high-frequency pulses to relay messages via the naturally conductive characteristics of the body's blood between each leadless pacemaker.
Image Source: Zacks Investment Research
Each implant communicates beat-to-beat with a paired, co-implanted device to support dual-chamber therapy. This conductive communication is critical because it uses far less battery current than inductive, radio frequency or Bluetooth communication.
AVEIR leadless pacemakers are designed for retrieval, which will help if therapy needs to be changed or the device needs to be replaced in the future.
News in Detail
With more than 80% of people requiring pacing in both the right atrium and the right ventricle, the currently available leadless pacing options have been limited to single-chamber ventricular devices. This stems from the significant engineering challenge of seamless, wireless synchronization of two leadless pacemakers.
The AVEIR DR system, which is roughly one-tenth the size of a traditional pacemaker, is also designed to provide real-time pacing analysis. This enables physicians to assess the proper placement of the device during the procedure and before implanting the device inside the heart chamber.
Industry Prospects
Per a Research report, the global leadless cardiac pacemaker market is expected to witness a CAGR of 17.2% by 2028.
Recent Developments
In June, Abbott announced a collaboration with the American Diabetes Association, to gain a deeper understanding of the role of Continuous Glucose Monitoring systems in personalized therapeutic nutrition for people with diabetes.
During the same month, ABT’s FreeStyle Libre 2 system became the first and only CGM system to be nationally reimbursed in France for people who use basal insulin.
Price Performance
In the past six months, Abbott shares have decreased 4.2% against the industry’s rise of 3.2%.
Zacks Rank and Other Key Picks
Abbott currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the overall healthcare sector are Haemonetics HAE, Zimmer Biomet ZBH and SiBone SIBN. While Haemonetics sports a Zacks Rank #1 (Strong Buy), Zimmer Biomet and SiBone each carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 25.6% in the past year. The Zacks Consensus Estimate for Haemonetics’ earnings per share (EPS) has increased from $3.55 to $3.56 for fiscal 2024 and remained constant at $3.96 for fiscal 2025 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, the company registered an earnings surprise of 13.24%.
The Zacks Consensus Estimate for Zimmer Biomet’s 2023 EPS has remained constant at $7.45 in the past 30 days. Shares of the company have improved 34.2% in the past year against the industry’s 21.6% decline.
ZBH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 7.38%. In the last reported quarter, the company recorded an earnings surprise of 13.86%.
The Zacks Consensus Estimate for SiBone’s 2023 loss per share has narrowed from $1.44 to $1.42 in the past 30 days. SIBN shares have improved 92.3% in the past year compared with the industry’s 9% growth.
SIBN’s earnings beat estimates in three of the trailing four quarters and missed the same in one, the average surprise being 11.11%. In the last reported quarter, the company recorded an earnings surprise of 21.95%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
SiBone (SIBN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT recently received FDA approval for its pioneering AVEIR dual chamber (DR) leadless pacemaker system. During the same month, ABT’s FreeStyle Libre 2 system became the first and only CGM system to be nationally reimbursed in France for people who use basal insulin. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT recently received FDA approval for its pioneering AVEIR dual chamber (DR) leadless pacemaker system. During the same month, ABT’s FreeStyle Libre 2 system became the first and only CGM system to be nationally reimbursed in France for people who use basal insulin. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT recently received FDA approval for its pioneering AVEIR dual chamber (DR) leadless pacemaker system. During the same month, ABT’s FreeStyle Libre 2 system became the first and only CGM system to be nationally reimbursed in France for people who use basal insulin. | Abbott ABT recently received FDA approval for its pioneering AVEIR dual chamber (DR) leadless pacemaker system. During the same month, ABT’s FreeStyle Libre 2 system became the first and only CGM system to be nationally reimbursed in France for people who use basal insulin. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report SiBone (SIBN) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30933.0 | 2023-07-05 00:00:00 UTC | Validea's Top 5 Health Care Stocks Based On Joel Greenblatt - 7/5/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-joel-greenblatt-7-5-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
BRISTOL-MYERS SQUIBB CO (BMY) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 40% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of BRISTOL-MYERS SQUIBB CO
BMY Guru Analysis
BMY Fundamental Analysis
HUMANA INC (HUM) is a large-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Humana Inc. is a health and well-being company. The Company operates through two segments: Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly through group Medicare accounts. It also includes its contract with the Centers for Medicare and Medicaid Services (CMS) to administer the Limited Income Newly Eligible Transition (LI-NET), prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. The Insurance segment also includes products consisting of employer group commercial fully-insured medical and specialty health. The CenterWell segment represents its payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The Company's subsidiaries include Mid-South Home Health Agency, LLC, Premier Home Health Agency, LLC and Humana Regional Health Plan, Inc.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of HUMANA INC
HUM Guru Analysis
HUM Fundamental Analysis
BOSTON SCIENTIFIC CORPORATION (BSX) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Boston Scientific Corporation is a developer, manufacturer, and marketer of medical devices. The Company's segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy and Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal and pulmonary conditions. Its Urology and Neuromodulation business develops and manufactures devices to treat various urological, neurological movement disorders and pelvic conditions. Its Cardiac Rhythm Management develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment include Interventional Cardiology and Peripheral Interventions. Its Interventional Cardiology develops and manufactures technologies for diagnosing and treating coronary artery disease and structural heart conditions. Its product offerings include 360 Clips and RESONATE, among others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of BOSTON SCIENTIFIC CORPORATION
BSX Guru Analysis
BSX Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
COMMUNITY HEALTH SYSTEMS INC (CYH) is a small-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Community Health Systems, Inc. is a healthcare company. The Company through its subsidiaries, owns or leases approximately 79 affiliated hospitals, with 13,000 beds, and operates more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers, and ambulatory surgery centers. The Company, through its affiliates, provides healthcare services, developing and operating healthcare delivery systems in approximately 44 distinct markets across 15 states. Its hospitals and other sites of care offer a broad variety of inpatient and outpatient medical and surgical services. These include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic services, and psychiatric and rehabilitation services. The Company serves governmental agencies, private insurers, and patients.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of COMMUNITY HEALTH SYSTEMS INC
CYH Guru Analysis
CYH Fundamental Analysis
Joel Greenblatt Portfolio
Top Joel Greenblatt Stocks
About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The "Magic Formula," as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis COMMUNITY HEALTH SYSTEMS INC (CYH) is a small-cap growth stock in the Healthcare Facilities industry. The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. | Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis COMMUNITY HEALTH SYSTEMS INC (CYH) is a small-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of HUMANA INC HUM Guru Analysis HUM Fundamental Analysis BOSTON SCIENTIFIC CORPORATION (BSX) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis COMMUNITY HEALTH SYSTEMS INC (CYH) is a small-cap growth stock in the Healthcare Facilities industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | Detailed Analysis of BOSTON SCIENTIFIC CORPORATION BSX Guru Analysis BSX Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis COMMUNITY HEALTH SYSTEMS INC (CYH) is a small-cap growth stock in the Healthcare Facilities industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. |
30934.0 | 2023-07-05 00:00:00 UTC | Abbott's Minimally Invasive Dual Chamber Leadless Pacemaker System Gets FDA Approval | ABT | https://www.nasdaq.com/articles/abbotts-minimally-invasive-dual-chamber-leadless-pacemaker-system-gets-fda-approval | nan | nan | (RTTNews) - Abbott Laboratories (ABT) a biopharmaceutical major, announced on Wednesday that it has received FDA approval for its dual chamber (DR) leadless pacemaker system dubbed AVEIR.
As per the company, more than 80 percent of the people need a pacemaker pacing in two chambers of the heart and the approval increases the access leadless pacing for millions of people across the U.S.
Shorter, smaller, and slimmer than a AAA battery, the pacemaker is implanted directly into the heart's interior surface through a minimally invasive procedure which uses a screw in mechanism called the Helix.
The leadless pacemaker limits the patients' exposure to potential lead and infection-related complications and offers a less restrictive and shorter recovery period post-implantation.
These devices are around one-tenth the size of a traditional pacemaker and are made up of 2 devices. The previously-approved AVEIR VR single chamber device paces the right ventricle, and the now-approved AVEIR AR single chamber device paces the right atrium.
The AVEIR DR system incorporates Abbott's novel i2i technology, which offers beat-to-beat communication between the two leadless pacemakers.
Currently, shares of Abbott are trading at $107.57 up 0.32% on the New York Stock Exchange.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott Laboratories (ABT) a biopharmaceutical major, announced on Wednesday that it has received FDA approval for its dual chamber (DR) leadless pacemaker system dubbed AVEIR. Shorter, smaller, and slimmer than a AAA battery, the pacemaker is implanted directly into the heart's interior surface through a minimally invasive procedure which uses a screw in mechanism called the Helix. The leadless pacemaker limits the patients' exposure to potential lead and infection-related complications and offers a less restrictive and shorter recovery period post-implantation. | (RTTNews) - Abbott Laboratories (ABT) a biopharmaceutical major, announced on Wednesday that it has received FDA approval for its dual chamber (DR) leadless pacemaker system dubbed AVEIR. As per the company, more than 80 percent of the people need a pacemaker pacing in two chambers of the heart and the approval increases the access leadless pacing for millions of people across the U.S. The previously-approved AVEIR VR single chamber device paces the right ventricle, and the now-approved AVEIR AR single chamber device paces the right atrium. | (RTTNews) - Abbott Laboratories (ABT) a biopharmaceutical major, announced on Wednesday that it has received FDA approval for its dual chamber (DR) leadless pacemaker system dubbed AVEIR. As per the company, more than 80 percent of the people need a pacemaker pacing in two chambers of the heart and the approval increases the access leadless pacing for millions of people across the U.S. The previously-approved AVEIR VR single chamber device paces the right ventricle, and the now-approved AVEIR AR single chamber device paces the right atrium. | (RTTNews) - Abbott Laboratories (ABT) a biopharmaceutical major, announced on Wednesday that it has received FDA approval for its dual chamber (DR) leadless pacemaker system dubbed AVEIR. Shorter, smaller, and slimmer than a AAA battery, the pacemaker is implanted directly into the heart's interior surface through a minimally invasive procedure which uses a screw in mechanism called the Helix. The previously-approved AVEIR VR single chamber device paces the right ventricle, and the now-approved AVEIR AR single chamber device paces the right atrium. |
30935.0 | 2023-07-04 00:00:00 UTC | Will Medtronic Stock Rebound To Its Pre-Inflation Shock Highs? | ABT | https://www.nasdaq.com/articles/will-medtronic-stock-rebound-to-its-pre-inflation-shock-highs | nan | nan | Medtronic stock (NYSE: MDT) currently trades at $87 per share, roughly 27% below its level in March 2021, and it has the potential for sizable gains. MDT saw its stock trading at around $90 in late June 2022, just before the Fed started increasing rates, and is now 3% below that level, underperforming the broader markets, with the S&P 500 rising 16% over this period. The decline in Medtronic stock over the recent past can be attributed to its downbeat guidance for fiscal 2024. It expects its earnings to be between $5.00 and $5.10 on a per-share and adjusted basis, compared to expected EPS of around $5.20. At the mid-point of the provided range, this reflects a 5% cut from its $5.29 figure reported in fiscal 2023. This did not sit well with the investors.
Returning to the pre-inflation shock level means that Medtronic stock will have to gain 56% from here. However, we do not believe that will materialize any time soon and estimate Medtronic’s valuation to be around $93 per share, implying about 7% gains. This is because of an expected decline in earnings in the near term. Moreover, the recent uncertainty in the financial sector has raised concerns about a potential recession, which may impact Medtronic’s business.
Our detailed analysis of Medtronic’s upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022. It compares these trends to the stock’s performance during the 2008 recession.
2022 Inflation Shock
Timeline of Inflation Shock So Far:
2020 – early 2021: Increase in money supply to cushion the impact of lockdowns led to high demand for goods; producers unable to match up.
Early 2021: Shipping snarls and worker shortages from the coronavirus pandemic continue to hurt supply.
April 2021: Inflation rates cross 4% and increase rapidly.
Early 2022: Energy and food prices spike due to the Russian invasion of Ukraine. Fed begins its rate hike process.
June 2022: Inflation levels peak at 9% – the highest level in 40 years. S&P 500 index declines more than 20% from peak levels.
July – September 2022: Fed hikes interest rates aggressively – resulting in an initial recovery in the S&P 500 followed by another sharp decline.
Since October 2022: Fed continues rate hike process; improving market sentiments help S&P500 recoup some of its losses.
In contrast, here’s how MDT stock and the broader market performed during the 2007/2008 crisis.
Timeline of 2007-08 Crisis
10/1/2007: Approximate pre-crisis peak in S&P 500 index
9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08)
3/1/2009: Approximate bottoming out of S&P 500 index
12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008)
Medtronic and S&P 500 Performance During 2007-08 Crisis
Medtronic stock declined from $58 in September 2007 (pre-crisis peak) to around $30 in March 2009 (as the markets bottomed out), implying MDT stock lost nearly 50% of its pre-crisis value. It recovered post the 2008 crisis to levels of around $44 in early 2010, rising nearly 49% between March 2009 and January 2010. The S&P 500 Index saw a decline of 51%, falling from levels of 1,540 in September 2007 to 757 in March 2009. It then rallied 48% between March 2009 and January 2010 to reach levels of 1,124.
Medtronic’s Fundamentals Over Recent Years
Medtronic’s revenue rose from $30.6 billion in 2019 to $31.2 billion in 2023. Although Medtronic’s sales were hurt during the pandemic due to the postponement of elective surgeries, this trend reversed in 2022, resulting in a rebound in sales. The company also benefited from its new product launches, including the Micra AV pacemaker. However, of late, its Medical Surgical segment sales have been weighed down due to a continued decline in ventilator demand. Furthermore, forex headwinds have also weighed on the overall top-line growth in recent quarters.
Medtronic’s operating margin slid from 20.5% in 2019 to 18.7% in 2023. Its EPS also declined from $3.44 to $2.83 over this period.
Does Medtronic Have A Sufficient Cash Cushion To Meet Its Obligations Through The Ongoing Inflation Shock?
Medtronic’s total debt decreased from $25.3 billion in 2019 to $24.4 billion in 2023, while its total cash decreased from around $9.8 billion to $8.0 billion over the same period. The company garnered $6 billion in cash flows from operations in 2023. Given its cash position, Medtronic appears to be in a comfortable position to meet its near-term obligations.
Conclusion
With the Fed’s efforts to tame runaway inflation rates helping market sentiment, we believe Medtronic (MDT) stock has the potential for some gains once fears of a potential recession are allayed. That said, the expected decline in near-term earnings, partly due to the higher inflation and foreign currency translation, remains a risk factor to realizing these gains.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Returns Jun 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
MDT Return 5% 12% 22%
S&P 500 Return 5% 15% 96%
Trefis Multi-Strategy Portfolio 8% 18% 271%
[1] Month-to-date and year-to-date as of 6/30/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MDT saw its stock trading at around $90 in late June 2022, just before the Fed started increasing rates, and is now 3% below that level, underperforming the broader markets, with the S&P 500 rising 16% over this period. Our detailed analysis of Medtronic’s upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022. That said, the expected decline in near-term earnings, partly due to the higher inflation and foreign currency translation, remains a risk factor to realizing these gains. | 2022 Inflation Shock Timeline of Inflation Shock So Far: 2020 – early 2021: Increase in money supply to cushion the impact of lockdowns led to high demand for goods; producers unable to match up. Since October 2022: Fed continues rate hike process; improving market sentiments help S&P500 recoup some of its losses. Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) Medtronic and S&P 500 Performance During 2007-08 Crisis Medtronic stock declined from $58 in September 2007 (pre-crisis peak) to around $30 in March 2009 (as the markets bottomed out), implying MDT stock lost nearly 50% of its pre-crisis value. | Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) Medtronic and S&P 500 Performance During 2007-08 Crisis Medtronic stock declined from $58 in September 2007 (pre-crisis peak) to around $30 in March 2009 (as the markets bottomed out), implying MDT stock lost nearly 50% of its pre-crisis value. Conclusion With the Fed’s efforts to tame runaway inflation rates helping market sentiment, we believe Medtronic (MDT) stock has the potential for some gains once fears of a potential recession are allayed. Total [2] MDT Return 5% 12% 22% S&P 500 Return 5% 15% 96% Trefis Multi-Strategy Portfolio 8% 18% 271% [1] Month-to-date and year-to-date as of 6/30/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MDT saw its stock trading at around $90 in late June 2022, just before the Fed started increasing rates, and is now 3% below that level, underperforming the broader markets, with the S&P 500 rising 16% over this period. Returning to the pre-inflation shock level means that Medtronic stock will have to gain 56% from here. The company garnered $6 billion in cash flows from operations in 2023. |
30936.0 | 2023-07-03 00:00:00 UTC | Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-sinks-as-market-gains%3A-what-you-should-know-6 | nan | nan | Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day. This change lagged the S&P 500's 0.12% gain on the day. Elsewhere, the Dow gained 0.03%, while the tech-heavy Nasdaq added 5.14%.
Wall Street will be looking for positivity from Abbott as it approaches its next earnings report date. This is expected to be July 20, 2023. The company is expected to report EPS of $0.97, down 32.17% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.67 billion, down 14.08% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.39 per share and revenue of $39.38 billion, which would represent changes of -17.79% and -9.79%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. Abbott is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Abbott is holding a Forward P/E ratio of 24.86. Its industry sports an average Forward P/E of 23.94, so we one might conclude that Abbott is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 4.88. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry currently had an average PEG ratio of 2.62 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 56, putting it in the top 23% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day. We can also see that ABT currently has a PEG ratio of 4.88. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. We can also see that ABT currently has a PEG ratio of 4.88. | Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day. We can also see that ABT currently has a PEG ratio of 4.88. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $107.22 in the latest trading session, marking a -1.65% move from the prior day. We can also see that ABT currently has a PEG ratio of 4.88. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30937.0 | 2023-07-02 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-25 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Healthcare Stocks
Dividend Aristocrats2023
Wide Moat Stocks2023
High Insider Ownership Stocks
Factor-Based Stock Portfolios
Excess Returns Investing Podcast
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. |
30938.0 | 2023-06-30 00:00:00 UTC | Abbott (ABT) Teams Up With the ADA to Evaluate CGM Systems | ABT | https://www.nasdaq.com/articles/abbott-abt-teams-up-with-the-ada-to-evaluate-cgm-systems | nan | nan | Abbott ABT recently teamed up with the American Diabetes Association (“ADA”) to launch a therapeutic nutrition program for people with diabetes. The first-of-its-kind project will evaluate how diabetes technology like continuous glucose monitoring (CGM) systems can help people living with diabetes make informed decisions about their food and activity.
For more than 20 years, Abbott and the ADA have collaborated with a shared mission to fight for all those affected by diabetes. By partnering with the ADA, Abbott expects to gather evidence on the potential of its FreeStyle Libre technology providing personalized insights to people about their dietary habits.
News in Detail
An individual’s dietary habits play a pivotal role in glucose control. Nonetheless, person-to-person variations in glycemic response to the same foods make it very challenging to prescribe a universal nutritional plan for diabetes management. Clinical studies have shown that keeping glucose levels steady over time leads to better outcomes for people with diabetes.
Image Source: Zacks Investment Research
Abbott’s CGM systems offer personalized, real-time data on how food and activity affect glucose levels. Over time, research has shown that the data from CGMs allows people with diabetes to learn patterns and create a personalized nutritional plan. This holds the potential to revolutionize diabetes management by providing steady glucose levels in the plan and reducing the risk of diabetes-related complications.
More on the News
Under the collaboration, Abbott is providing a $2.65 million grant over the next three years to the Association. The funds will allow the ADA to engage with healthcare professionals and key opinion leaders to evaluate existing clinical evidence on the use of CGM systems for personalized, therapeutic nutrition.
Other activities will include launching two pilot programs targeted at adults with Type 2 diabetes and conducting roundtable discussions with renowned health care experts to review and evaluate the existing clinical evidence.
Industry Prospects
Per a Research report, the global CGM devices market was valued at $7.82 billion in 2022 and is expected to witness a CAGR of 4.4% by 2030.
Recent Highlights
Of late, Abbott has been reaching headlines for a number of achievements. Its FreeStyle Libre 2 system is the first and only CGM system to be nationally reimbursed in France for people who use basal insulin as part of their diabetes management. ABT’s TactiFlex Ablation Catheter has been approved by the FDA for the treatment of abnormal heart rhythm.
The company’s latest addition to the connected health devices portfolio, Assert-IQ Insertable Cardiac Monitor, received FDA clearance in May.
Price Performance
In the past six months, ABT shares have declined 2% against the industry’s rise of 5.2%.
Zacks Rank and Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the overall healthcare sector are Penumbra PEN, Lantheus LNTH and Haemonetics HAE, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has surged 170.8% in the past year. The Zacks Consensus Estimate for the company’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat the consensus mark in all the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have rallied 30.7% in the past year against the industry’s 22.2% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Haemonetics’ EPS for 2023 have increased from $3.55 to $3.56 in the past 30 days. Shares of the company have surged 26.1% in the past year against the industry’s 22.2% decline.
HAE’s earnings beat estimates in all the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, Haemonetics delivered an earnings surprise of 13.2%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT recently teamed up with the American Diabetes Association (“ADA”) to launch a therapeutic nutrition program for people with diabetes. ABT’s TactiFlex Ablation Catheter has been approved by the FDA for the treatment of abnormal heart rhythm. Price Performance In the past six months, ABT shares have declined 2% against the industry’s rise of 5.2%. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT recently teamed up with the American Diabetes Association (“ADA”) to launch a therapeutic nutrition program for people with diabetes. ABT’s TactiFlex Ablation Catheter has been approved by the FDA for the treatment of abnormal heart rhythm. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT recently teamed up with the American Diabetes Association (“ADA”) to launch a therapeutic nutrition program for people with diabetes. ABT’s TactiFlex Ablation Catheter has been approved by the FDA for the treatment of abnormal heart rhythm. | Abbott ABT recently teamed up with the American Diabetes Association (“ADA”) to launch a therapeutic nutrition program for people with diabetes. ABT’s TactiFlex Ablation Catheter has been approved by the FDA for the treatment of abnormal heart rhythm. Price Performance In the past six months, ABT shares have declined 2% against the industry’s rise of 5.2%. |
30939.0 | 2023-06-28 00:00:00 UTC | Validea's Top 5 Health Care Stocks Based On Benjamin Graham - 6/28/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-benjamin-graham-6-28-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.
VERTEX PHARMACEUTICALS INCORPORATED (VRTX) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Benjamin Graham is 57% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of VERTEX PHARMACEUTICALS INCORPORATED
VRTX Guru Analysis
VRTX Fundamental Analysis
OWENS & MINOR, INC. (OMI) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Benjamin Graham is 57% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Owens & Minor, Inc. is a global healthcare solutions company integrating product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. The Company operates through two segments: Products & Healthcare Services and Patient Direct. Its Products & Healthcare Services segment provides distribution, outsourced logistics and value-added services, and manufactures and sources medical surgical products, through its production and kitting operations. Its Patient Direct segment expands its business along the continuum of care through delivery of disposable medical supplies sold directly to patients and home health agencies and is a provider of integrated home healthcare equipment and related services in the United States. It offers technology and solutions, personal protective equipment (PPE) and surgical products, as well as a products and services for patients managing chronic and acute conditions in the home setting.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: FAIL
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: PASS
PRICE/BOOK RATIO: PASS
Detailed Analysis of OWENS & MINOR, INC.
OMI Guru Analysis
OMI Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: FAIL
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL
LONG-TERM EPS GROWTH: PASS
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
CORVEL CORPORATION (CRVL) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: CorVel Corporation is engaged in applying technology, including artificial intelligence, machine learning, and natural language processing designed to address the management of episodes of care and the related health-care costs. The Company's services include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and Medicare services. It partners with employers, third party administrators (TPAs), insurance companies, and government agencies to assist its customers in managing the medical costs of workers compensation, group health, and auto insurance and in monitoring the quality of care provided to claimants. Its network solutions services include professional nurse review, expert fee negotiations, specialty networks, preferred provider organization management, medical bill repricing, automated adjudication, and electronic reimbursement. Its bill review services include coding review and re-bundling.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: FAIL
CURRENT RATIO: FAIL
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: PASS
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of CORVEL CORPORATION
CRVL Guru Analysis
CRVL Fundamental Analysis
LIGAND PHARMACEUTICALS INC (LGND) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. The Company is focused on acquiring or funding programs and technologies that pharmaceutical companies use to discover and develop medicines. The Company's Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Its Pelican Expression technology is a scalable platform for recombinant protein production, and is especially suited for complex, large-scale protein production. The Company's products include Kyprolis, Teriparatide, Evomela, Rylaze, Nexterone, Pneumosil, Vaxneuvance, and Other. Kyprolis is formulated with Ligand's Captisol technology. Teriparatide Injection is a drug indicated for uses including the treatment of osteoporosis in certain patients at high risk for fracture. Evomela is a Captisol-enabled melphalan IV formulation. Its other products include Pneumosil, Rylaze, Nexterone, Veklury, Zulresso, and Noxafil-IV.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: FAIL
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of LIGAND PHARMACEUTICALS INC
LGND Guru Analysis
LGND Fundamental Analysis
Benjamin Graham Portfolio
Top Benjamin Graham Stocks
About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Known as both the "Father of Value Investing" and the founder of the entire field of security analysis, Graham mentored several of history's greatest investors -- including Warren Buffett -- and inspired a slew of others, including John Templeton, Mario Gabelli, and another of Validea's gurus, John Neff. Graham built his fortune and reputation after living through some extremely difficult times, including both the Great Depression and his own family's financial woes following his father's death when Benjamin was a young man. His investment firm posted per annum returns of about 20 percent from 1936 to 1956, far outpacing the 12.2 percent average return for the market during that time.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of OWENS & MINOR, INC. OMI Guru Analysis OMI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORVEL CORPORATION (CRVL) is a mid-cap growth stock in the Healthcare Facilities industry. Company Description: CorVel Corporation is engaged in applying technology, including artificial intelligence, machine learning, and natural language processing designed to address the management of episodes of care and the related health-care costs. | Detailed Analysis of OWENS & MINOR, INC. OMI Guru Analysis OMI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORVEL CORPORATION (CRVL) is a mid-cap growth stock in the Healthcare Facilities industry. Detailed Analysis of VERTEX PHARMACEUTICALS INCORPORATED VRTX Guru Analysis VRTX Fundamental Analysis OWENS & MINOR, INC. (OMI) is a small-cap growth stock in the Medical Equipment & Supplies industry. | Detailed Analysis of OWENS & MINOR, INC. OMI Guru Analysis OMI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORVEL CORPORATION (CRVL) is a mid-cap growth stock in the Healthcare Facilities industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. | Detailed Analysis of OWENS & MINOR, INC. OMI Guru Analysis OMI Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis CORVEL CORPORATION (CRVL) is a mid-cap growth stock in the Healthcare Facilities industry. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. |
30940.0 | 2023-06-27 00:00:00 UTC | Abbott (ABT) Stock Sinks As Market Gains: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-sinks-as-market-gains%3A-what-you-should-know-5 | nan | nan | Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day. This change lagged the S&P 500's 1.15% gain on the day. Elsewhere, the Dow gained 0.63%, while the tech-heavy Nasdaq added 7.23%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had gained 5.48% in the past month. In that same time, the Medical sector gained 2.4%, while the S&P 500 gained 3.08%.
Wall Street will be looking for positivity from Abbott as it approaches its next earnings report date. The company is expected to report EPS of $1.04, down 27.27% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $9.67 billion, down 14.08% from the prior-year quarter.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.39 per share and revenue of $39.38 billion. These results would represent year-over-year changes of -17.79% and -9.79%, respectively.
Any recent changes to analyst estimates for Abbott should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. Abbott is currently a Zacks Rank #3 (Hold).
Digging into valuation, Abbott currently has a Forward P/E ratio of 24.74. For comparison, its industry has an average Forward P/E of 24.2, which means Abbott is trading at a premium to the group.
Also, we should mention that ABT has a PEG ratio of 4.86. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.6 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 65, putting it in the top 26% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.39 per share and revenue of $39.38 billion. Also, we should mention that ABT has a PEG ratio of 4.86. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.39 per share and revenue of $39.38 billion. Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day. Also, we should mention that ABT has a PEG ratio of 4.86. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.39 per share and revenue of $39.38 billion. Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day. Also, we should mention that ABT has a PEG ratio of 4.86. | Abbott (ABT) closed at $107.79 in the latest trading session, marking a -0.66% move from the prior day. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.39 per share and revenue of $39.38 billion. Also, we should mention that ABT has a PEG ratio of 4.86. |
30941.0 | 2023-06-27 00:00:00 UTC | Abbott (ABT) EPD Sales Aid Growth Amid Currency Headwind | ABT | https://www.nasdaq.com/articles/abbott-abt-epd-sales-aid-growth-amid-currency-headwind | nan | nan | Abbott’s ABT new product launches and acquisitions are expected to boost its sales. However, the macroeconomic environment continues to be challenging for the business. The stock carries a Zacks Rank #3 (Hold).
Over the past year, Abbott has been outperforming the industry it belongs to. The stock has gained 0.9% against the industry’s 22.7% fall.
Abbott exited the first quarter of 2023 with better-than-expected earnings and revenues. Organic sales growth, excluding COVID testing, increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals Division (EPD) and Nutrition. Within EPD, sales increased 11% in the quarter, led by strong performance in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, central nervous system (CNS) and pain management. EPD continued to witness double-digit sales growth momentum in the last two years.
Within Nutrition, sales increased more than 10%. In the United States, pediatric nutrition growth of more than 35% was driven by favorable year-over-year comparisons (lower sales in the first quarter of 2022 were due to a voluntary recall of certain infant formula products). Abbott continued to make progress, increasing manufacturing production and recovering market share in this business. Internationally, total nutrition sales grew mid-single digits overall. Sales in global adult nutrition also grew in mid-single digits, driven by the strong performance of the company’s market-leading Ensure brand.
Abbott Laboratories Price
Abbott Laboratories price | Abbott Laboratories Quote
Within Diagnostics, excluding COVID testing, organic sales growth was led by mid-to-high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. Despite dull sales in China, Core Lab Diagnostics' sales showed year-over-year improvement, led by strong performance in the United States and Europe.
Within Medical Devices, sales grew 12.5% globally on an organic basis, including mid-teens growth in the United States and double-digit growth internationally. In Diabetes Care, sales of FreeStyle Libre grew more than 25% on an organic basis in the quarter, including approximately 50% growth in the United States and mid-teens growth internationally.
Abbott currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in high-single digits for 2023.
On the flip side, Abbott’s first-quarter worldwide sales were down 18.1% year over year on a reported basis. Total sales were negatively impacted by COVID-19 testing-related sales decline. Diagnostics sales, as forecast, were negatively impacted by a significant decrease in COVID testing sales compared to the first quarter of 2023.
Worldwide COVID-19 testing sales were $730 million in the first quarter compared with $3.3 billion in the year-ago period. Further, in Core Lab Diagnostics, growth was partially offset by soft market conditions in China.
The challenging macroeconomic environment and stubborn inflationary situation severely impacted the company’s profitability in the first quarter. The ongoing inflation situation across the globe is adversely impacting the input cost for Abbott.
Meanwhile, foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has been constantly hampering the company’s performance in the international markets.
In the first quarter, foreign exchange had an unfavorable year-over-year impact of 5.9% on sales. Abbott noted that during the quarter, the strengthening of the U.S. dollar versus several currencies resulted in an unfavorable impact on sales.
Key Picks
Some better-ranked stocks in the overall healthcare sector are Penumbra PEN, Lantheus LNTH and Haemonetics HAE. While Penumbra and Lantheus each sport a Zacks Rank #1 (Strong Buy), Haemonetics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has risen 156.1% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has remained constant at $1.56 for 2023 and $2.56 for 2024 in the past 30 days.
PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have improved 35.6% in the past year against the industry’s 22.4% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Haemonetics’ EPS have increased from $3.43 to $3.55 for 2023 in the past 30 days. Shares of the company have increased 31.3% in the past year against the industry’s 22.4% decline.
HAE’s earnings beat estimates in each of the trailing four quarters, the average surprise being 12.21%. In the last reported quarter, Haemonetics delivered an earnings surprise of 13.24%.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott’s ABT new product launches and acquisitions are expected to boost its sales. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Within EPD, sales increased 11% in the quarter, led by strong performance in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, central nervous system (CNS) and pain management. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT new product launches and acquisitions are expected to boost its sales. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Within Diagnostics, excluding COVID testing, organic sales growth was led by mid-to-high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT new product launches and acquisitions are expected to boost its sales. Abbott Laboratories Price Abbott Laboratories price | Abbott Laboratories Quote Within Diagnostics, excluding COVID testing, organic sales growth was led by mid-to-high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. | Abbott’s ABT new product launches and acquisitions are expected to boost its sales. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report To read this article on Zacks.com click here. Despite dull sales in China, Core Lab Diagnostics' sales showed year-over-year improvement, led by strong performance in the United States and Europe. |
30942.0 | 2023-06-27 00:00:00 UTC | Here's How Much a $1000 Investment in Abbott Made 10 Years Ago Would Be Worth Today | ABT | https://www.nasdaq.com/articles/heres-how-much-a-%241000-investment-in-abbott-made-10-years-ago-would-be-worth-today | nan | nan | For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Abbott (ABT) ten years ago? It may not have been easy to hold on to ABT for all that time, but if you did, how much would your investment be worth today?
Abbott's Business In-Depth
With that in mind, let's take a look at Abbott's main business drivers.
Abbott Park, IL-based Abbott discovers, develops, manufactures and sells a diversified line of health care products.
Established Pharmaceuticals Division (EPD) includes branded generics business in the emerging markets. The division accounted for 10.9% of total sales in 2021 and registered organic growth of 10.4% from 2020.
Medical Devices includes the diabetes care, vision care and vascular businesses and accounted for 33.4% of total sales in 2021 and reported 19.4% rise in organic growth from the year-ago number.
Diagnostics manufactures and markets diagnostic systems and tests in four business lines – core laboratory, molecular, point of care and rapid diagnostics (reflects sales from Alere, which was acquired on Oct. 3, 2017). The division accounted for 36.3% of total sales in 2021, a 42.7% organic growth from 2020.
Nutrition includes a broad line of pediatric and adult nutritional products. The division accounted for 19.3% of total sales in 2021 and registered 7.7% organic growth from the year-ago period.
Abbott has been actively pursuing acquisitions to expand and diversify its portfolio. In 2014, Abbott acquired CFR Pharmaceuticals for $2.9 billion. In Aug 2015, the company acquired Tendyne Holdings, Inc., In Jan 2017, Abbott acquired St. Jude Medical and in October 2017 the company acquired Alere Inc.
On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan in Feb 2015, for 110 million shares of Mylan N.V. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc in Feb 2015. Also the company divested its vision care business, Medical Optics, to Johnson and Johnson for $4.325 billion in cash.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Abbott, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in June 2013 would be worth $3,048.03, or a gain of 204.80%, as of June 27, 2023, according to our calculations. This return excludes dividends but includes price appreciation.
The S&P 500 rose 170% and the price of gold increased 50.92% over the same time frame in comparison.
Analysts are anticipating more upside for ABT.
Abbott exited the first quarter of 2023 with better-than-expected earnings and revenues. Organic sales growth excluding COVID testing increased 10%, led by double-digit growth in Medical Devices, EPD and Nutrition. EPD successfully continued with its double-digit sales growth momentum for the last two years. Medical Device registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. The Diabetes Care business continued to benefit from the growing sales of its sensor-based continuous glucose monitoring system, FreeStyle Libre. Over the past year, Abbott outperformed the industry it belongs to. However, the figures declined on a year-over-year basis. Total sales in the first quarter were negatively impacted by a year-over-year decline in COVID testing-related sales.
The stock is up 5.48% over the past four weeks, and no earnings estimate has gone lower in the past two months, compared to 1 higher, for fiscal 2023. The consensus estimate has moved up as well.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What if you'd invested in Abbott (ABT) ten years ago? It may not have been easy to hold on to ABT for all that time, but if you did, how much would your investment be worth today? Analysts are anticipating more upside for ABT. | What if you'd invested in Abbott (ABT) ten years ago? It may not have been easy to hold on to ABT for all that time, but if you did, how much would your investment be worth today? Analysts are anticipating more upside for ABT. | What if you'd invested in Abbott (ABT) ten years ago? It may not have been easy to hold on to ABT for all that time, but if you did, how much would your investment be worth today? Analysts are anticipating more upside for ABT. | It may not have been easy to hold on to ABT for all that time, but if you did, how much would your investment be worth today? What if you'd invested in Abbott (ABT) ten years ago? Analysts are anticipating more upside for ABT. |
30943.0 | 2023-06-27 00:00:00 UTC | How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings | ABT | https://www.nasdaq.com/articles/how-to-boost-your-portfolio-with-top-medical-stocks-set-to-beat-earnings-25 | nan | nan | Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the metrics and results to consider, earnings is one of the most important.
The earnings figure itself is key, of course, but a beat or miss on the bottom line can sometimes be just as, if not more, important. Therefore, investors should consider paying close attention to these earnings surprises, as a big beat can help a stock climb and vice versa.
Now that we know how important earnings and earnings surprises are, it's time to show investors how to take advantage of these events to boost their returns by utilizing the Zacks Earnings ESP filter.
The Zacks Earnings ESP, Explained
The Zacks Earnings ESP, or Expected Surprise Prediction, aims to find earnings surprises by focusing on the most recent analyst revisions. The basic premise is that if an analyst reevaluates their earnings estimate ahead of an earnings release, it means they likely have new information that could possibly be more accurate.
With this in mind, the Expected Surprise Prediction compares the Most Accurate Estimate (being the most recent) against the overall Zacks Consensus Estimate. The percentage difference provides the ESP figure. The system also utilizes our core Zacks Rank to provide a stronger system for identifying stocks that might beat their next quarterly earnings estimate and possibly see the stock price climb.
In fact, when we combined a Zacks Rank #3 (Hold) or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time. Perhaps most importantly, using these parameters has helped produce 28.3% annual returns on average, according to our 10 year backtest.
Stocks with a ranking of #3 (Hold), or 60% of all stocks covered by the Zacks Rank, are expected to perform in-line with the broader market. Stocks with rankings of #2 (Buy) and #1 (Strong Buy), or the top 15% and top 5% of stocks, respectively, should outperform the market; Strong Buy stocks should outperform more than any other rank.
Should You Consider Baxter International?
The last thing we will do today, now that we have a grasp on the ESP and how powerful of a tool it can be, is to quickly look at a qualifying stock. Baxter International (BAX) holds a #3 (Hold) at the moment and its Most Accurate Estimate comes in at $0.61 a share 30 days away from its upcoming earnings release on July 27, 2023.
Baxter International's Earnings ESP sits at +0.99%, which, as explained above, is calculated by taking the percentage difference between the $0.61 Most Accurate Estimate and the Zacks Consensus Estimate of $0.60. BAX is also part of a large group of stocks that boast a positive ESP. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
BAX is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Abbott (ABT) as well.
Abbott, which is readying to report earnings on July 19, 2023, sits at a Zacks Rank #3 (Hold) right now. It's Most Accurate Estimate is currently $1.04 a share, and ABT is 22 days out from its next earnings report.
For Abbott, the percentage difference between its Most Accurate Estimate and its Zacks Consensus Estimate of $1.04 is +0.21%.
BAX and ABT's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report.
Find Stocks to Buy or Sell Before They're Reported
Use the Zacks Earnings ESP Filter to turn up stocks with the highest probability of positively, or negatively, surprising to buy or sell before they're reported for profitable earnings season trading. Check it out here >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Baxter International Inc. (BAX) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | BAX and ABT's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report. BAX is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Abbott (ABT) as well. It's Most Accurate Estimate is currently $1.04 a share, and ABT is 22 days out from its next earnings report. | Click to get this free report Baxter International Inc. (BAX) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. BAX is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Abbott (ABT) as well. It's Most Accurate Estimate is currently $1.04 a share, and ABT is 22 days out from its next earnings report. | BAX is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Abbott (ABT) as well. It's Most Accurate Estimate is currently $1.04 a share, and ABT is 22 days out from its next earnings report. BAX and ABT's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report. | It's Most Accurate Estimate is currently $1.04 a share, and ABT is 22 days out from its next earnings report. BAX is part of a big group of Medical stocks that boast a positive ESP, and investors may want to take a look at Abbott (ABT) as well. BAX and ABT's positive ESP figures tell us that both stocks have a good chance at beating analyst expectations in their next earnings report. |
30944.0 | 2023-06-26 00:00:00 UTC | Here's Why Investors Should Retain Abbott (ABT) Stock Now | ABT | https://www.nasdaq.com/articles/heres-why-investors-should-retain-abbott-abt-stock-now-1 | nan | nan | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of the continued growth in the Diabetes business. Solid first-quarter 2023 performance buoys optimism. However, forex woes and lower sales impede growth.
In the past year, this Zacks Rank #3 (Hold) stock has gained 0.9% against a 22.7% decline of the industry and a 13.3% rise of the S&P 500 composite.
This renowned provider of a diversified line of healthcare products has a market capitalization of $187.89 billion. The company projects a 5.1% growth for the next five years and expects to maintain its strong performance. Abbott’s earnings surpassed estimates in all of the trailing four quarters, the average surprise being 19.28%.
Let’s delve deeper.
Factors at Play
Q1 Upsides: Abbott exited the first quarter of 2023 with better-than-expected earnings and revenues. Organic sales growth excluding COVID testing increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals and Nutrition. Within EPD, sales increased 11% in the quarter led by strong performance in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management. EPD has been sustaining its double-digit sales growth momentum for the last two years.
Progress With Diabetes Business: This business achieved organic sales growth of 21% in the first quarter of 2023, led by a more than 25% growth in FreeStyle Libre, including approximately 50% growth in the United States and mid-teens internationally. In the quarter, sales of FreeStyle Libre were $1.2 billion. During the quarter, Libre received FDA clearance for connectivity with automated insulin delivery systems. Abbott is currently working with leading insulin pump manufacturers to integrate their systems with Libre 2 and Libre 3.
Image Source: Zacks Investment Research
In a relatively short span, Libre has achieved global leadership among CGM systems for Type 1 and Type 2 users. In 2020, the company received the U.S. approval of Freestyle Libre 2 (an integrated continuous glucose monitoring or iCGM system for adults and children) and CE Mark for Libre 3(integrates Libre's accuracy and performance into the world's smallest fitness disposable sensor) and Libre Sense Glucose Sport (which is Abbott’s initial step in a very intentional approach to pursue mass market biosensor opportunities beyond diabetes).
Upbeat Guidance: Abbott provided its 2023 earnings per share guidance.
Full-year adjusted earnings (excluding specified items of $1.25 per share) are expected in the range of $4.30-$4.50. The current Zacks Consensus Estimate is pegged at $4.36. Abbott projects full-year 2023 organic sales growth, excluding COVID-19 testing-related sales, of at least high-single digits and COVID testing-related sales of around $1.5 billion.
Downsides
Foreign Exchange Translation Impacts Sales: Foreign exchange is a major headwind for Abbott due to considerable percentage of its revenues coming from outside the United States. The strengthening of Euro and some other developed market currencies have been hampering the company’s performance in the international markets.
Lower Sales: Abbott’s first-quarter worldwide sales were down 18.1% year over year on a reported basis. Total sales were affected by COVID-19 testing-related sales decline. Diagnostics’ sales growth, as projected, was dented by a significant decline in COVID testing sales compared with first-quarter 2023 levels.
Estimate Trends
In the past 90 days, the Zacks Consensus Estimate for earnings has moved 0.2% north to $4.39.
The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at $39.38 billion, suggesting a 9.8% decline from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Hologic, Inc. HOLX, Merit Medical Systems, Inc. MMSI and Boston Scientific Corporation BSX.
Hologic, carrying a Zacks Rank #2 (Buy), has an estimated growth rate of 5.1% for fiscal 2024. HOLX’s earnings surpassed estimates in all the trailing four quarters, the average being 27.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Hologic has gained 14% compared with the industry’s 9.4% rise in the past year.
Merit Medical, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
Merit Medical has gained 49.7% compared with the industry’s 17% rise in the past year.
Boston Scientific, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 11.5%. BSX’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 1.9%.
Boston Scientific has gained 42.7% against the industry’s 22.7% decline in the past year.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of the continued growth in the Diabetes business. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. Within EPD, sales increased 11% in the quarter led by strong performance in Brazil, China and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of the continued growth in the Diabetes business. Organic sales growth excluding COVID testing increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals and Nutrition. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of the continued growth in the Diabetes business. Progress With Diabetes Business: This business achieved organic sales growth of 21% in the first quarter of 2023, led by a more than 25% growth in FreeStyle Libre, including approximately 50% growth in the United States and mid-teens internationally. | Abbott Laboratories ABT is well-poised for growth in the coming quarters, courtesy of the continued growth in the Diabetes business. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report To read this article on Zacks.com click here. Progress With Diabetes Business: This business achieved organic sales growth of 21% in the first quarter of 2023, led by a more than 25% growth in FreeStyle Libre, including approximately 50% growth in the United States and mid-teens internationally. |
30945.0 | 2023-06-26 00:00:00 UTC | The Health Care Select Sector SPDR Fund Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/the-health-care-select-sector-spdr-fund-experiences-big-outflow-1 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $198.0 million dollar outflow -- that's a 0.5% decrease week over week (from 310,420,000 to 308,920,000). Among the largest underlying components of XLV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.7%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average:
Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $130.78. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
PX Historical Stock Prices
Top Ten Hedge Funds Holding DGNU
Top Ten Hedge Funds Holding CTSO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of XLV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.7%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $198.0 million dollar outflow -- that's a 0.5% decrease week over week (from 310,420,000 to 308,920,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of XLV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.7%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.8%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $130.78. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of XLV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.7%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $198.0 million dollar outflow -- that's a 0.5% decrease week over week (from 310,420,000 to 308,920,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $130.78. | Among the largest underlying components of XLV, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.7%, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Danaher Corp (Symbol: DHR) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $198.0 million dollar outflow -- that's a 0.5% decrease week over week (from 310,420,000 to 308,920,000). For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $119.95 per share, with $141.77 as the 52 week high point — that compares with a last trade of $130.78. |
30946.0 | 2023-06-25 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-24 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top NASDAQ 100 Stocks
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
High Shareholder Yield Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30947.0 | 2023-06-23 00:00:00 UTC | Abbott (ABT) Just Overtook the 50-Day Moving Average | ABT | https://www.nasdaq.com/articles/abbott-abt-just-overtook-the-50-day-moving-average | nan | nan | Abbott (ABT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ABT broke out above the 50-day moving average, suggesting a short-term bullish trend.
The 50-day simple moving average is a widely used technical indicator that helps determine support or resistance levels for different types of securities. It's one of three major moving averages, but takes precedent because it's the first sign of an up or down trend.
ABT could be on the verge of another rally after moving 6% higher over the last four weeks. Plus, the company is currently a Zacks Rank #3 (Hold) stock.
The bullish case only gets stronger once investors take into account ABT's positive earnings estimate revisions. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well.
Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on ABT for more gains in the near future.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on ABT for more gains in the near future. Abbott (ABT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ABT broke out above the 50-day moving average, suggesting a short-term bullish trend. | The bullish case only gets stronger once investors take into account ABT's positive earnings estimate revisions. Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on ABT for more gains in the near future. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Given this move in earnings estimate revisions and the positive technical factor, investors may want to keep their eye on ABT for more gains in the near future. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. | The bullish case only gets stronger once investors take into account ABT's positive earnings estimate revisions. Abbott (ABT) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ABT broke out above the 50-day moving average, suggesting a short-term bullish trend. |
30948.0 | 2023-06-22 00:00:00 UTC | Will Abbott Stock Rebound To Its 2022 Highs? | ABT | https://www.nasdaq.com/articles/will-abbott-stock-rebound-to-its-2022-highs | nan | nan | Abbott stock (NYSE: ABT) currently trades at $106 per share, over 10% below its level in March 2021, and it has the potential for sizable gains. Abbott saw its stock trading at around $109 in late June 2022, just before the Fed started increasing rates, and is marginally below that level. The stock has gained 10% since September 2022 compared to the S&P 500, which gained about 23% during this period. The rise in ABT stock over the recent past can be attributed to an expected uptick in total procedures volume, aiding its medical devices business. Recently, UnitedHealth’s management stated that their medical costs may be high in the near term as more elective procedures are being performed. Still, ABT stock has underperformed in the broader markets in recent months. This can be attributed to rising concerns about a potential recession and its impact on Abbott’s businesses. The decline in Abbott’s revenues over recent quarters has also contributed to the stock’s underperformance. The U.S. FTC is also investigating Abbott along with a few other companies that make baby formula for collusion to win state contracts.
Returning to the pre-inflation shock level of $141 means that ABT stock will have to gain 33% from here. However, we do not believe that will materialize any time soon and estimate Abbott’s valuation to be around $122 per share, implying about 15% gains. This is because of a decline in sales and earnings in the near term after a pickup in the diagnostics business during the pandemic. Abbott’s operating margin has contracted from 19.6% in 2021 to 16.8% now. Our Abbott Operating Income Comparison dashboard has more details. Still, from a valuation perspective, ABT stock appears to have room for growth from its current level of $106.
Our detailed analysis of Abbott’s upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022. It compares these trends to the stock’s performance during the 2008 recession.
2022 Inflation Shock
Timeline of Inflation Shock So Far:
2020 – early 2021: Increase in money supply to cushion the impact of lockdowns led to high demand for goods; producers unable to match up.
Early 2021: Shipping snarls and worker shortages from the coronavirus pandemic continue to hurt the supply
April 2021: Inflation rates cross 4% and increase rapidly
Early 2022: Energy and food prices spike due to the Russian invasion of Ukraine. Fed begins its rate hike process
June 2022: Inflation levels peak at 9% – the highest level in 40 years. S&P 500 index declines more than 20% from peak levels.
July – September 2022: Fed hikes interest rates aggressively – resulting in an initial recovery in the S&P 500 followed by another sharp decline
Since October 2022: Fed continues rate hike process; improving market sentiments help S&P500 recoup some of its losses.
In contrast, here’s how ABT stock and the broader market performed during the 2007/2008 crisis.
Timeline of 2007-08 Crisis
10/1/2007: Approximate pre-crisis peak in S&P 500 index
9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08)
3/1/2009: Approximate bottoming out of S&P 500 index
12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008)
ABT and S&P 500 Performance During 2007-08 Crisis
ABT stock rose from $26 in September 2007 to $28 in August 2008 (pre-crisis peak) before falling to around $22 in March 2009 (as the markets bottomed out), implying ABT stock lost nearly 20% of its pre-crisis value. It recovered post the 2008 crisis to levels of around $26 in early 2010, rising 14% between March 2009 and January 2010. The S&P 500 Index saw a decline of 51%, falling from levels of 1,540 in September 2007 to 757 in March 2009. It then rallied 48% between March 2009 and January 2010 to reach levels of 1,124.
ABT Fundamentals Over Recent Years
ABT revenues rose from $31.9 billion in 2019 to $43.7 billion in 2022, as the Covid-19 outbreak resulted in very high demand for testing, driving the company’s diagnostics business. Revenues declined gradually over the recent quarters reaching $41.5 billion in the last twelve months amid falling demand for Covid-19 testing. Abbott’s reported earnings increased from $2.07 in 2019 to $3.94 in 2022 due to higher revenues and operating margin expansion. Looking forward, diagnostics revenues are expected to see a decline in the near term, while the company’s other businesses, including medical devices and established pharmaceuticals, will likely see steady growth.
Does Abbott Have A Sufficient Cash Cushion To Meet Its Obligations Through The Ongoing Inflation Shock?
Abbott’s total debt decreased from $18 billion in 2019 to $17 billion in 2022, while its total cash increased from around $4 billion to $10 billion over the same period. The company garnered $10 billion in cash flows from operations in 2022. Given its solid cash position, Abbott appears to be in a comfortable position to meet its near-term obligations.
Conclusion
With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Abbott (ABT) stock has the potential for solid gains once fears of a potential recession are allayed. That said, the fading demand for Covid-19 testing resulting in near-term revenue headwinds remains a risk factor to realizing these gains.
While ABT stock looks like it can see some gains, it is helpful to see how Abbott’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Furthermore, the Covid-19 crisis has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Proto Labs vs. Abbott.
With inflation rising and the Fed raising interest rates, among other factors, ABT stock has fallen 3% this year. Can it drop more? See how low Abbott stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Returns Jun 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
ABT Return 4% -3% 176%
S&P 500 Return 5% 15% 97%
Trefis Multi-Strategy Portfolio 7% 17% 267%
[1] Month-to-date and year-to-date as of 6/20/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The rise in ABT stock over the recent past can be attributed to an expected uptick in total procedures volume, aiding its medical devices business. Abbott stock (NYSE: ABT) currently trades at $106 per share, over 10% below its level in March 2021, and it has the potential for sizable gains. Still, ABT stock has underperformed in the broader markets in recent months. | Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) ABT and S&P 500 Performance During 2007-08 Crisis ABT stock rose from $26 in September 2007 to $28 in August 2008 (pre-crisis peak) before falling to around $22 in March 2009 (as the markets bottomed out), implying ABT stock lost nearly 20% of its pre-crisis value. Conclusion With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Abbott (ABT) stock has the potential for solid gains once fears of a potential recession are allayed. Abbott stock (NYSE: ABT) currently trades at $106 per share, over 10% below its level in March 2021, and it has the potential for sizable gains. | Abbott stock (NYSE: ABT) currently trades at $106 per share, over 10% below its level in March 2021, and it has the potential for sizable gains. Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) ABT and S&P 500 Performance During 2007-08 Crisis ABT stock rose from $26 in September 2007 to $28 in August 2008 (pre-crisis peak) before falling to around $22 in March 2009 (as the markets bottomed out), implying ABT stock lost nearly 20% of its pre-crisis value. Conclusion With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Abbott (ABT) stock has the potential for solid gains once fears of a potential recession are allayed. | Abbott stock (NYSE: ABT) currently trades at $106 per share, over 10% below its level in March 2021, and it has the potential for sizable gains. Returning to the pre-inflation shock level of $141 means that ABT stock will have to gain 33% from here. ABT Fundamentals Over Recent Years ABT revenues rose from $31.9 billion in 2019 to $43.7 billion in 2022, as the Covid-19 outbreak resulted in very high demand for testing, driving the company’s diagnostics business. |
30949.0 | 2023-06-21 00:00:00 UTC | DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth | ABT | https://www.nasdaq.com/articles/dexcom-clears-base-wall-street-eyes-double-digit-earnings-growth | nan | nan | You generally associate Super Bowl commercials with products made by PepsiCo Inc. (NYSE: PEP) or the Coca-Cola Co. (NYSE: KO), but earlier this year, glucose-monitoring geat maker DexCom Inc. (NASDAQ: DXCM) forked over some bucks to advertise its G7 sensors.
Pop singer Nick Jonas, a paid DexCom spokesperson, appeared in the Super Bowl ad, as well as in other corporate marketing campaigns.
DexCom is moving into the forefront in other ways. Its stock recently cleared a price consolidation above a $126.54 buy point. You can see the stock’s recent base and breakout using MarketBeat’s DexCom chart.
Shares are trading at their best levels in over a year, with upside volume heavy in the past several weeks, a good indication of institutional buying.
Earnings Rebound
Analysts are eyeing strong double-digit earnings increases this year and next. Earnings growth rebounded last year, after decreasing in 2021, although the company has been profitable every year since 2018.
As DexCom is essentially a technology company in the healthcare industry, it’s in fast growth mode. That means there’s no dividend, and the company says it does not intend to pay dividends for the foreseeable future.
“We currently intend to retain any future earnings to finance the operation and expansion of our business,” it said in regulatory filings, adding, “As a result, stockholders … may only receive a return on their investment in our common stock if the market price of our common stock increases.”
That’s the company throwing down and raising the stakes, acknowledging that it will only reward shareholders with price appreciation, not reward share owners with that comfortable, cozy feeling of getting a dividend payout, even when the stock’s price languishes.
Double-Digit Revenue Growth
In the past eight quarters, DexCom revenue grew at rates between 17% and 32%.
DexCom is one of several large-cap price leaders within the medical device industry. Fellow S&P 500 components with good recent price gains include Medtronic plc (NYSE: MDT), Stryker Corp. (NYSE: SYK), Boston Scientific Corp. (NYSE: BSX), and Zimmer Biomet Holdings Inc. (NYSE: ZBH)
Using MarketBeat’s DexCom analyst ratings, you can see that five analysts boosted their price targets on DexCom after the company’s most recent earnings report on April 27.
The DexCom G7 Super Bowl ad highlighted the company’s innovative solution for diabetes management, eliminating the need to draw blood from fingers. With readings sent directly to smartphones or smartwatches, the real-time continuous glucose management system is an advancement in diabetes care.
Doubled Prescriber And Patient Base
In a recent investors’ presentation, the company touted some of its recent growth initiatives. In the past two years, the company doubled its total primary care prescriber base, along with the average number of monthly new patients starting in primary care.
Those are significant growth metrics.
The stock got a large boost in early March, after the Centers for Medicare and Medicaid Services approved expanded coverage for CGM products to a wider group of type 2 diabetics. Now, patients who don't require insulin treatment and those with low blood sugar qualify for reimbursements. That shift resulted in a larger market of potential users, as it now includes the majority of U.S. diabetes patients.
DexCom says its CGM competitors include the Diabetes Care division of Abbott Laboratories (NYSE: ABT), Medtronic’s Diabetes Group; Roche Holding AG’s (OTCMKTS: RHHVF) Diabetes Care unit, and privately-held LifeScan and Ascensia DiabetesCare. Collectively, these companies currently account for the majority of the worldwide sales of self-monitored glucose testing systems, DexCom says.
Company Aiming For More Growth
It’s pretty obvious that continued innovation and expanding the customer base are the keys to DexCom’s continued growth. In its investors’ presentation, the company said it’s aiming to make inroads in several additional patient markets, including:
Type 2 Non-Insulin
Pre-Diabetes
Gestational Diabetes
Patient Monitoring
Health & Wellness
DexCom shares are currently in the buy range after clearing the $126.54 buy point. However, the broader market was showing weakness in the June 16 and June 20 sessions, and the stock moved slightly lower in after-hours trading on June 20.
That’s not to say the market is going into a correction, but a pullback may be near, meaning investors should use some extra caution when considering the addition of any stock at this time.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | DexCom says its CGM competitors include the Diabetes Care division of Abbott Laboratories (NYSE: ABT), Medtronic’s Diabetes Group; Roche Holding AG’s (OTCMKTS: RHHVF) Diabetes Care unit, and privately-held LifeScan and Ascensia DiabetesCare. Pop singer Nick Jonas, a paid DexCom spokesperson, appeared in the Super Bowl ad, as well as in other corporate marketing campaigns. The DexCom G7 Super Bowl ad highlighted the company’s innovative solution for diabetes management, eliminating the need to draw blood from fingers. | DexCom says its CGM competitors include the Diabetes Care division of Abbott Laboratories (NYSE: ABT), Medtronic’s Diabetes Group; Roche Holding AG’s (OTCMKTS: RHHVF) Diabetes Care unit, and privately-held LifeScan and Ascensia DiabetesCare. Doubled Prescriber And Patient Base In a recent investors’ presentation, the company touted some of its recent growth initiatives. In the past two years, the company doubled its total primary care prescriber base, along with the average number of monthly new patients starting in primary care. | DexCom says its CGM competitors include the Diabetes Care division of Abbott Laboratories (NYSE: ABT), Medtronic’s Diabetes Group; Roche Holding AG’s (OTCMKTS: RHHVF) Diabetes Care unit, and privately-held LifeScan and Ascensia DiabetesCare. “We currently intend to retain any future earnings to finance the operation and expansion of our business,” it said in regulatory filings, adding, “As a result, stockholders … may only receive a return on their investment in our common stock if the market price of our common stock increases.” That’s the company throwing down and raising the stakes, acknowledging that it will only reward shareholders with price appreciation, not reward share owners with that comfortable, cozy feeling of getting a dividend payout, even when the stock’s price languishes. Fellow S&P 500 components with good recent price gains include Medtronic plc (NYSE: MDT), Stryker Corp. (NYSE: SYK), Boston Scientific Corp. (NYSE: BSX), and Zimmer Biomet Holdings Inc. (NYSE: ZBH) Using MarketBeat’s DexCom analyst ratings, you can see that five analysts boosted their price targets on DexCom after the company’s most recent earnings report on April 27. | DexCom says its CGM competitors include the Diabetes Care division of Abbott Laboratories (NYSE: ABT), Medtronic’s Diabetes Group; Roche Holding AG’s (OTCMKTS: RHHVF) Diabetes Care unit, and privately-held LifeScan and Ascensia DiabetesCare. Fellow S&P 500 components with good recent price gains include Medtronic plc (NYSE: MDT), Stryker Corp. (NYSE: SYK), Boston Scientific Corp. (NYSE: BSX), and Zimmer Biomet Holdings Inc. (NYSE: ZBH) Using MarketBeat’s DexCom analyst ratings, you can see that five analysts boosted their price targets on DexCom after the company’s most recent earnings report on April 27. In its investors’ presentation, the company said it’s aiming to make inroads in several additional patient markets, including: Type 2 Non-Insulin Pre-Diabetes Gestational Diabetes Patient Monitoring Health & Wellness DexCom shares are currently in the buy range after clearing the $126.54 buy point. |
30950.0 | 2023-06-21 00:00:00 UTC | Surmodics (SRDX) Rallies on FDA Approval for SurVeil DCB | ABT | https://www.nasdaq.com/articles/surmodics-srdx-rallies-on-fda-approval-for-surveil-dcb | nan | nan | Surmodics, Inc. SRDX announced that the FDA has approved its new medical device — SurVeil drug-coated balloon (DCB). The SurVeil DCB will now be available in the United States to treat percutaneous transluminal angioplasty in patients with peripheral artery disease (PAD). The device is threaded into a blood vessel, which is then inflated to open blocked or narrowed areas in the same.
The approval is based on data from a 24-month pivotal clinical study that evaluated SurVeil DCB for non-inferiority to Medtronic’s MDT IN.PACT Admiral DCB. Data from the study demonstrated the sustained durability of SurVeil DCB for safety and effectiveness that was non-inferior to MDT’s IN.PACT Admiral DCB.
Almost 81.8% of patients treated with SurVeil DCB attained freedom from device and procedure-related death as well as major target limb amputation compared to 83.2% of those treated with IN.PACT Admiral DCB. Less than 15% of patients needed repeat revascularization procedures for both DCBs.
It’s important to note that while both SurVeil DCB and IN.PACT Admiral DCB use paclitaxel drug coatings, the latter has a 75% higher drug load of paclitaxel compared with the former.
Medtronic’s IN.PACT Admiral DCB is being used for treating percutaneous transluminal angioplasty for several years. The device is also a market leader in its category in certain regions, especially Europe. A non-inferior study result for SurVeil DCB, with a substantially lower drug dose, should help in overcoming competition from IN.PACT Admiral DCB.
Price Performance
Shares of Surmodics rallied 16.1% on Jun 20, following the FDA approval for SurVeil DCB. Surmodics stock has lost 18.2% in the past year compared with the industry’s 20.4% decline. The S&P 500 Index has risen 17% in the same time frame.
Image Source: Zacks Investment Research
FDA Review History
SRDX completed submission of a pre-market approval (PMA) application to the FDA for SurVeil DCB in 2021. In January, the company announced a negative regulatory outcome. It stated that the FDA rejected the PMA application, requesting additional biocompatibility and labeling. The adverse regulatory outcome had an unfavorable impact on the company’s business outlook, leading to several layoffs.
Although Surmodics adopted several cost-cutting measures following this setback, it was in discussion with the FDA for regulatory pathway for a potential approval for SurVeil DCB. In March, the company received formal feedback from the FDA related to its proposed approach to submit a PMA application.
Based on the regulatory authority’s feedback, Surmodics submitted an amended PMA application during the third quarter of fiscal 2023. The approval came earlier than the scheduled time, which was in the fourth quarter of fiscal 2023 (September end).
Please note that SurVeil DCB is already approved in Europe for similar indication since 2020.
Commercialization Plan
Surmodics has a deal in place with Abbott Laboratories ABT for commercialization of SurVeil DCB. Per the terms of the agreement, Abbott has exclusive worldwide commercialization rights for SRDX’s DCB.
SRDX is responsible for manufacturing and supply of the product to Abbott. It will also record these sales as product revenues. The company will receive a share of profit on third-party sales made by ABT.
Per the deal, Surmodics is eligible to receive a milestone payment of $27 million from Abbott, following the FDA approval for SurVeil DCB. SRDX expects revenues in the range of $24.0-$24.5 million related to the milestone payment in the third quarter.
Industry Prospects
Per a report by InsightAce Analytics, the DCB market was valued at $600.3 million in 2019 and is anticipated to grow at a CAGR of 16.7% during 2020-2028. According to the same report, application of DCBs for treating PAD patients is likely to almost double by 2030 from the 2021 level.
Factors like the prevalence of peripheral and coronary artery diseases, and growth in demand for minimally invasive procedures are likely to drive the market.
Given the market potential, the latest regulatory clearance raises optimism for Surmodics.
Notable Development
Earlier this month, Surmodics announced its receipt of the FDA’s 510(k) clearance for its Pounce LP (Low Profile) Thrombectomy System. The company expects to initiate limited market evaluation (LME) for the Pounce LP Thrombectomy System by the end of the first quarter of fiscal 2024.
SRDX is planning the commercialization of SurVeil DCB, following the completion of the LME. The Pounce Thrombectomy System was intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature in 3.5-6 mm thick vessels.
In April, Surmodics reported fiscal second-quarter 2023 results, wherein it experienced a solid uptick in the overall top line. The company registered robust revenues from its Medical Device segment. It also recorded growth in Product sales, and Research, development and other revenues.During the quarter, Surmodics saw strong contributions from sales of its Pounce and Sublime products, indicating their continued solid demand.
The same month, the company announced the enrollment of the first patient in PROWL, the Pounce Thrombectomy System Retrospective Registry. PROWL is an open-label, retrospective, multi-center U.S. registry of the Surmodics Pounce system for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.
Also, in April, Surmodics announced the first usage of the company’s Sublime radial access microcatheter, which is currently in limited market evaluation. The full suite of Sublime microcatheters will be launched in fiscal 2024.
Surmodics, Inc. Price
Surmodics, Inc. price | Surmodics, Inc. Quote
Zacks Rank & Another Stock to Consider
Currently, Surmodics carries a Zacks Rank #2 (Buy).
Another top-ranked stock in the broader medical space is Haemonetics HAE, sporting a Zacks Rank #1 (Strong Buy) at present. Haemonetics has an estimated growth rate of 5.1% for fiscal 2024. HAE’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 27.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ shares have risen 37.9% in the past year against the industry’s 20.4% decline.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Commercialization Plan Surmodics has a deal in place with Abbott Laboratories ABT for commercialization of SurVeil DCB. The company will receive a share of profit on third-party sales made by ABT. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Commercialization Plan Surmodics has a deal in place with Abbott Laboratories ABT for commercialization of SurVeil DCB. The company will receive a share of profit on third-party sales made by ABT. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Commercialization Plan Surmodics has a deal in place with Abbott Laboratories ABT for commercialization of SurVeil DCB. The company will receive a share of profit on third-party sales made by ABT. | Commercialization Plan Surmodics has a deal in place with Abbott Laboratories ABT for commercialization of SurVeil DCB. The company will receive a share of profit on third-party sales made by ABT. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Surmodics, Inc. (SRDX) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30951.0 | 2023-06-21 00:00:00 UTC | Agilent Technologies Stock: Ready to Rise off the Floor | ABT | https://www.nasdaq.com/articles/agilent-technologies-stock%3A-ready-to-rise-off-the-floor | nan | nan | Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down 19% year-to-date. Agilent is a leading global provider of laboratory technologies and equipment.
It counts some of the most well-known biotechnology, healthcare, diagnostic and applied materials companies in the world as clients, including Abbott Laboratories (NYSE: ABT), Thermo Fisher Scientific Inc. (NYSE: TMO) and Roche Holding AG (OTCMKTS: RHHBY). While shares were punished for their lowered guidance, the company is still very profitable. The company has stated that has seen longer sales cycles, especially with startup biotechs tightening their wallets in the uncertain macroeconomic climate.
Core Growth
On May 23, Agilent released its fiscal second-quarter 2023 results for the quarter ending April 2023. The company reported a non-GAAP earnings-per-share (EPS) profit of $1.27 versus consensus analyst estimates of $1.26, beating estimates by one cent. GAAP net income was $302 million, up from $274 million in the year-ago period. Revenues rose 6.8% year-over-year (YoY) to $1.72 billion, beating analyst estimates of $1.67 billion. Revenues were up 9.5% core with growth across all end markets and regions.
Revenues by Segment
Agilent has several divisions focused on each respective product and service. Its life sciences and applied markets group (LSAG) grew 8% year-over-year (YoY) revenue to $968 million. The operating margin was 27.3%. This division provides instruments and services to enable researchers and scientists to perform life science applications like DNA sequencing, metabolomics and protein analysis. It also provides products for applied markets like food safety, forensics and environmental testing.
Its Agilent cross-lab group (ACG) segment saw 10% YoY revenue growth with 26.6% operating margins. This division provides equipment, instruments, software and services to laboratories in various industries, including healthcare, pharmaceuticals, food and beverage, environmental and forensics.
Its diagnostics and genome group (DGG) had a 1% YoY revenue increase to $362 million and a 20.2% operating margin. This division provides products and services for clients to perform clinical diagnostics and genomic research.
Cutting Down Guidance
Agilent issues downside guidance for fiscal quarter three 2023 EPS between $1.36 to $1.38 versus $1.44 consensus analyst estimates. Revenues are expected between $1.64 billion to $1.77 billion versus $1.77 billion. Fiscal full-year 2023 EPS is expected between $5.60 to $5.65 versus $5.69 consensus analyst estimates on revenues between $6.93 billion to $7.03 billion versus $7.09 billion consensus analyst estimates.
Analysts Piling into the Clown Car
At least 10 analysts reiterated their existing ratings and lowered price targets. Key Banc lowered its analyst rating to "sector weight" from "overweight."
Key Banc’s analyst Paul Knight commented that the company's emerging biotech (3% of historical revenue) was at zero level of activity while large biopharma (33% of revenue) was more conservative on spending. Agilent cited no slowdown in its bioprocess business and more normalized China growth. He explained that a recovery needed in margins and a lack of revenue catalysts in the back half the analyst downgraded Agilent to "sector weight."
You can find Agilent Technologies analyst ratings and price targets on MarketBeat.
Weekly Descending Triangle
The weekly candlestick chart illustrates a weekly triangle with a clear descending trendline and flat-bottom trendline at $113.28. The triangle commenced after peaking at $159.33 in January and selling off, making lower highs on the descending trendline. A fell to a low of $113.28 in May. Shares continued to fall, forming consecutive lower-body lows.
A weekly market structure low (MSL) trigger forms on a breakout through $122.22. The weekly RSI is bouncing off the oversold 30-band indicating the weekly reversal in momentum back to the upside. The weekly 20-period exponential moving average (EMA) resistance falls at $131.64, followed by the weekly 50-period MA at $136.75. Pullback support levels are at $117.51, $115.51, $113.28 triangle low and $110.65.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It counts some of the most well-known biotechnology, healthcare, diagnostic and applied materials companies in the world as clients, including Abbott Laboratories (NYSE: ABT), Thermo Fisher Scientific Inc. (NYSE: TMO) and Roche Holding AG (OTCMKTS: RHHBY). This division provides instruments and services to enable researchers and scientists to perform life science applications like DNA sequencing, metabolomics and protein analysis. This division provides equipment, instruments, software and services to laboratories in various industries, including healthcare, pharmaceuticals, food and beverage, environmental and forensics. | It counts some of the most well-known biotechnology, healthcare, diagnostic and applied materials companies in the world as clients, including Abbott Laboratories (NYSE: ABT), Thermo Fisher Scientific Inc. (NYSE: TMO) and Roche Holding AG (OTCMKTS: RHHBY). The company reported a non-GAAP earnings-per-share (EPS) profit of $1.27 versus consensus analyst estimates of $1.26, beating estimates by one cent. Cutting Down Guidance Agilent issues downside guidance for fiscal quarter three 2023 EPS between $1.36 to $1.38 versus $1.44 consensus analyst estimates. | It counts some of the most well-known biotechnology, healthcare, diagnostic and applied materials companies in the world as clients, including Abbott Laboratories (NYSE: ABT), Thermo Fisher Scientific Inc. (NYSE: TMO) and Roche Holding AG (OTCMKTS: RHHBY). Revenues rose 6.8% year-over-year (YoY) to $1.72 billion, beating analyst estimates of $1.67 billion. Fiscal full-year 2023 EPS is expected between $5.60 to $5.65 versus $5.69 consensus analyst estimates on revenues between $6.93 billion to $7.03 billion versus $7.09 billion consensus analyst estimates. | It counts some of the most well-known biotechnology, healthcare, diagnostic and applied materials companies in the world as clients, including Abbott Laboratories (NYSE: ABT), Thermo Fisher Scientific Inc. (NYSE: TMO) and Roche Holding AG (OTCMKTS: RHHBY). Its life sciences and applied markets group (LSAG) grew 8% year-over-year (YoY) revenue to $968 million. Its Agilent cross-lab group (ACG) segment saw 10% YoY revenue growth with 26.6% operating margins. |
30952.0 | 2023-06-21 00:00:00 UTC | Validea's Top 5 Health Care Stocks Based On Peter Lynch - 6/21/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-peter-lynch-6-21-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Peter Lynch is 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Integra LifeSciences Holdings Corporation is a medical technology company. The Company operates through two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS segment consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield and Bactiseal. Its product offering includes CereLink in the Unites States and Europe. The Company's TT segment focuses on three areas, which include complex wound surgery, surgical reconstruction and peripheral nerve repair. TT's regenerative platform includes multiple brands, such as Integra Dermal Matrices, AmnioExcel, SurgiMend, MicroMatrix and NeuraGen. The Company's manufacturing and research facilities are located in California, Indiana, Maryland, Massachusetts, New Jersey, Ohio, Puerto Rico, Tennessee, Utah, France, Germany, Ireland and Switzerland.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of INTEGRA LIFESCIENCES HOLDINGS CORP
IART Guru Analysis
IART Fundamental Analysis
AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. The rating according to our strategy based on Peter Lynch is 72% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution services company. The Company's U.S. Healthcare Solutions segment distributes an offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services. This segment consists of Alliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on specialty services and a global platform of pharma manufacturer services capabilities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: FAIL
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of AMERISOURCEBERGEN CORP.
ABC Guru Analysis
ABC Fundamental Analysis
AGENUS INC (AGEN) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Peter Lynch is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. The Company is focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company's antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of AGENUS INC
AGEN Guru Analysis
AGEN Fundamental Analysis
MIMEDX GROUP INC (MDXG) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Peter Lynch is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. The Company is focused on addressing unmet clinical needs in the areas of Advanced Wound Care, Surgical Recovery, and osteoarthritis. The Company operates through two segments: Wound and Surgical, and Regenerative Medicine. The Wound and Surgical segment focuses on the Advanced Wound Care and Surgical Recovery markets. Its platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc. The Regenerative Medicine segment focuses solely on Regenerative Medicine technologies. The Company's product portfolio and pipeline include EPIFIX, AMNIOFIX, mDHACM, AMNIOBURN, EPICORD and AMNIOCORD, AXIOFILL, and AMNIOEFFECT.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of MIMEDX GROUP INC
MDXG Guru Analysis
MDXG Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. Detailed Analysis of INTEGRA LIFESCIENCES HOLDINGS CORP IART Guru Analysis IART Fundamental Analysis AMERISOURCEBERGEN CORP. (ABC) is a large-cap growth stock in the Major Drugs industry. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. | ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis INTEGRA LIFESCIENCES HOLDINGS CORP (IART) is a mid-cap growth stock in the Scientific & Technical Instr. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. |
30953.0 | 2023-06-21 00:00:00 UTC | Abbott (ABT) Stock Moves -0.42%: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-stock-moves-0.42%3A-what-you-should-know | nan | nan | Abbott (ABT) closed at $106.25 in the latest trading session, marking a -0.42% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.53%.
Heading into today, shares of the maker of infant formula, medical devices and drugs had gained 0.91% over the past month, outpacing the Medical sector's gain of 0.15% and lagging the S&P 500's gain of 4.86% in that time.
Abbott will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $1.05, down 26.57% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $9.67 billion, down 14.08% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.39 per share and revenue of $39.38 billion. These totals would mark changes of -17.79% and -9.79%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Abbott. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.07% higher. Abbott is holding a Zacks Rank of #3 (Hold) right now.
In terms of valuation, Abbott is currently trading at a Forward P/E ratio of 24.33. This represents a discount compared to its industry's average Forward P/E of 24.53.
Investors should also note that ABT has a PEG ratio of 4.78 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.62 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 65, putting it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $106.25 in the latest trading session, marking a -0.42% move from the prior day. Investors should also note that ABT has a PEG ratio of 4.78 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $106.25 in the latest trading session, marking a -0.42% move from the prior day. Investors should also note that ABT has a PEG ratio of 4.78 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $106.25 in the latest trading session, marking a -0.42% move from the prior day. Investors should also note that ABT has a PEG ratio of 4.78 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $106.25 in the latest trading session, marking a -0.42% move from the prior day. Investors should also note that ABT has a PEG ratio of 4.78 right now. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30954.0 | 2023-06-20 00:00:00 UTC | 3 Passive Income Stocks to Hold for the Next 20 Years | ABT | https://www.nasdaq.com/articles/3-passive-income-stocks-to-hold-for-the-next-20-years-1 | nan | nan | Receiving dividends from your stocks is one of the nicest rewards you can experience. Dividends not only represent a tangible return on your investment but also act as a stream of passive income that goes straight into your bank account. Fortunately, many stocks dole out a dividend every quarter, and accumulating a portfolio of such companies means you'll receive a regular stream of additional income every three months.
One important factor in looking for suitable dividend stocks is the sustainability of the dividend. The business should be backed by a strong competitive moat that helps it generate healthy profits and free cash flow. In turn, this increase in cash flow will lead to ever-increasing levels of dividends over the years. By owning such stocks, you can enjoy a steadily rising flow of dividends that help to more than offset the effects of inflation.
Here are three attractive stocks that can supply you with a dependable stream of passive income over the next two decades.
Image source: Getty Images.
Abbott Labs
Abbott Laboratories (NYSE: ABT) is a healthcare company with a wide portfolio of products spanning the diagnostics, medical devices, and nutrition segments. The business has been improving the lives of its customers for 135 years in the areas of diabetes care, cardiovascular care, and the treatment of chronic pain, to name a few.
The company has reported steadily improving financials over the past three years, with revenue rising from $34.6 billion in 2020 to $43.7 billion in 2022. Net income climbed from $4.5 billion to $6.9 billion over the same period, and the company generated an average free cash flow of $7.4 billion over the three years.
The good performance carried into the first quarter of the current fiscal year. Organic sales growth (less COVID-19-related revenue) rose 10% year over year, led by the company's medical devices, pharmaceuticals and nutrition units.
Abbott Labs feels confident about 2023 and has raised its outlook for the year to high-single-digit year-over-year organic sales growth. What's more impressive is that the company has increased its dividend without fail over the past 51 years, making it a Dividend King.
The company's dividend track record can likely continue. It has bulked up its vascular disease treatment portfolio with the recent acquisition of Cardiovascular Systems for approximately $890 million. Just last month, the medical devices company received approval for two new products: the world's first ablation catheter to treat patients with atrial fibrillation and an insertable cardiac monitor to provide continuous monitoring for abnormal heart rhythms.
In addition, the company also announced a series of partnerships and collaborations to increase diversity in clinical trials and help advance its research on new drugs and devices.
Nike
Nike (NYSE: NKE) is well-known for its sports footwear and apparel, which has garnered a worldwide following and engendered strong customer loyalty. The company has posted healthy growth since pandemic-related restrictions were lifted, with revenue rising sharply from $37.4 billion in fiscal 2020 to $46.7 billion in 2022. Net income surged from just $2.5 billion to $6 billion over the same period, demonstrating the resilience of its business model.
Revenue for the first nine months of fiscal 2023 continued to rise 11% year over year to $38.4 billion, but net income saw a 12% year-over-year fall, due to higher expenses and supply-chain bottlenecks. Despite the lower profit, Nike continued to generate healthy free cash flow over all the periods mentioned.
Dividends have been on an unbroken upward trajectory for the past 15 years, rising sevenfold from a quarterly $0.046 in 2007 to $0.34 in 2023. There's reason to believe Nike can continue to deliver, as its Consumer Direct Acceleration strategy helps it to tap into customer insights to increase engagement and deliver the right products to consumers amid changing preferences.
Nike also has an innovative culture that saw the introduction of new running shoes, such as the Invincible 3 and Pegasus Trail 4, with special features that should continue to endear customers to the brand.
Tractor Supply
Tractor Supply (NASDAQ: TSCO) is the largest rural-lifestyle retailer in the U.S. with 2,164 stores in 49 states, as of April 1. The company has touted its "Life Out Here" strategy, which has attracted customers who appreciate rural lifestyles and see the business as an essential supplier for their needs.
The pandemic accelerated this demand as more people tended to their homes and farms, thus helping to push Tractor Supply's sales from $10.6 billion in 2020 to $14.2 billion in 2022. Over the same period, net income jumped from $749 million to $1.1 billion, with all three years seeing healthy free-cash-flow generation.
Tractor Supply started paying a quarterly dividend of $0.04 per share in 2010 and has increased it without fail to $0.52 by 2021. In 2022, the company massively hiked its dividend by 77% to $0.92 per share. This year, it raised the dividend further to $1.03. Over the past 13 years, Tractor Supply's dividend has increased by a compound annual growth rate of 28.4%.
Further increases look likely as the rural-lifestyle retailer reported a 9.1% year-over-year sales increase for the first quarter of 2023. Comparable-store sales were also positive at 2.1%, with the company maintaining its full-year outlook for sales of between $15 billion to $15.3 billion and comparable-store sales improvement of 3.5% to 5.5%.
Tractor Supply plans to open a total of 70 new Tractor Supply stores, and its highly successful rewards program, Neighbors Club, has seen double-digit year-over-year increases to its current 29 million members. Management believes that the company has a large total addressable market of around $180 billion and has pegged its new long-term store target to 2,700.
10 stocks we like better than Nike
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Nike wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of June 12, 2023
Royston Yang has positions in Nike and Tractor Supply. The Motley Fool has positions in and recommends Abbott Laboratories and Nike. The Motley Fool recommends Tractor Supply and recommends the following options: long January 2025 $47.50 calls on Nike. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs Abbott Laboratories (NYSE: ABT) is a healthcare company with a wide portfolio of products spanning the diagnostics, medical devices, and nutrition segments. Fortunately, many stocks dole out a dividend every quarter, and accumulating a portfolio of such companies means you'll receive a regular stream of additional income every three months. In addition, the company also announced a series of partnerships and collaborations to increase diversity in clinical trials and help advance its research on new drugs and devices. | Abbott Labs Abbott Laboratories (NYSE: ABT) is a healthcare company with a wide portfolio of products spanning the diagnostics, medical devices, and nutrition segments. Organic sales growth (less COVID-19-related revenue) rose 10% year over year, led by the company's medical devices, pharmaceuticals and nutrition units. Revenue for the first nine months of fiscal 2023 continued to rise 11% year over year to $38.4 billion, but net income saw a 12% year-over-year fall, due to higher expenses and supply-chain bottlenecks. | Abbott Labs Abbott Laboratories (NYSE: ABT) is a healthcare company with a wide portfolio of products spanning the diagnostics, medical devices, and nutrition segments. The company has reported steadily improving financials over the past three years, with revenue rising from $34.6 billion in 2020 to $43.7 billion in 2022. Net income climbed from $4.5 billion to $6.9 billion over the same period, and the company generated an average free cash flow of $7.4 billion over the three years. | Abbott Labs Abbott Laboratories (NYSE: ABT) is a healthcare company with a wide portfolio of products spanning the diagnostics, medical devices, and nutrition segments. The company has reported steadily improving financials over the past three years, with revenue rising from $34.6 billion in 2020 to $43.7 billion in 2022. Net income climbed from $4.5 billion to $6.9 billion over the same period, and the company generated an average free cash flow of $7.4 billion over the three years. |
30955.0 | 2023-06-19 00:00:00 UTC | ANALYSIS-New rules set to shake up China's shrinking infant formula market | ABT | https://www.nasdaq.com/articles/analysis-new-rules-set-to-shake-up-chinas-shrinking-infant-formula-market | nan | nan | By Farah Master
HONG KONG, June 20 (Reuters) - China's introduction of the world's strictest nutrient standards for infant formula are likely to see scores of brands give up on a market that is shrinking along with the country's falling birth rates, industry executives and analysts say.
New rules imposed in February force infant formula makers to invest heavily to re-make, test, certify and re-register their products for China, before potentially conducting new marketing campaigns.
This will further shake up an industry already at the forefront of China's demographic decline, with bigger domestic and international brands likely to increase their market share as smaller ones exit, analysts said.
“The new standard requires higher product quality as well as stronger manufacturing techniques which are expected to eliminate many small-to-medium-size players,” said Quinn Mai, analyst at Euromonitor International, which estimates China’s infant formula market will fall 12.5% to $21 billion by 2025 due to shrinking demand.
China's new requirements revise the minimum and maximum values of nutrients such as selenium, manganese and choline, mandate lactose content and ban fructose and sucrose.
Many experts describe the regulations as the world's toughest, aiming to get as close as possible to breast milk.
In 2008, at least six infants died and more than 300,000 fell ill from Chinese formulas tainted with melamine, a toxic chemical used to boost milk protein scores in tests. More than 20 Chinese firms were implicated, one of a series of food safety scandals in the early 2000s which industry executives say still weigh on consumer trust.
China's National Health Commission (NHC) cited infant safety when announcing the latest rules. NHC and the State Administration for Market Regulation (SAMR) did not immediately respond to comment requests.
“Beijing is very clear in their goal. They want to see fewer and fewer players in the market.”
Chinese regulators have approved submissions by 200 brands, according to analysts and industry executives who expect only a few dozen more to be authorised in coming months.
Celia Ning, director at the nutrition research institute of formula maker Junlebao, said the registration process could "easily" take a year. Companies cannot sell new stock until they are approved and if they fail to register their new products early they are “out of the market.”
The process requires many "resources from designing a new formulation, to trial, analysis and registration as well as good documentation and factory inspection."
She said smaller brands may be put off by extra costs, especially when the whole industry was in a "critical situation" due to an ageing population.
China's birth rate last year was just 6.77 births per 1,000 people, its lowest on record, and U.N. experts forecast China's population to shrink by 109 million by 2050.
"Maybe we can increase our market share, but everyone will see total sales reduced," said Ning, whose company is targeting other milk products such as yoghurt for future growth.
MARKET RESHUFFLE
U.S.-based Abbott Laboratories ABT.N is the biggest global brand known to have pulled out so far, telling Reuters the decision reflected "a changed market for paediatric nutrition products and that the market is well served by multiple other companies."
"We have decided to focus on our growing adult nutrition business," it said in an email.
New Zealand's Ministry for Primary Industries told Reuters up to 15 companies have applied or intend to apply for China's new product registration. SAMR has so far registered the products of three of those companies, the ministry said.
One of them, A2 Milk Company ATM.NZ said this month it had received approval.
Another, Fonterra FCG.NZ, said it was progressing through the re-registration process but that infant formula made up a relatively small part of its China business, with declining birth rates and regulation driving industry consolidation.
Global players Nestle NESN.S and Danone DANO.PA said they welcomed the new standards. Nestle said several products had already been approved under the new requirements.
Hong Kong-listed Health and Happiness (H&H) 1112.HK said four of its formulas had been approved as of May and would be valid for the next five years.
H&H's new formula cost around 9% more to produce than the old recipe but the company said the rigorous approval process would help its image.
“Companies such as H&H group that are able to gain approval will not only be viewed by consumers as more qualitative than other brands, but also more trustworthy,” H&H told Reuters in an email.
(Additional reporting by the Beijing newsroom; Editing by Marius Zaharia and Lincoln Feast.)
((farah.master@thomsonreuters.com; +852 3462 7709;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | U.S.-based Abbott Laboratories ABT.N is the biggest global brand known to have pulled out so far, telling Reuters the decision reflected "a changed market for paediatric nutrition products and that the market is well served by multiple other companies." By Farah Master HONG KONG, June 20 (Reuters) - China's introduction of the world's strictest nutrient standards for infant formula are likely to see scores of brands give up on a market that is shrinking along with the country's falling birth rates, industry executives and analysts say. “The new standard requires higher product quality as well as stronger manufacturing techniques which are expected to eliminate many small-to-medium-size players,” said Quinn Mai, analyst at Euromonitor International, which estimates China’s infant formula market will fall 12.5% to $21 billion by 2025 due to shrinking demand. | U.S.-based Abbott Laboratories ABT.N is the biggest global brand known to have pulled out so far, telling Reuters the decision reflected "a changed market for paediatric nutrition products and that the market is well served by multiple other companies." By Farah Master HONG KONG, June 20 (Reuters) - China's introduction of the world's strictest nutrient standards for infant formula are likely to see scores of brands give up on a market that is shrinking along with the country's falling birth rates, industry executives and analysts say. They want to see fewer and fewer players in the market.” Chinese regulators have approved submissions by 200 brands, according to analysts and industry executives who expect only a few dozen more to be authorised in coming months. | U.S.-based Abbott Laboratories ABT.N is the biggest global brand known to have pulled out so far, telling Reuters the decision reflected "a changed market for paediatric nutrition products and that the market is well served by multiple other companies." By Farah Master HONG KONG, June 20 (Reuters) - China's introduction of the world's strictest nutrient standards for infant formula are likely to see scores of brands give up on a market that is shrinking along with the country's falling birth rates, industry executives and analysts say. “The new standard requires higher product quality as well as stronger manufacturing techniques which are expected to eliminate many small-to-medium-size players,” said Quinn Mai, analyst at Euromonitor International, which estimates China’s infant formula market will fall 12.5% to $21 billion by 2025 due to shrinking demand. | U.S.-based Abbott Laboratories ABT.N is the biggest global brand known to have pulled out so far, telling Reuters the decision reflected "a changed market for paediatric nutrition products and that the market is well served by multiple other companies." SAMR has so far registered the products of three of those companies, the ministry said. One of them, A2 Milk Company ATM.NZ said this month it had received approval. |
30956.0 | 2023-06-19 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABT | https://www.nasdaq.com/articles/5-dividend-growth-stocks-with-upside-to-analyst-targets-91 | nan | nan | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention — and furthermore, "tracking" funds that follow the Dividend Aristocrats Index must own them. With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets.
But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. Which means, if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.
In the first table below, we present the five stocks. The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented.
STOCK RECENT PRICE AVG. ANALYST 12-MO. TARGET % UPSIDE TO TARGET
Chevron Corporation (Symbol: CVX) $157.26 $190.67 21.24%
Royal Gold Inc (Symbol: RGLD) $117.62 $142.12 20.83%
NU Skin Enterprises, Inc. (Symbol: NUS) $33.52 $40.25 20.08%
Abbott Laboratories (Symbol: ABT) $106.20 $123.12 15.94%
Coca-Cola Co (Symbol: KO) $61.67 $69.87 13.29%
The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential:
STOCK DIVIDEND YIELD % UPSIDE TO ANALYST TARGET IMPLIED TOTAL RETURN POTENTIAL
Chevron Corporation (Symbol: CVX) 3.84% 21.24% 25.08%
Royal Gold Inc (Symbol: RGLD) 1.28% 20.83% 22.11%
NU Skin Enterprises, Inc. (Symbol: NUS) 4.65% 20.08% 24.73%
Abbott Laboratories (Symbol: ABT) 1.92% 15.94% 17.86%
Coca-Cola Co (Symbol: KO) 2.98% 13.29% 16.27%
Another consideration with dividend growth stocks is just how much the dividend is growing. We looked up the trailing twelve months worth of dividends shareholders of each of the above five companies have collected, and then also looked up the same number for the prior trailing twelve months. This gives us a rough yardstick to see how much the dividend has grown, from one trailing twelve month period to another.
STOCK PRIOR TTM DIVIDEND TTM DIVIDEND % GROWTH
Chevron Corporation (Symbol: CVX) $5.52 $5.86 6.16%
Royal Gold Inc (Symbol: RGLD) $1.3 $1.45 11.54%
NU Skin Enterprises, Inc. (Symbol: NUS) $1.53 $1.55 1.31%
Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52%
Coca-Cola Co (Symbol: KO) $1.72 $1.8 4.65%
These five stocks are part of our full Dividend Aristocrats List. The average analyst target price data upon which this article was based, is courtesy of data provided by Zacks Investment Research via Quandl.com.
Get the latest Zacks research report on ABT — FREE
Get the latest Zacks research report on KO — FREE
Dividend Growth Stocks: 25 Aristocrats »
Also see:
EXEL Stock Predictions
Funds Holding SOXX
Institutional Holders of TYLG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Get the latest Zacks research report on ABT — FREE Get the latest Zacks research report on KO — FREE Dividend Growth Stocks: 25 Aristocrats » Also see: EXEL Stock Predictions Funds Holding SOXX Institutional Holders of TYLG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Chevron Corporation (Symbol: CVX) $157.26 $190.67 21.24% Royal Gold Inc (Symbol: RGLD) $117.62 $142.12 20.83% NU Skin Enterprises, Inc. (Symbol: NUS) $33.52 $40.25 20.08% Abbott Laboratories (Symbol: ABT) $106.20 $123.12 15.94% Coca-Cola Co (Symbol: KO) $61.67 $69.87 13.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.84% 21.24% 25.08% Royal Gold Inc (Symbol: RGLD) 1.28% 20.83% 22.11% NU Skin Enterprises, Inc. (Symbol: NUS) 4.65% 20.08% 24.73% Abbott Laboratories (Symbol: ABT) 1.92% 15.94% 17.86% Coca-Cola Co (Symbol: KO) 2.98% 13.29% 16.27% Another consideration with dividend growth stocks is just how much the dividend is growing. | Chevron Corporation (Symbol: CVX) $157.26 $190.67 21.24% Royal Gold Inc (Symbol: RGLD) $117.62 $142.12 20.83% NU Skin Enterprises, Inc. (Symbol: NUS) $33.52 $40.25 20.08% Abbott Laboratories (Symbol: ABT) $106.20 $123.12 15.94% Coca-Cola Co (Symbol: KO) $61.67 $69.87 13.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.84% 21.24% 25.08% Royal Gold Inc (Symbol: RGLD) 1.28% 20.83% 22.11% NU Skin Enterprises, Inc. (Symbol: NUS) 4.65% 20.08% 24.73% Abbott Laboratories (Symbol: ABT) 1.92% 15.94% 17.86% Coca-Cola Co (Symbol: KO) 2.98% 13.29% 16.27% Another consideration with dividend growth stocks is just how much the dividend is growing. Chevron Corporation (Symbol: CVX) $5.52 $5.86 6.16% Royal Gold Inc (Symbol: RGLD) $1.3 $1.45 11.54% NU Skin Enterprises, Inc. (Symbol: NUS) $1.53 $1.55 1.31% Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% Coca-Cola Co (Symbol: KO) $1.72 $1.8 4.65% These five stocks are part of our full Dividend Aristocrats List. | Chevron Corporation (Symbol: CVX) $157.26 $190.67 21.24% Royal Gold Inc (Symbol: RGLD) $117.62 $142.12 20.83% NU Skin Enterprises, Inc. (Symbol: NUS) $33.52 $40.25 20.08% Abbott Laboratories (Symbol: ABT) $106.20 $123.12 15.94% Coca-Cola Co (Symbol: KO) $61.67 $69.87 13.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.84% 21.24% 25.08% Royal Gold Inc (Symbol: RGLD) 1.28% 20.83% 22.11% NU Skin Enterprises, Inc. (Symbol: NUS) 4.65% 20.08% 24.73% Abbott Laboratories (Symbol: ABT) 1.92% 15.94% 17.86% Coca-Cola Co (Symbol: KO) 2.98% 13.29% 16.27% Another consideration with dividend growth stocks is just how much the dividend is growing. Chevron Corporation (Symbol: CVX) $5.52 $5.86 6.16% Royal Gold Inc (Symbol: RGLD) $1.3 $1.45 11.54% NU Skin Enterprises, Inc. (Symbol: NUS) $1.53 $1.55 1.31% Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% Coca-Cola Co (Symbol: KO) $1.72 $1.8 4.65% These five stocks are part of our full Dividend Aristocrats List. | Chevron Corporation (Symbol: CVX) $157.26 $190.67 21.24% Royal Gold Inc (Symbol: RGLD) $117.62 $142.12 20.83% NU Skin Enterprises, Inc. (Symbol: NUS) $33.52 $40.25 20.08% Abbott Laboratories (Symbol: ABT) $106.20 $123.12 15.94% Coca-Cola Co (Symbol: KO) $61.67 $69.87 13.29% The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period — so the expected total return if these stocks reach their analyst targets is actually the share price upside seen by the analysts plus the dividend yield shareholders can expect. Chevron Corporation (Symbol: CVX) 3.84% 21.24% 25.08% Royal Gold Inc (Symbol: RGLD) 1.28% 20.83% 22.11% NU Skin Enterprises, Inc. (Symbol: NUS) 4.65% 20.08% 24.73% Abbott Laboratories (Symbol: ABT) 1.92% 15.94% 17.86% Coca-Cola Co (Symbol: KO) 2.98% 13.29% 16.27% Another consideration with dividend growth stocks is just how much the dividend is growing. Chevron Corporation (Symbol: CVX) $5.52 $5.86 6.16% Royal Gold Inc (Symbol: RGLD) $1.3 $1.45 11.54% NU Skin Enterprises, Inc. (Symbol: NUS) $1.53 $1.55 1.31% Abbott Laboratories (Symbol: ABT) $1.84 $1.96 6.52% Coca-Cola Co (Symbol: KO) $1.72 $1.8 4.65% These five stocks are part of our full Dividend Aristocrats List. |
30957.0 | 2023-06-18 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-23 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top NASDAQ 100 Stocks
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
High Shareholder Yield Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30958.0 | 2023-06-15 00:00:00 UTC | ABT February 2024 Options Begin Trading | ABT | https://www.nasdaq.com/articles/abt-february-2024-options-begin-trading | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the February 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new February 2024 contracts and identified one put and one call contract of particular interest.
The put contract at the $100.00 strike price has a current bid of $4.35. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $100.00, but will also collect the premium, putting the cost basis of the shares at $95.65 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $103.62/share today.
Because the $100.00 strike represents an approximate 3% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.35% return on the cash commitment, or 6.45% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $100.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $105.00 strike price has a current bid of $7.00. If an investor was to purchase shares of ABT stock at the current price level of $103.62/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $105.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.09% if the stock gets called away at the February 2024 expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red:
Considering the fact that the $105.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 6.76% boost of extra return to the investor, or 10.02% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $103.62) to be 23%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of Stocks Analysts Like »
Also see:
ROYL Videos
NAII Historical Stock Prices
Ralph Lauren MACD
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the February 2024 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the February 2024 expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the February 2024 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new February 2024 contracts and identified one put and one call contract of particular interest. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABT options chain for the new February 2024 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $105.00 strike highlighted in red: Considering the fact that the $105.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the February 2024 expiration. |
30959.0 | 2023-06-15 00:00:00 UTC | ABT Crosses Above Key Moving Average Level | ABT | https://www.nasdaq.com/articles/abt-crosses-above-key-moving-average-level | nan | nan | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $104.83, changing hands as high as $105.11 per share. Abbott Laboratories shares are currently trading up about 1.8% on the day. The chart below shows the one year performance of ABT shares, versus its 200 day moving average:
Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $115.69 as the 52 week high point — that compares with a last trade of $105.05. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com
Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average »
Also see:
Top Ten Hedge Funds Holding NIB
Top Ten Hedge Funds Holding HWAY
TM Stock Predictions
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $104.83, changing hands as high as $105.11 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $115.69 as the 52 week high point — that compares with a last trade of $105.05. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Top Ten Hedge Funds Holding NIB Top Ten Hedge Funds Holding HWAY TM Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $104.83, changing hands as high as $105.11 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $115.69 as the 52 week high point — that compares with a last trade of $105.05. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Top Ten Hedge Funds Holding NIB Top Ten Hedge Funds Holding HWAY TM Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $104.83, changing hands as high as $105.11 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $115.69 as the 52 week high point — that compares with a last trade of $105.05. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Top Ten Hedge Funds Holding NIB Top Ten Hedge Funds Holding HWAY TM Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) crossed above their 200 day moving average of $104.83, changing hands as high as $105.11 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $115.69 as the 52 week high point — that compares with a last trade of $105.05. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed above their 200 day moving average » Also see: Top Ten Hedge Funds Holding NIB Top Ten Hedge Funds Holding HWAY TM Stock Predictions The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
30960.0 | 2023-06-14 00:00:00 UTC | Validea's Top 5 Health Care Stocks Based On Benjamin Graham - 6/14/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-benjamin-graham-6-14-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.
FULGENT GENETICS INC (FLGT) is a small-cap stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Benjamin Graham is 71% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Fulgent Genetics, Inc. is a technology-based company with a clinical diagnostic business and a therapeutic development business. The Company's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its business is built on its technology platform, which includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The Company's technology platform offers a test menu. The Company also offers next-generation sequencing (NGS) services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: FAIL
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: PASS
PRICE/BOOK RATIO: PASS
Detailed Analysis of FULGENT GENETICS INC
FLGT Guru Analysis
FLGT Fundamental Analysis
APOLLO MEDICAL HOLDINGS INC (AMEH) is a small-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Benjamin Graham is 57% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Apollo Medical Holdings, Inc. is a healthcare company. The Company provides care coordination services to each constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists. The Company operates an integrated healthcare delivery platform that enables providers to participate successfully in value-based care arrangements. To implement a patient-centered, physician-centric experience, the Company also have other integrated and synergistic operations, including management service organizations (MSOs) that provide management and other services to its affiliated independent practice associations (IPAs), outpatient clinics, and hospitalists that coordinate the care of patients in hospitals.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of APOLLO MEDICAL HOLDINGS INC
AMEH Guru Analysis
AMEH Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: FAIL
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL
LONG-TERM EPS GROWTH: PASS
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
KURA ONCOLOGY INC (KURA) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of medicines for the treatment of cancer. The Company's pipeline consists of small molecule product candidates that target cancer signaling pathways. The Company's products candidate includes Ziftomenib, Tipifarnib, and KO-2806. The Ziftomenib is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene for the treatment of genetically defined acute myeloid leukemia (AML) patients. Tipifarnib is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. KO-2806, is a next generation farnesyl transferase inhibitor (FTI), which it demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: FAIL
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of KURA ONCOLOGY INC
KURA Guru Analysis
KURA Fundamental Analysis
LEXICON PHARMACEUTICALS INC (LXRX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Its LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of SGLT2 in the kidney.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: FAIL
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of LEXICON PHARMACEUTICALS INC
LXRX Guru Analysis
LXRX Fundamental Analysis
Benjamin Graham Portfolio
Top Benjamin Graham Stocks
About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Known as both the "Father of Value Investing" and the founder of the entire field of security analysis, Graham mentored several of history's greatest investors -- including Warren Buffett -- and inspired a slew of others, including John Templeton, Mario Gabelli, and another of Validea's gurus, John Neff. Graham built his fortune and reputation after living through some extremely difficult times, including both the Great Depression and his own family's financial woes following his father's death when Benjamin was a young man. His investment firm posted per annum returns of about 20 percent from 1936 to 1956, far outpacing the 12.2 percent average return for the market during that time.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of APOLLO MEDICAL HOLDINGS INC AMEH Guru Analysis AMEH Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis KURA ONCOLOGY INC (KURA) is a small-cap growth stock in the Biotechnology & Drugs industry. Its business is built on its technology platform, which includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. | Detailed Analysis of APOLLO MEDICAL HOLDINGS INC AMEH Guru Analysis AMEH Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis KURA ONCOLOGY INC (KURA) is a small-cap growth stock in the Biotechnology & Drugs industry. The Company's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information. | Detailed Analysis of APOLLO MEDICAL HOLDINGS INC AMEH Guru Analysis AMEH Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis KURA ONCOLOGY INC (KURA) is a small-cap growth stock in the Biotechnology & Drugs industry. The Company's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information. | Detailed Analysis of APOLLO MEDICAL HOLDINGS INC AMEH Guru Analysis AMEH Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis KURA ONCOLOGY INC (KURA) is a small-cap growth stock in the Biotechnology & Drugs industry. The Company's clinical diagnostic business offers molecular diagnostic testing services, genetic testing, and anatomic pathology laboratory services designed to provide physicians and patients with clinically actionable diagnostic information. |
30961.0 | 2023-06-13 00:00:00 UTC | Abbott (ABT) Gains But Lags Market: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-but-lags-market%3A-what-you-should-know-16 | nan | nan | Abbott (ABT) closed at $101.86 in the latest trading session, marking a +0.45% move from the prior day. This change lagged the S&P 500's 0.69% gain on the day. Elsewhere, the Dow gained 0.43%, while the tech-heavy Nasdaq lost 8.94%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 7.68% over the past month. This has lagged the Medical sector's loss of 1.27% and the S&P 500's gain of 5.41% in that time.
Investors will be hoping for strength from Abbott as it approaches its next earnings release. In that report, analysts expect Abbott to post earnings of $1.05 per share. This would mark a year-over-year decline of 26.57%. Our most recent consensus estimate is calling for quarterly revenue of $9.67 billion, down 14.08% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.39 per share and revenue of $39.38 billion, which would represent changes of -17.79% and -9.79%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. Abbott currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Abbott is holding a Forward P/E ratio of 23.12. Its industry sports an average Forward P/E of 23.59, so we one might conclude that Abbott is trading at a discount comparatively.
Meanwhile, ABT's PEG ratio is currently 4.54. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.51 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 56, which puts it in the top 23% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed at $101.86 in the latest trading session, marking a +0.45% move from the prior day. Meanwhile, ABT's PEG ratio is currently 4.54. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $101.86 in the latest trading session, marking a +0.45% move from the prior day. Meanwhile, ABT's PEG ratio is currently 4.54. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $101.86 in the latest trading session, marking a +0.45% move from the prior day. Meanwhile, ABT's PEG ratio is currently 4.54. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. | Abbott (ABT) closed at $101.86 in the latest trading session, marking a +0.45% move from the prior day. Meanwhile, ABT's PEG ratio is currently 4.54. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. |
30962.0 | 2023-06-12 00:00:00 UTC | Health Care Sector Update for 06/12/2023: ME, BIIB, ABT, BNTX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-06-12-2023%3A-me-biib-abt-bntx | nan | nan | Health care stocks were mostly higher late Monday, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both up about 0.3%.
The iShares Biotechnology ETF (IBB) was up 0.7%.
In company news, 23andMe (ME) said in a late Friday filing that it will lay off about 75 employees, or 9%, of its workforce to reduce operating costs. The company's shares were down 2.6%.
Biogen (BIIB) and partner Eisai said Saturday that a US Food and Drug Administration advisory committee supported the approval of Leqembi to treat Alzheimer's disease. Biogen shares were rising 1.4%.
Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. The company's shares were down 0.2%.
A court hearing over a lawsuit against BioNTech (BNTX) in Germany seeking damages for alleged side effects of its COVID-19 vaccine was postponed on Monday after the plaintiff's lawyer requested the case to be heard by different judges, Reuters reported. BioNTech shares were up 0.5%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. Biogen (BIIB) and partner Eisai said Saturday that a US Food and Drug Administration advisory committee supported the approval of Leqembi to treat Alzheimer's disease. A court hearing over a lawsuit against BioNTech (BNTX) in Germany seeking damages for alleged side effects of its COVID-19 vaccine was postponed on Monday after the plaintiff's lawyer requested the case to be heard by different judges, Reuters reported. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. Health care stocks were mostly higher late Monday, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both up about 0.3%. The company's shares were down 2.6%. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. Health care stocks were mostly higher late Monday, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both up about 0.3%. The company's shares were down 2.6%. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. The company's shares were down 2.6%. Biogen shares were rising 1.4%. |
30963.0 | 2023-06-12 00:00:00 UTC | Health Care Sector Update for 06/12/2023: BIIB, ABT, BNTX | ABT | https://www.nasdaq.com/articles/health-care-sector-update-for-06-12-2023%3A-biib-abt-bntx | nan | nan | Health care stocks were lower in afternoon trading, with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.1% softer.
The iShares Biotechnology ETF (IBB) was up 0.2%.
In company news, Biogen (BIIB) and partner Eisai said Saturday that a US Food and Drug Administration advisory committee supported the approval of Leqembi to treat Alzheimer's disease. Biogen shares were rising 1.4%.
Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. The company's shares were down 0.8%.
A court hearing over a lawsuit against BioNTech (BNTX) in Germany seeking damages for alleged side effects of its COVID-19 vaccine was postponed on Monday after the plaintiff's lawyer requested the case to be heard by different judges, Reuters reported. BioNTech was little changed. BioNTech shares were little changed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. In company news, Biogen (BIIB) and partner Eisai said Saturday that a US Food and Drug Administration advisory committee supported the approval of Leqembi to treat Alzheimer's disease. A court hearing over a lawsuit against BioNTech (BNTX) in Germany seeking damages for alleged side effects of its COVID-19 vaccine was postponed on Monday after the plaintiff's lawyer requested the case to be heard by different judges, Reuters reported. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. Health care stocks were lower in afternoon trading, with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.1% softer. Biogen shares were rising 1.4%. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. In company news, Biogen (BIIB) and partner Eisai said Saturday that a US Food and Drug Administration advisory committee supported the approval of Leqembi to treat Alzheimer's disease. A court hearing over a lawsuit against BioNTech (BNTX) in Germany seeking damages for alleged side effects of its COVID-19 vaccine was postponed on Monday after the plaintiff's lawyer requested the case to be heard by different judges, Reuters reported. | Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. Health care stocks were lower in afternoon trading, with the NYSE Health Care Index down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.1% softer. The company's shares were down 0.8%. |
30964.0 | 2023-06-12 00:00:00 UTC | Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers | ABT | https://www.nasdaq.com/articles/abbott-abt-epd-sales-gain-traction-margin-pressure-lingers | nan | nan | Abbott’s ABT Established Pharmaceuticals and Nutrition businesses should drive growth in the coming quarters. Yet, the macro-economic environment continues to be challenging. The stock carries a Zacks Rank #3 (Hold).
Over the past year, Abbott has been outperforming the industry it belongs to. The stock has lost 9.8% compared with the industry’s 29.8% fall.
Abbott exited the first quarter of 2023 with better-than-expected earnings and revenues. Organic sales growth, excluding COVID testing, increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals (EPD) and Nutrition. Within EPD, sales increased 11% in the quarter led by strong performance in Brazil, China, and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management. EPD has been witnessing double-digit sales growth momentum for the last two years.
Within Nutrition, sales increased by more than 10%. In the United States, pediatric nutrition growth of more than 35% was driven by favorable year-over-year comparisons (lower sales in the first quarter of 2022 were due to a voluntary recall of certain infant formula products). Abbott continued to progress, increasing manufacturing production and recovering market share in this business.
Within Diagnostics, excluding COVID testing, organic sales growth was led by mid-to-high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. Despite dull sales in China, Core Lab Diagnostics sales showed year-over-year improvement led by strong performance in the United States and Europe.
Abbott Laboratories Price
Abbott Laboratories price | Abbott Laboratories Quote
Within Medical Devices, sales grew 12.5% globally on an organic basis, including mid-teens growth in the United States and double-digit growth internationally. In Diabetes Care, sales of FreeStyle Libre grew more than 25% on an organic basis in the quarter, including approximately 50% growth in the United States and mid-teens growth internationally.
Abbott currently forecasts total organic sales growth, excluding the impact of COVID testing-related sales, to be in high-single digits for 2023.
On the flip side, Abbott’s first-quarter worldwide sales were down 18.1% year over year on a reported basis. Total sales were negatively impacted by COVID-19 testing-related sales decline. In Diagnostics, as forecast, sales were negatively impacted by a significant decrease in COVID testing sales compared to the first quarter of 2022.
Worldwide COVID-19 testing sales were $730 million in the first quarter compared with $3.3 billion in the year-ago period. Further, in Core Lab Diagnostics, growth was partially offset by soft market conditions in China.
A challenging macroscopic environment, adverse currency translation and stubborn inflationary situation severely impacted the company’s profitability in the first quarter. The ongoing inflation situation across the globe is adversely impacting input cost for Abbott.
Gross profit in the first quarter fell 21.6% year over year. Gross margin contracted 251 basis points (bps) to 55.6%.
The company reported a 41.6% decline in adjusted operating profit. Adjusted operating margin contracted 827 bps to 20.5%.
Key Picks
Some better-ranked stocks in the overall healthcare sector are Penumbra PEN, Lantheus LNTH and Neuronetics STIM. While Penumbra and Lantheus sport a Zacks Rank #1 (Strong Buy), Neuronetics carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Penumbra’s stock has risen 139.2% in the past year. The Zacks Consensus Estimate for Penumbra’s earnings per share (EPS) has increased from $1.55 to $1.56 for 2023 and remained constant at $2.56 for 2024 in the past 30 days.
PEN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 109.42%. In the last reported quarter, the company registered an earnings surprise of 109.09%.
The Zacks Consensus Estimate for Lantheus’ 2023 EPS has remained constant at $5.60 in the past 30 days. Shares of the company have improved 39% in the past year against the industry’s 27.6% decline.
LNTH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 25.77%. In the last reported quarter, the company recorded an earnings surprise of 13.95%.
Estimates for Neuronetics’ loss per share have narrowed from $1.32 to $1.29 for 2023 in the past 30 days. Shares of the company have declined 30.4% in the past year against the industry’s 6.7% growth.
STIM’s earnings beat estimates in each of the trailing four quarters, the average surprise being 19.61%. In the last reported quarter, Neuronetics delivered an earnings surprise of 2.56%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
Neuronetics, Inc. (STIM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott’s ABT Established Pharmaceuticals and Nutrition businesses should drive growth in the coming quarters. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report Neuronetics, Inc. (STIM) : Free Stock Analysis Report To read this article on Zacks.com click here. Within EPD, sales increased 11% in the quarter led by strong performance in Brazil, China, and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report Neuronetics, Inc. (STIM) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT Established Pharmaceuticals and Nutrition businesses should drive growth in the coming quarters. Organic sales growth, excluding COVID testing, increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals (EPD) and Nutrition. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report Neuronetics, Inc. (STIM) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT Established Pharmaceuticals and Nutrition businesses should drive growth in the coming quarters. In Diabetes Care, sales of FreeStyle Libre grew more than 25% on an organic basis in the quarter, including approximately 50% growth in the United States and mid-teens growth internationally. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report Neuronetics, Inc. (STIM) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott’s ABT Established Pharmaceuticals and Nutrition businesses should drive growth in the coming quarters. Organic sales growth, excluding COVID testing, increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals (EPD) and Nutrition. |
30965.0 | 2023-06-12 00:00:00 UTC | What's Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock? | ABT | https://www.nasdaq.com/articles/whats-next-for-boston-scientific-stock-after-outperforming-during-the-2022-inflation-shock | nan | nan | Boston Scientific stock (NYSE: BSX) currently trades at $51 per share, roughly 30% above its level in March 2021, and it now seems to be fully valued. Boston Scientific saw its stock trading at around $37 in late June 2022, just before the Fed started increasing rates, and is now 36% above that level. The stock has gained 31% since September 2022 compared to the S&P 500, which gained about 13% during this period. The outperformance of BSX stock over the recent past can be attributed to its upbeat Q1 performance and raised outlook for 2023, driven by its new product launches. The notable rise in Boston Scientific’s revenues in the recent past has also contributed to the stock’s outperformance.
BSX stock is already trading above its pre-inflation shock level, and we believe that it doesn’t have much room for growth in the near term. We estimate Boston Scientific’s valuation to be around $52 per share, close to its current market price. This is because the positives appear to have been priced in the stock, and it’s now trading at a valuation multiple of 26x expected forward earnings of $1.97 on a per share and adjusted basis, higher than its last three-year average of about 23x.
This analysis captures trends in the company’s stock during the turbulent market conditions seen over 2022. It compares these trends to the stock’s performance during the 2008 recession.
2022 Inflation Shock
Timeline of Inflation Shock So Far:
2020 – early 2021: Increase in money supply to cushion the impact of lockdowns led to high demand for goods; producers unable to match up.
Early 2021: Shipping snarls and worker shortages from the coronavirus pandemic continue to hurt the supply
April 2021: Inflation rates cross 4% and increase rapidly
Early 2022: Energy and food prices spike due to the Russian invasion of Ukraine. Fed begins its rate hike process
June 2022: Inflation levels peak at 9% – the highest level in 40 years. S&P 500 index declines more than 20% from peak levels.
July – September 2022: Fed hikes interest rates aggressively – resulting in an initial recovery in the S&P 500 followed by another sharp decline
Since October 2022: Fed continues rate hike process; improving market sentiments help S&P500 recoup some of its losses.
In contrast, here’s how BSX stock and the broader market performed during the 2007/2008 crisis.
Timeline of 2007-08 Crisis
10/1/2007: Approximate pre-crisis peak in S&P 500 index
9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08)
3/1/2009: Approximate bottoming out of S&P 500 index
12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008)
BSX and S&P 500 Performance During 2007-08 Crisis
BSX stock declined from $14 in September 2007 (pre-crisis peak) to around $7 in March 2009 (as the markets bottomed out), implying it lost nearly 50% of its pre-crisis value. It recovered post the 2008 crisis to levels of around $9 in early 2010, rising 28% between March 2009 and January 2010. The S&P 500 Index saw a decline of 51%, falling from levels of 1,540 in September 2007 to 757 in March 2009. It then rallied 48% between March 2009 and January 2010 to reach levels of 1,124.
BSX Fundamentals Over Recent Years
Boston Scientific’s revenues rose from $18.4 billion in 2019 to $20.2 billion in 2022, driven by an uptick in total procedures after a decline during the pandemic period. It has also benefited from new product launches, including POLARx (Japan), Vercise, and XL valves, among others. This trend is expected to continue going forward. Its recent acquisitions, including Baylis, will further bolster its top-line growth. The company has acquired a majority stake in Acotec, which will aid its future sales growth in China. Considering these factors, we have assigned a slightly higher valuation multiple vis-à-vis its historical average mentioned above. Looking at earnings, BSX posted a slight decline in reported EPS of $5.72 in 2022, vs. $6.24 in 2019, due to higher costs. Its operating margin contracted to 13.3% from 16.2% over the same period.
Does BSX Have A Sufficient Cash Cushion To Meet Its Obligations Through The Ongoing Inflation Shock?
Boston Scientific’s total debt increased slightly from $7.7 billion in 2019 to $8.4 billion in 2022, while its total cash remained around $0.7 billion over this period. The company garnered $2.7 billion in cash flows from operations in 2022. Given its cash position, BSX appears to be in a comfortable situation to meet its near-term obligations.
Conclusion
With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Boston Scientific (BSX) stock has little room for growth even once fears of a potential recession are allayed, given its rich valuation. Also, its declining operating margin remains a risk factor to realizing any substantial gains in the near term, in our view.
While BSX stock looks fully valued, it is helpful to see how Boston Scientific’s Peers fare on metrics that matter. You will find other valuable comparisons for companies across industries at Peer Comparisons.
Despite higher inflation and the Fed raising interest rates, among other factors, BSX stock has risen 10% this year. Can it drop from here? See how low Boston Scientific stock can go by comparing its decline in previous market crashes. Here is a performance summary of all stocks in previous market crashes.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Returns Jun 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
BSX Return -2% 10% 134%
S&P 500 Return 2% 11% 91%
Trefis Multi-Strategy Portfolio 4% 14% 259%
[1] Month-to-date and year-to-date as of 6/8/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The outperformance of BSX stock over the recent past can be attributed to its upbeat Q1 performance and raised outlook for 2023, driven by its new product launches. This is because the positives appear to have been priced in the stock, and it’s now trading at a valuation multiple of 26x expected forward earnings of $1.97 on a per share and adjusted basis, higher than its last three-year average of about 23x. Conclusion With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Boston Scientific (BSX) stock has little room for growth even once fears of a potential recession are allayed, given its rich valuation. | July – September 2022: Fed hikes interest rates aggressively – resulting in an initial recovery in the S&P 500 followed by another sharp decline Since October 2022: Fed continues rate hike process; improving market sentiments help S&P500 recoup some of its losses. Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) BSX and S&P 500 Performance During 2007-08 Crisis BSX stock declined from $14 in September 2007 (pre-crisis peak) to around $7 in March 2009 (as the markets bottomed out), implying it lost nearly 50% of its pre-crisis value. Conclusion With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Boston Scientific (BSX) stock has little room for growth even once fears of a potential recession are allayed, given its rich valuation. | Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) BSX and S&P 500 Performance During 2007-08 Crisis BSX stock declined from $14 in September 2007 (pre-crisis peak) to around $7 in March 2009 (as the markets bottomed out), implying it lost nearly 50% of its pre-crisis value. Conclusion With the Fed’s efforts to tame runaway inflation rates helping market sentiments, we believe Boston Scientific (BSX) stock has little room for growth even once fears of a potential recession are allayed, given its rich valuation. Total [2] BSX Return -2% 10% 134% S&P 500 Return 2% 11% 91% Trefis Multi-Strategy Portfolio 4% 14% 259% [1] Month-to-date and year-to-date as of 6/8/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It recovered post the 2008 crisis to levels of around $9 in early 2010, rising 28% between March 2009 and January 2010. See how low Boston Scientific stock can go by comparing its decline in previous market crashes. Total [2] BSX Return -2% 10% 134% S&P 500 Return 2% 11% 91% Trefis Multi-Strategy Portfolio 4% 14% 259% [1] Month-to-date and year-to-date as of 6/8/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
30966.0 | 2023-06-11 00:00:00 UTC | Validea's Top 5 Health Care Stocks Based On Joel Greenblatt - 6/11/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-joel-greenblatt-6-11-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.
MCKESSON CORP (MCK) is a large-cap growth stock in the Major Drugs industry. The rating according to our strategy based on Joel Greenblatt is 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: McKesson Corporation is a provider of diversified healthcare services. The Company is engaged in advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over the counter (OTC) pharmaceutical drugs and other healthcare-related products in the United States. Its Prescription Technology Solutions segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home healthcare agencies. Its International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of MCKESSON CORP
MCK Guru Analysis
MCK Fundamental Analysis
CARDINAL HEALTH INC (CAH) is a large-cap growth stock in the Major Drugs industry. The rating according to our strategy based on Joel Greenblatt is 10% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cardinal Health, Inc. is a globally integrated healthcare services and products company. The Company is focused on providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products and solutions. The Company's segments include Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and patient management.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of CARDINAL HEALTH INC
CAH Guru Analysis
CAH Fundamental Analysis
HENRY SCHEIN, INC. (HSIC) is a mid-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Henry Schein, Inc. is a solutions company for health care professionals. The Company's business, clinical, technology, and supply chain solutions help office-based dental and medical practitioners work efficiently so they can provide quality care. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. The Company's Health Care distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products, diagnostic tests, infection-control products, personal protective equipment products (PPE) and vitamins. Its Technology and Value-added services segment provide software, technology and other value-added services to healthcare practitioners. The Company is also engaged in serving public- and private-sector customers in Australia and New Zealand.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of HENRY SCHEIN, INC.
HSIC Guru Analysis
HSIC Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Joel Greenblatt is 0% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Agilent Technologies, Inc. is engaged in providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets business offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics businesses are comprised of six areas of activity, providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. Its product categories include liquid chromatography systems and components and liquid chromatography mass spectrometry systems.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
EARNINGS YIELD: NEUTRAL
RETURN ON TANGIBLE CAPITAL: NEUTRAL
FINAL RANKING: FAIL
Detailed Analysis of AGILENT TECHNOLOGIES INC
A Guru Analysis
A Fundamental Analysis
Joel Greenblatt Portfolio
Top Joel Greenblatt Stocks
About Joel Greenblatt: In his 2005 bestseller The Little Book That Beats The Market, hedge fund manager Joel Greenblatt laid out a stunningly simple way to beat the market using two -- and only two -- fundamental variables. The "Magic Formula," as he called it, produced back-tested returns of 30.8 percent per year from 1988 through 2004, more than doubling the S&P 500's 12.4 percent return during that time. Greenblatt also produced exceptional returns as managing partner at Gotham Capital, a New York City-based hedge fund he founded. The firm averaged a remarkable 40 percent annualized return over more than two decades.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of HENRY SCHEIN, INC. HSIC Guru Analysis HSIC Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. The Company is focused on providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. | Detailed Analysis of HENRY SCHEIN, INC. HSIC Guru Analysis HSIC Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. Detailed Analysis of MCKESSON CORP MCK Guru Analysis MCK Fundamental Analysis CARDINAL HEALTH INC (CAH) is a large-cap growth stock in the Major Drugs industry. | Detailed Analysis of HENRY SCHEIN, INC. HSIC Guru Analysis HSIC Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. The Company's Health Care distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products, diagnostic tests, infection-control products, personal protective equipment products (PPE) and vitamins. | Detailed Analysis of HENRY SCHEIN, INC. HSIC Guru Analysis HSIC Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis AGILENT TECHNOLOGIES INC (A) is a large-cap growth stock in the Scientific & Technical Instr. The following are the top rated Health Care stocks according to Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. |
30967.0 | 2023-06-09 00:00:00 UTC | Daily Dividend Report: ODC,AMAT,CL,ABT,PM | ABT | https://www.nasdaq.com/articles/daily-dividend-report%3A-odcamatclabtpm | nan | nan | The Board of Directors of Oil-Dri Corporation of America yesterday declared quarterly cash dividends of $0.29 per share of the Company's Common Stock and $0.218 per share of the Company's Class B Stock, an approximate 4% increase for both classes of stock. The dividends declared will be payable on August 25, 2023 to stockholders of record at the close of business on August 11, 2023. The Company has paid cash dividends continuously since 1974. This declaration marks the twentieth consecutive year Oil-Dri has increased dividends. Based on the increased declared dividend and today's closing price of $40.55, the dividend yield on Common Stock is 2.9%.
Applied Materials today announced that its Board of Directors has approved a quarterly cash dividend of $0.32 per share payable on the company's common stock. The dividend is payable on Sept. 14, 2023 to shareholders of record as of Aug. 24, 2023. The quarterly cash dividend is a key component of Applied's capital allocation strategy. On March 13, 2023, Applied announced a 23.1-percent increase in the quarterly cash dividend from $0.26 to $0.32 per share along with a new share repurchase authorization enabling Applied to buyback an additional $10 billion of its shares over time. The first $0.32 dividend will be payable on June 15, 2023 to shareholders of record as of May 25, 2023.
The Board of Directors of Colgate-Palmolive today declared a quarterly cash dividend of $0.48 per common share, payable on August 15, 2023, to shareholders of record on July 21, 2023. The Company has paid uninterrupted dividends on its common stock since 1895.
The board of directors of Abbott today declared a quarterly common dividend of 51 cents per share. This marks the 398th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2023, to shareholders of record at the close of business on July 14, 2023. Abbott has increased its dividend payout for 51 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.
The Board of Directors of Philip Morris International today declared a regular quarterly dividend of $1.27 per common share, payable on July 11, 2023, to shareholders of record as of June 23, 2023. The ex-dividend date is June 22, 2023.
VIDEO: Daily Dividend Report: ODC,AMAT,CL,ABT,PM
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Daily Dividend Report: ODC,AMAT,CL,ABT,PM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Applied Materials today announced that its Board of Directors has approved a quarterly cash dividend of $0.32 per share payable on the company's common stock. The Board of Directors of Colgate-Palmolive today declared a quarterly cash dividend of $0.48 per common share, payable on August 15, 2023, to shareholders of record on July 21, 2023. | VIDEO: Daily Dividend Report: ODC,AMAT,CL,ABT,PM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Board of Directors of Oil-Dri Corporation of America yesterday declared quarterly cash dividends of $0.29 per share of the Company's Common Stock and $0.218 per share of the Company's Class B Stock, an approximate 4% increase for both classes of stock. Applied Materials today announced that its Board of Directors has approved a quarterly cash dividend of $0.32 per share payable on the company's common stock. | VIDEO: Daily Dividend Report: ODC,AMAT,CL,ABT,PM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Board of Directors of Oil-Dri Corporation of America yesterday declared quarterly cash dividends of $0.29 per share of the Company's Common Stock and $0.218 per share of the Company's Class B Stock, an approximate 4% increase for both classes of stock. The Board of Directors of Colgate-Palmolive today declared a quarterly cash dividend of $0.48 per common share, payable on August 15, 2023, to shareholders of record on July 21, 2023. | VIDEO: Daily Dividend Report: ODC,AMAT,CL,ABT,PM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Board of Directors of Oil-Dri Corporation of America yesterday declared quarterly cash dividends of $0.29 per share of the Company's Common Stock and $0.218 per share of the Company's Class B Stock, an approximate 4% increase for both classes of stock. Applied Materials today announced that its Board of Directors has approved a quarterly cash dividend of $0.32 per share payable on the company's common stock. |
30968.0 | 2023-06-08 00:00:00 UTC | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | ABT | https://www.nasdaq.com/articles/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now-7 | nan | nan | A smart beta exchange traded fund, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) debuted on 10/09/2013, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the market, and the ETF industry has traditionally been dominated by products based on this strategy.
Because market cap weighted indexes provide a low-cost, convenient, and transparent way of replicating market returns, they work well for investors who believe in market efficiency.
But, there are some investors who would rather invest in smart beta funds; these funds track non-cap weighted strategies, and are a strong option for those who prefer choosing great stocks in order to beat the market.
By attempting to pick stocks that have a better chance of risk-return performance, non-cap weighted indexes are based on certain fundamental characteristics, or a combination of such.
The smart beta space gives investors many different choices, from equal-weighting, one of the simplest strategies, to more complicated ones like fundamental and volatility/momentum based weighting. However, not all of these methodologies have been able to deliver remarkable returns.
Fund Sponsor & Index
Because the fund has amassed over $11.23 billion, this makes it one of the larger ETFs in the Style Box - Large Cap Value. NOBL is managed by Proshares. Before fees and expenses, NOBL seeks to match the performance of the S&P 500 DividendAristocrats Index.
The S&P 500 Dividend Aristocrats Index targets companies that are currently members of the S&P 500, have increased dividend payments each year for at least 25 years & meet certain market capitalization & liquidity requirements.
Cost & Other Expenses
Expense ratios are an important factor in the return of an ETF and in the long-term, cheaper funds can significantly outperform their more expensive cousins, other things remaining the same.
With on par with most peer products in the space, this ETF has annual operating expenses of 0.35%.
NOBL's 12-month trailing dividend yield is 1.91%.
Performance and Risk
Year-to-date, the ProShares S&P 500 Dividend Aristocrats ETF return is roughly 2.20% so far, and is up about 1.10% over the last 12 months (as of 06/08/2023). NOBL has traded between $79.96 and $95.15 in this past 52-week period.
The fund has a beta of 0.89 and standard deviation of 16.86% for the trailing three-year period, which makes NOBL a medium risk choice in this particular space. With about 67 holdings, it effectively diversifies company-specific risk.
Alternatives
ProShares S&P 500 Dividend Aristocrats ETF is an excellent option for investors seeking to outperform the Style Box - Large Cap Value segment of the market. There are other ETFs in the space which investors could consider as well.
IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. IShares Core Dividend Growth ETF has $23.18 billion in assets, Vanguard Dividend Appreciation ETF has $66.79 billion. DGRO has an expense ratio of 0.08% and VIG charges 0.06%.
Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Style Box - Large Cap Value.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports
Abbott Laboratories (ABT) : Free Stock Analysis Report
Aflac Incorporated (AFL) : Free Stock Analysis Report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports
iShares Core Dividend Growth ETF (DGRO): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. A smart beta exchange traded fund, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) debuted on 10/09/2013, and offers broad exposure to the Style Box - Large Cap Value category of the market. The fund has a beta of 0.89 and standard deviation of 16.86% for the trailing three-year period, which makes NOBL a medium risk choice in this particular space. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. IShares Core Dividend Growth ETF has $23.18 billion in assets, Vanguard Dividend Appreciation ETF has $66.79 billion. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. A smart beta exchange traded fund, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) debuted on 10/09/2013, and offers broad exposure to the Style Box - Large Cap Value category of the market. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Reports iShares Core Dividend Growth ETF (DGRO): ETF Research Reports To read this article on Zacks.com click here. But, there are some investors who would rather invest in smart beta funds; these funds track non-cap weighted strategies, and are a strong option for those who prefer choosing great stocks in order to beat the market. IShares Core Dividend Growth ETF (DGRO) tracks Morningstar US Dividend Growth Index and the Vanguard Dividend Appreciation ETF (VIG) tracks NASDAQ US Dividend Achievers Select Index. |
30969.0 | 2023-06-08 00:00:00 UTC | Top Stock Reports for Procter & Gamble, Bank of America & Abbott Laboratories | ABT | https://www.nasdaq.com/articles/top-stock-reports-for-procter-gamble-bank-of-america-abbott-laboratories | nan | nan | Thursday, June 8, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Procter & Gamble shares have modestly lagged the Zacks Consumer Staples sector (-3.6% vs. -2.4%) as well as the broader market (-3.6% vs. +12.2% for the S&P 500 index) this year. Driving the underperformance is the company's drab guidance in the last quarterly release and expectations of continued margin pressures.
Procter & Gamble’s organic sales grew in the last reported quarter, driven by robust pricing and a favorable mix, along with strength across segments. It has been focused on productivity and cost-saving plans to boost margins. Consequently, it raised the sales view to 1% growth compared with our estimate of a 1.1% rise for fiscal 2023.
(You can read the full research report on Procter & Gamble here >>>)
Bank of America shares have underperformed the Zacks Banks - Major Regional industry over the past six months (-7.7% vs. -2.8%). The company is suffering due to worsening economic backdrop which keep weighing on investment banking (IB) business. This, along with the volatile nature of the capital markets, will hurt non-interest income.
A tough operating backdrop will lead to higher provisions, with we projecting a substantial jump in the metric this year. Inflationary pressure will result in mounting expenses. Our estimate for total non-interest expenses implies a rise of 1.7% this year.
Nevertheless, Higher rates and decent loan demand will aid net interest income (NII). According to the Zacks analyst estimates NII reflect a CAGR of 2.6% by 2025. The opening of new financial centers and improving digital capabilities will bolster the top line.
(You can read the full research report on Bank of America here >>>)
Abbott Laboratories shares have declined -8.5% over the past year against the Zacks Medical - Products industry’s decline of -28.8%. The company’s figures declined on a year-over-year basis. Total sales in the first quarter were negatively impacted by a year-over-year decline in COVID testing-related sales.
However, Organic sales growth excluding COVID testing increased 10%, led by double-digit growth in Medical Devices, EPD and Nutrition. EPD successfully continued with its double-digit sales growth momentum for the last two years.
Medical Device registered strong sales led by double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. The Diabetes Care business continued to benefit from the growing sales of its sensor-based continuous glucose monitoring system, FreeStyle Libre.
(You can read the full research report on Abbott Laboratories here >>>)
Other noteworthy reports we are featuring today include Cisco Systems, Inc. (CSCO), Sony Group Corporation (SONY) and Duke Energy Corporation (DUK).
Director of Research
Sheraz Mian
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
P&G's (PG) Productivity & Cost Savings Plan to Aid Margins
Higher Rates, Loans Support BofA (BAC) Amid Fee Income Woes
Organic Sales Gain, Growing EPD Business Aid Abbott (ABT)
Featured Reports
Cisco (CSCO) Benefits From Strong Security Products Adoption
Per Zacks analyst, Cisco is benefiting from a rapidly growing security market driven by robust adoption of identity and access, advanced threat and unified threat management security solutions.
SONY Benefits From Improving Music & G&NS Segment Sales
Per the Zacks analyst, Sony is gaining from strong performance of its Music and G&NS segments. However, stiff competition and weak global macroeconomic conditions remain major concerns.
Solid Investments Aid Duke Energy (DUK), Weak Solvency Woes
Per the Zacks analyst, Duke Energy's investment in infrastructure and expansion projects tend to boost its long-term growth prospects. However, its weak solvency position remains a bottleneck.
CNG Vehicles Aid Republic Services (RSG) Amid Low Liquidity
Per the Zacks analyst, Republic Services is focused on increasing its operational efficiency by shifting to compressed natural gas (CNG) collection vehicles. Low liquidity remains a concern.
Cost-Control Efforts & Solid Balance Sheet Aid MetLife (MET)
Per the Zacks analyst, strategic initiatives have enabled MetLife to control costs, which is driving margins. Its strong capital position allows investment for long-term growth.
Solid Comps Growth & Loyalty Program Aid Yum China (YUMC)
Per the Zacks analyst, solid growth in same-store sales backed by menu innovation, unit expansion and digitalization efforts aid Yum China. Also, growth in loyalty programs bode well.
Growth in Galafold Fuels Amicus' (FOLD) Growth
Amicus's Fabry disease drug, Galafold has shown solid uptake since launch. Per the Zacks analyst, successful approval of Pombiliti + Opfolda can strengthen its portfolio further.
New Upgrades
Palo Alto (PANW) Rides on Product Strength, Marketing Effort
Per the Zacks analyst, Palo Alto Networks is gaining from solid contributions of its growth-oriented products including Strata, Prisma and Cortex. Increasing marketing efforts are also positive.
Strong Sales Volumes & EV Push Drive Honda (HMC)
Honda is benefiting from robust pent-up demand for vehicles amid improving inventory levels. The Zacks analyst also likes the company's commitment to expanding its electric vehicle lineup.
Urban Outfitters' (URBN) FP Initiative Appears Promising
Per the Zacks analyst, Urban Outfitters' strategic growth initiative, FP Movement, bodes well. The FP Movement offers a major growth opportunity and is expected to boost Free People's brand revenues.
New Downgrades
Higher Input & Production Costs Hurt Kronos Worldwide (KRO)
Per the Zacks analyst, higher raw material costs due to disruptions in supply chains will weigh on the company's bottom line. It also faces headwind from increased production costs.
EPAM Systems' (EPAM) Hurt by Weakening Demand Environment
Per the Zacks analyst, EPAM's growth prospects might be hurt by the deteriorating demand environment as organizations are turning more cautious on IT spending amid the ongoing macroeconomic headwinds.
Huge Debt, Rising Costs Hurt DCP Midstream's (DCP) Margins
The Zacks analyst is worried about DCP Midstream's increasing debt load, which can lead to volatile earnings. The partnership's rising operating and maintenance expenses are concerning.
Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom
It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They’re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation.
>>Show me how I could profit from the metaverse!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Bank of America Corporation (BAC) : Free Stock Analysis Report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Duke Energy Corporation (DUK) : Free Stock Analysis Report
Procter & Gamble Company (The) (PG) : Free Stock Analysis Report
Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report
Sony Corporation (SONY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read P&G's (PG) Productivity & Cost Savings Plan to Aid Margins Higher Rates, Loans Support BofA (BAC) Amid Fee Income Woes Organic Sales Gain, Growing EPD Business Aid Abbott (ABT) Featured Reports Cisco (CSCO) Benefits From Strong Security Products Adoption Per Zacks analyst, Cisco is benefiting from a rapidly growing security market driven by robust adoption of identity and access, advanced threat and unified threat management security solutions. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT). Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Duke Energy Corporation (DUK) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Sony Corporation (SONY) : Free Stock Analysis Report To read this article on Zacks.com click here. | Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read P&G's (PG) Productivity & Cost Savings Plan to Aid Margins Higher Rates, Loans Support BofA (BAC) Amid Fee Income Woes Organic Sales Gain, Growing EPD Business Aid Abbott (ABT) Featured Reports Cisco (CSCO) Benefits From Strong Security Products Adoption Per Zacks analyst, Cisco is benefiting from a rapidly growing security market driven by robust adoption of identity and access, advanced threat and unified threat management security solutions. Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Duke Energy Corporation (DUK) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Sony Corporation (SONY) : Free Stock Analysis Report To read this article on Zacks.com click here. | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read P&G's (PG) Productivity & Cost Savings Plan to Aid Margins Higher Rates, Loans Support BofA (BAC) Amid Fee Income Woes Organic Sales Gain, Growing EPD Business Aid Abbott (ABT) Featured Reports Cisco (CSCO) Benefits From Strong Security Products Adoption Per Zacks analyst, Cisco is benefiting from a rapidly growing security market driven by robust adoption of identity and access, advanced threat and unified threat management security solutions. Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Duke Energy Corporation (DUK) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Sony Corporation (SONY) : Free Stock Analysis Report To read this article on Zacks.com click here. Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT). | Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Bank of America Corporation (BAC) and Abbott Laboratories (ABT). Click to get this free report Bank of America Corporation (BAC) : Free Stock Analysis Report Abbott Laboratories (ABT) : Free Stock Analysis Report Duke Energy Corporation (DUK) : Free Stock Analysis Report Procter & Gamble Company (The) (PG) : Free Stock Analysis Report Cisco Systems, Inc. (CSCO) : Free Stock Analysis Report Sony Corporation (SONY) : Free Stock Analysis Report To read this article on Zacks.com click here. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read P&G's (PG) Productivity & Cost Savings Plan to Aid Margins Higher Rates, Loans Support BofA (BAC) Amid Fee Income Woes Organic Sales Gain, Growing EPD Business Aid Abbott (ABT) Featured Reports Cisco (CSCO) Benefits From Strong Security Products Adoption Per Zacks analyst, Cisco is benefiting from a rapidly growing security market driven by robust adoption of identity and access, advanced threat and unified threat management security solutions. |
30970.0 | 2023-06-07 00:00:00 UTC | Relative Strength Alert For Abbott Laboratories | ABT | https://www.nasdaq.com/articles/relative-strength-alert-for-abbott-laboratories-0 | nan | nan | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) entered into oversold territory, hitting an RSI reading of 29.98, after changing hands as low as $101.25 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 62.2. A bullish investor could look at ABT's 29.98 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABT shares:
Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $116.15 as the 52 week high point — that compares with a last trade of $101.69.
Free Report: Top 8%+ Dividends (paid monthly)
Find out what 9 other oversold stocks you need to know about »
Also see:
GROW Dividend Growth Rate
ACHR Videos
CORT shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A bullish investor could look at ABT's 29.98 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABT shares: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $116.15 as the 52 week high point — that compares with a last trade of $101.69. In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) entered into oversold territory, hitting an RSI reading of 29.98, after changing hands as low as $101.25 per share. | A bullish investor could look at ABT's 29.98 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABT shares: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $116.15 as the 52 week high point — that compares with a last trade of $101.69. In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) entered into oversold territory, hitting an RSI reading of 29.98, after changing hands as low as $101.25 per share. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) entered into oversold territory, hitting an RSI reading of 29.98, after changing hands as low as $101.25 per share. The chart below shows the one year performance of ABT shares: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $116.15 as the 52 week high point — that compares with a last trade of $101.69. A bullish investor could look at ABT's 29.98 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) entered into oversold territory, hitting an RSI reading of 29.98, after changing hands as low as $101.25 per share. A bullish investor could look at ABT's 29.98 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ABT shares: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $116.15 as the 52 week high point — that compares with a last trade of $101.69. |
30971.0 | 2023-06-07 00:00:00 UTC | Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True? | ABT | https://www.nasdaq.com/articles/abbott-abt-is-considered-a-good-investment-by-brokers%3A-is-that-true | nan | nan | The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT).
Abbott currently has an average brokerage recommendation (ABR) of 1.67, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 18 brokerage firms. An ABR of 1.67 approximates between Strong Buy and Buy.
Of the 18 recommendations that derive the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.7% and 11.1% of all recommendations.
Brokerage Recommendation Trends for ABT
Check price target & stock forecast for Abbott here>>>
While the ABR calls for buying Abbott, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.
In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
ABR Should Not Be Confused With Zacks Rank
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
Is ABT Worth Investing In?
In terms of earnings estimate revisions for Abbott, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.38.
Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Abbott. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Abbott.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT). Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT). Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT). Brokerage Recommendation Trends for ABT Is ABT Worth Investing In? | Brokerage Recommendation Trends for ABT Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Abbott (ABT). Is ABT Worth Investing In? |
30972.0 | 2023-06-07 00:00:00 UTC | Abbott (ABT) Dips More Than Broader Markets: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-dips-more-than-broader-markets%3A-what-you-should-know-3 | nan | nan | Abbott (ABT) closed the most recent trading day at $101.66, moving -0.94% from the previous trading session. This move lagged the S&P 500's daily loss of 0.38%. Elsewhere, the Dow gained 0.27%, while the tech-heavy Nasdaq lost 4.19%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 6.92% over the past month. This has lagged the Medical sector's loss of 2.31% and the S&P 500's gain of 3.78% in that time.
Investors will be hoping for strength from Abbott as it approaches its next earnings release. On that day, Abbott is projected to report earnings of $1.04 per share, which would represent a year-over-year decline of 27.27%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.67 billion, down 14.08% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.38 billion. These results would represent year-over-year changes of -17.98% and -9.8%, respectively.
Investors should also note any recent changes to analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Abbott is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Abbott is holding a Forward P/E ratio of 23.41. This valuation marks a premium compared to its industry's average Forward P/E of 22.69.
It is also worth noting that ABT currently has a PEG ratio of 4.6. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.52 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 53, which puts it in the top 22% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $101.66, moving -0.94% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.38 billion. It is also worth noting that ABT currently has a PEG ratio of 4.6. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $101.66, moving -0.94% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.38 billion. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $101.66, moving -0.94% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.38 billion. | Abbott (ABT) closed the most recent trading day at $101.66, moving -0.94% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.38 billion. It is also worth noting that ABT currently has a PEG ratio of 4.6. |
30973.0 | 2023-06-07 00:00:00 UTC | Validea's Top 5 Health Care Stocks Based On Benjamin Graham - 6/7/2023 | ABT | https://www.nasdaq.com/articles/valideas-top-5-health-care-stocks-based-on-benjamin-graham-6-7-2023 | nan | nan | The following are the top rated Health Care stocks according to Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.
CROSS COUNTRY HEALTHCARE, INC. (CCRN) is a small-cap value stock in the Business Services industry. The rating according to our strategy based on Benjamin Graham is 86% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cross Country Healthcare, Inc. is a technology-enabled workforce solution and advisory company. The Company operates through two segments: Nurse and Allied Staffing and Physician Staffing. The Nurse and Allied Staffing segment provides workforce solutions and traditional staffing, recruiting, and value-added total talent solutions, including temporary and permanent placement of travel and local nurse and allied professionals, temporary placement of healthcare leaders within nursing, allied, physician, human resources, and managed services programs (MSP) services, in-home care services, and outsourcing services. The Physician Staffing segment provides physicians in many specialties, as well as certified registered nurse anesthetists, nurse practitioners, and physician assistants as independent contractors on temporary assignments throughout the United States at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, and government facilities.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: PASS
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: PASS
PRICE/BOOK RATIO: PASS
Detailed Analysis of CROSS COUNTRY HEALTHCARE, INC.
CCRN Guru Analysis
CCRN Fundamental Analysis
GRIFOLS SA - ADR (GRFS) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Benjamin Graham is 57% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL
LONG-TERM EPS GROWTH: PASS
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of GRIFOLS SA - ADR
GRFS Guru Analysis
GRFS Fundamental Analysis
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: FAIL
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL
LONG-TERM EPS GROWTH: PASS
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
EXACT SCIENCES CORP (EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company's products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient's breast tumor tissue.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: PASS
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: FAIL
PRICE/BOOK RATIO: FAIL
Detailed Analysis of EXACT SCIENCES CORP
EXAS Guru Analysis
EXAS Fundamental Analysis
COMMUNITY HEALTH SYSTEMS INC (CYH) is a small-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Benjamin Graham is 43% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Community Health Systems, Inc. is a healthcare company. The Company through its subsidiaries, owns or leases approximately 79 affiliated hospitals, with 13,000 beds, and operates more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers, and ambulatory surgery centers. The Company, through its affiliates, provides healthcare services, developing and operating healthcare delivery systems in approximately 44 distinct markets across 15 states. Its hospitals and other sites of care offer a broad variety of inpatient and outpatient medical and surgical services. These include general acute care, emergency room, general and specialty surgery, critical care, internal medicine, obstetrics, diagnostic services, and psychiatric and rehabilitation services. The Company serves governmental agencies, private insurers, and patients.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SECTOR: PASS
SALES: PASS
CURRENT RATIO: FAIL
LONG-TERM DEBT IN RELATION TO NET CURRENT ASSETS: FAIL
LONG-TERM EPS GROWTH: FAIL
P/E RATIO: PASS
PRICE/BOOK RATIO: FAIL
Detailed Analysis of COMMUNITY HEALTH SYSTEMS INC
CYH Guru Analysis
CYH Fundamental Analysis
Benjamin Graham Portfolio
Top Benjamin Graham Stocks
About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. Known as both the "Father of Value Investing" and the founder of the entire field of security analysis, Graham mentored several of history's greatest investors -- including Warren Buffett -- and inspired a slew of others, including John Templeton, Mario Gabelli, and another of Validea's gurus, John Neff. Graham built his fortune and reputation after living through some extremely difficult times, including both the Great Depression and his own family's financial woes following his father's death when Benjamin was a young man. His investment firm posted per annum returns of about 20 percent from 1936 to 1956, far outpacing the 12.2 percent average return for the market during that time.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of GRIFOLS SA - ADR GRFS Guru Analysis GRFS Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis EXACT SCIENCES CORP (EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The following are the top rated Health Care stocks according to Validea's Value Investor model based on the published strategy of Benjamin Graham. | Detailed Analysis of GRIFOLS SA - ADR GRFS Guru Analysis GRFS Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis EXACT SCIENCES CORP (EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The Company's products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. | Detailed Analysis of GRIFOLS SA - ADR GRFS Guru Analysis GRFS Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis EXACT SCIENCES CORP (EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. | Detailed Analysis of GRIFOLS SA - ADR GRFS Guru Analysis GRFS Fundamental Analysis ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis EXACT SCIENCES CORP (EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. |
30974.0 | 2023-06-06 00:00:00 UTC | Noteworthy ETF Inflows: VT, WMT, BAC, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vt-wmt-bac-abt | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $615.1 million dollar inflow -- that's a 2.3% increase week over week in outstanding units (from 286,847,202 to 293,352,298). Among the largest underlying components of VT, in trading today Walmart Inc (Symbol: WMT) is down about 0.2%, Bank of America Corp (Symbol: BAC) is up about 2%, and Abbott Laboratories (Symbol: ABT) is lower by about 1%. For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average:
Looking at the chart above, VT's low point in its 52 week range is $76.80 per share, with $95.04 as the 52 week high point — that compares with a last trade of $94.80. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
Also see:
Oversold Canadian Stocks
Top Ten Hedge Funds Holding MVG
FINM Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VT, in trading today Walmart Inc (Symbol: WMT) is down about 0.2%, Bank of America Corp (Symbol: BAC) is up about 2%, and Abbott Laboratories (Symbol: ABT) is lower by about 1%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of VT, in trading today Walmart Inc (Symbol: WMT) is down about 0.2%, Bank of America Corp (Symbol: BAC) is up about 2%, and Abbott Laboratories (Symbol: ABT) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $615.1 million dollar inflow -- that's a 2.3% increase week over week in outstanding units (from 286,847,202 to 293,352,298). For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $76.80 per share, with $95.04 as the 52 week high point — that compares with a last trade of $94.80. | Among the largest underlying components of VT, in trading today Walmart Inc (Symbol: WMT) is down about 0.2%, Bank of America Corp (Symbol: BAC) is up about 2%, and Abbott Laboratories (Symbol: ABT) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $615.1 million dollar inflow -- that's a 2.3% increase week over week in outstanding units (from 286,847,202 to 293,352,298). For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $76.80 per share, with $95.04 as the 52 week high point — that compares with a last trade of $94.80. | Among the largest underlying components of VT, in trading today Walmart Inc (Symbol: WMT) is down about 0.2%, Bank of America Corp (Symbol: BAC) is up about 2%, and Abbott Laboratories (Symbol: ABT) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard Total World Stock ETF (Symbol: VT) where we have detected an approximate $615.1 million dollar inflow -- that's a 2.3% increase week over week in outstanding units (from 286,847,202 to 293,352,298). For a complete list of holdings, visit the VT Holdings page » The chart below shows the one year price performance of VT, versus its 200 day moving average: Looking at the chart above, VT's low point in its 52 week range is $76.80 per share, with $95.04 as the 52 week high point — that compares with a last trade of $94.80. |
30975.0 | 2023-06-05 00:00:00 UTC | Should You Pick Stryker Stock Over BAX For Better Returns? | ABT | https://www.nasdaq.com/articles/should-you-pick-stryker-stock-over-bax-for-better-returns | nan | nan | We believe Stryker stock (NYSE: SYK) is a better pick in the Medical Devices industry than Baxter stock (NYSE: BAX), given its better prospects. Although SYK trades at a superior valuation of 5.5x trailing revenues vs. 1.4x for BAX, this gap in valuation makes sense to a large extent, given the former’s better profitability and financial position, as discussed below.
Looking at stock returns, SYK has fared much better with 13% returns this year vs. -20% returns for BAX and 9% gains for the broader S&P500 index. There is more to the comparison, and in the sections below, we discuss why we believe that SYK will offer better returns than BAX in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Stryker vs. Baxter: Which Stock Is A Better Bet? Parts of the analysis are summarized below.
1. Baxter’s Revenue Growth Is Better
Baxter’s revenue growth has been slightly better, with a 10.2% average annual growth rate in the last three years, compared to 7.8% for Stryker.
Stryker’s revenue growth has been driven by new product launches, such as – Surgi-Count+ – a surgical sponge counting system, Insignia Hip Stem, Power-PRO 2 ambulance cot, and Vecta 71/74 aspiration system, among others. Of late, it has seen a rise in volume for both of its segments – MedSurg & Neurotechnology and Orthopedics and Spine.
Stryker’s revenue growth has also been buoyed by the acquisition of Wright Medical, a medical device company, in late 2020, and Vocera Communications – a company focused on communications systems for the healthcare industry – last year.
Baxter’s sales growth has been led by increased demand for its advanced surgery products. In December 2021, Baxter completed the Hillrom acquisition, which added connected care offerings, including Smart Beds and patient monitoring products, to Baxter’s existing portfolio of the acute, nutritional, renal, hospital, and surgical care products.
However, Baxter’s 2023 guidance of low single-digit sales growth, and earnings falling to $2.92 on a per share and adjusted basis at the mid-point of its guidance, didn’t sit well with the investors. The company’s management cited external macroeconomic factors and supply-chain constraints for the lower guidance.
Our Stryker Revenue Comparison and Baxter Revenue Comparison dashboards provide more insight into the companies’ sales.
Looking forward, Stryker’s revenue is expected to grow faster than Baxter’s over the next three years. The table below summarizes our revenue expectations for the two companies over the next three years. It points to a CAGR of 7.2% for Stryker, compared to a 3.6% CAGR for Baxter, based on Trefis Machine Learning analysis.
Note that we have different methodologies for companies negatively impacted by Covid and those not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to predict recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months.
2. Stryker Is More Profitable
Stryker’s operating margin has slid from 18.2% in 2019 to 15.4% in 2022, while Baxter’s operating margin declined from 15.0% to -15.5% over this period.
Looking at the last twelve-month period, Stryker’s operating margin of 16.5% fares much better than -15.6% for Baxter.
This sharp decline for Baxter can be attributed to an impairment charge of $3.2 billion on the goodwill related to the Hillrom acquisition.
Our Stryker Operating Income Comparison and Baxter Operating Income Comparison dashboards have more details.
Stryker’s free cash flow margin of 15.1% is higher than 9.8% for Baxter.
Looking at financial risk, Stryker fares better with its 12.5% debt as a percentage of equity, lower than 79.8% for Baxter. However, Baxter’s 5.9% cash as a percentage of assets is marginally higher than 4.8% for Stryker, implying that Stryker has a better debt position and Baxter has more cash cushion.
3. The Net of It All
We see that Stryker is more profitable and has a better debt position. On the other hand, Baxter has seen better revenue growth, is trading at a lower valuation multiple, and has more cash cushion.
Now, looking at prospects, using P/S as a base, due to high fluctuations in P/E and P/EBIT, we believe Stryker is the better choice of the two, despite its higher valuation.
If we compare the current valuation multiples to the historical averages, Baxter fares better, with its stock currently trading at 1.3x trailing revenues vs. the last five-year average of 3.2x. In contrast, Stryker stock trades at 5.4x trailing revenues vs. the last five-year average of 5.9x. Still, we believe Stryker’s better prospects make it a better pick.
Our Stryker (SYK) Valuation Ratios Comparison and Baxter (BAX) Valuation Ratios Comparison have more details.
The table below summarizes our revenue and return expectations for Stryker and Baxter over the next three years and points to an expected return of 20% for Stryker over this period vs. an 11% expected return for Baxter, based on Trefis Machine Learning analysis – Stryker vs. Baxter – which also provides more details on how we arrive at these numbers.
While SYK may outperform BAX in the next three years, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Baxter vs. Copart.
What if you’re looking for a high-performance portfolio with a low downside instead? Here’s a reinforced value portfolio that has beaten the market consistently while limiting losses during periods of sharp market declines.
Returns Jun 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
SYK Return 0% 13% 130%
BAX Return 0% -20% -8%
S&P 500 Return 0% 9% 87%
Trefis Multi-Strategy Portfolio 0% 10% 245%
[1] Month-to-date and year-to-date as of 6/1/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Stryker vs. Baxter: Which Stock Is A Better Bet? Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. While SYK may outperform BAX in the next three years, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. | Our Stryker Operating Income Comparison and Baxter Operating Income Comparison dashboards have more details. Our Stryker (SYK) Valuation Ratios Comparison and Baxter (BAX) Valuation Ratios Comparison have more details. The table below summarizes our revenue and return expectations for Stryker and Baxter over the next three years and points to an expected return of 20% for Stryker over this period vs. an 11% expected return for Baxter, based on Trefis Machine Learning analysis – Stryker vs. Baxter – which also provides more details on how we arrive at these numbers. | Baxter’s Revenue Growth Is Better Baxter’s revenue growth has been slightly better, with a 10.2% average annual growth rate in the last three years, compared to 7.8% for Stryker. However, Baxter’s 5.9% cash as a percentage of assets is marginally higher than 4.8% for Stryker, implying that Stryker has a better debt position and Baxter has more cash cushion. The table below summarizes our revenue and return expectations for Stryker and Baxter over the next three years and points to an expected return of 20% for Stryker over this period vs. an 11% expected return for Baxter, based on Trefis Machine Learning analysis – Stryker vs. Baxter – which also provides more details on how we arrive at these numbers. | Looking at stock returns, SYK has fared much better with 13% returns this year vs. -20% returns for BAX and 9% gains for the broader S&P500 index. Baxter’s Revenue Growth Is Better Baxter’s revenue growth has been slightly better, with a 10.2% average annual growth rate in the last three years, compared to 7.8% for Stryker. The table below summarizes our revenue and return expectations for Stryker and Baxter over the next three years and points to an expected return of 20% for Stryker over this period vs. an 11% expected return for Baxter, based on Trefis Machine Learning analysis – Stryker vs. Baxter – which also provides more details on how we arrive at these numbers. |
30976.0 | 2023-06-04 00:00:00 UTC | 2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip | ABT | https://www.nasdaq.com/articles/2-dividend-kings-down-12-and-14-youll-regret-not-buying-on-the-dip | nan | nan | Dividend Kings are among the most steady corporations on the market. While many businesses don't even last a decade, these companies have survived and thrived and raised their payouts for at least 50 consecutive years to become a member of this elite group.
Still, being a Dividend King does not make a company immune to challenges. Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns. But these longtime dividend payers remain excellent stocks to buy on the dip. Here's why.
ABT data by YCharts
1. Abbott Laboratories
In the first quarter, medical devices specialist Abbott Laboratories saw its sales slump 18.1% to $9.7 billion. That was primarily due to a substantial drop in demand for coronavirus diagnostic products. In the early days of the pandemic, Abbott developed and marketed several COVID-19 tests, which helped its top line stay afloat while pandemic-related factors harmed its core medical devices business.
These dynamics have made Abbott's financial results somewhat unpredictable and volatile in the past couple of years. Further, the company has faced other issues, including safety concerns within its nutrition business. Those factors explain Abbott's poor stock market performance over the past year.
Even so, there is plenty to look forward to today. First, the company's results will soon be free from pandemic-related distortions. In the first quarter, Abbott's organic sales (excluding coronavirus diagnostics) increased by 10% year over year.
Second, Abbott Laboratories boasts plenty of long-term growth opportunities. The company is a proven innovator that has constantly developed new medical devices to address the needs of patients. One of its most promising areas is diabetes care. Abbott is a leader in continuous glucose monitoring thanks to its FreeStyle Libre franchise.
Other aspects of its business, such as structural heart and heart failure, also boast real promise. And thanks to the patents that protect its inventions, Abbott Labs can benefit from them for a long time.
Third, there is the company's dividend. Abbott is on its 51st consecutive year of payout increases. The company won't risk breaking this fantastic run, so expect more yearly dividend hikes. The healthcare giant offers a yield of 2.01%, slightly higher than the S&P 500's 1.66%. And Abbott's 49% cash payout ratio suggests more room for dividend growth.
Despite the company's recent struggles, dividend investors can't go wrong by initiating a position in Abbott, especially while its shares are down.
2. Johnson & Johnson
Johnson & Johnson has performed relatively well in terms of its financial results of late. However, the company is still being held back by a barrage of lawsuits related to its talc powder products. The pharmaceutical giant seems to be moving closer toward a favorable settlement, but this dark cloud is still hovering above the company.
Fortunately, J&J has a strong balance sheet and enough financial resources to manage these legal problems. Elsewhere, the company is evolving. It recently spun off its consumer health division into a stand-alone company, and bolstered its medical device business with an acquisition. These moves should help increase Johnson & Johnson's revenue and earnings growth.
One of the company's greatest strengths is its extensive portfolio of medicines. Physicians don't stop recommending medications during economic downturns, especially not those like cancer drugs Darzalex and Erleada or immunosuppressants Tremfya and Stelara. These are among the many therapies helping Johnson & Johnson grow its revenue.
The company's vast pipeline, which features several dozen programs, usually spits out brand-new approvals or label expansions several times a year. Ditto for J&J's medtech unit, where the company is also an adept innovator and boasts exciting opportunities, including with its robotic-assisted surgery device Ottava. Johnson & Johnson's business should allow it to record consistent revenue and earnings, just as it has in the past.
In the first quarter, the company's top line jumped 5.6% year over year to $24.7 billion, while its adjusted net income declined by almost 1% to $7.1 billion. Johnson & Johnson has raised its payouts for 61 consecutive years, and it should continue doing so for a while, even with a seemingly high 73% cash payout ratio. Johnson & Johnson has the profile of a Dividend King that income-seeking investors can buy and hold forever.
10 stocks we like better than Abbott Laboratories
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Abbott Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of May 30, 2023
Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns. ABT data by YCharts 1. In the early days of the pandemic, Abbott developed and marketed several COVID-19 tests, which helped its top line stay afloat while pandemic-related factors harmed its core medical devices business. | Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns. ABT data by YCharts 1. In the early days of the pandemic, Abbott developed and marketed several COVID-19 tests, which helped its top line stay afloat while pandemic-related factors harmed its core medical devices business. | Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns. ABT data by YCharts 1. Abbott Laboratories In the first quarter, medical devices specialist Abbott Laboratories saw its sales slump 18.1% to $9.7 billion. | Case in point: Abbott Laboratories (NYSE: ABT) and Johnson & Johnson (NYSE: JNJ) are two members of this prominent clique that have lagged the market recently, partly due to company-specific concerns. ABT data by YCharts 1. Third, there is the company's dividend. |
30977.0 | 2023-06-04 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-22 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top NASDAQ 100 Stocks
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30978.0 | 2023-06-01 00:00:00 UTC | Abbott (ABT) Gains But Lags Market: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-but-lags-market%3A-what-you-should-know-15 | nan | nan | Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. This change lagged the S&P 500's 0.99% gain on the day.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 8.73% over the past month. This has lagged the Medical sector's loss of 3.51% and the S&P 500's gain of 0.42% in that time.
Investors will be hoping for strength from Abbott as it approaches its next earnings release. In that report, analysts expect Abbott to post earnings of $1.04 per share. This would mark a year-over-year decline of 27.27%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.67 billion, down 14.08% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. These results would represent year-over-year changes of -17.98% and -9.83%, respectively.
Investors should also note any recent changes to analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.07% higher. Abbott currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Abbott is holding a Forward P/E ratio of 23.27. Its industry sports an average Forward P/E of 22.06, so we one might conclude that Abbott is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 4.57. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.45 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 47, putting it in the top 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. We can also see that ABT currently has a PEG ratio of 4.57. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. | ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.57. | Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. We can also see that ABT currently has a PEG ratio of 4.57. |
30979.0 | 2023-06-01 00:00:00 UTC | Abbott (ABT) Gains But Lags Market: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-but-lags-market%3A-what-you-should-know-14 | nan | nan | Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. This change lagged the S&P 500's 0.99% gain on the day.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 8.73% over the past month. This has lagged the Medical sector's loss of 3.51% and the S&P 500's gain of 0.42% in that time.
Investors will be hoping for strength from Abbott as it approaches its next earnings release. In that report, analysts expect Abbott to post earnings of $1.04 per share. This would mark a year-over-year decline of 27.27%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $9.67 billion, down 14.08% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. These results would represent year-over-year changes of -17.98% and -9.83%, respectively.
Investors should also note any recent changes to analyst estimates for Abbott. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.07% higher. Abbott currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Abbott is holding a Forward P/E ratio of 23.27. Its industry sports an average Forward P/E of 22.06, so we one might conclude that Abbott is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 4.57. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products industry currently had an average PEG ratio of 2.45 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 47, putting it in the top 19% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. We can also see that ABT currently has a PEG ratio of 4.57. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. | Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. We can also see that ABT currently has a PEG ratio of 4.57. | Abbott (ABT) closed the most recent trading day at $102.82, moving +0.8% from the previous trading session. ABT's full-year Zacks Consensus Estimates are calling for earnings of $4.38 per share and revenue of $39.36 billion. We can also see that ABT currently has a PEG ratio of 4.57. |
30980.0 | 2023-05-31 00:00:00 UTC | What's Next For Medtronic Stock After A 9% Fall In A Week? | ABT | https://www.nasdaq.com/articles/whats-next-for-medtronic-stock-after-a-9-fall-in-a-week | nan | nan | Medtronic stock (NYSE: MDT) is down 9% in a week, underperforming the broader markets, with the S&P500 up 0.4%. Although the company posted upbeat Q1 results last week, the stock has declined due to lower-than-expected guidance for fiscal 2024. After its recent fall, MDT stock appears to have room for growth, as discussed below.
Medtronic’s revenue was up 6% to $8.5 billion in Q4’23, compared to our forecast of $8.2 billion, driven by continued recovery in procedure volume. Looking at segments, Cardiovascular sales were up 12% and Neuroscience up 5%, while Medical Surgical, and Diabetes saw a 0.3% decline. The company held its operating margin above 29%, reflecting a modest 30 bps decline y-o-y. On a reported basis, the operating margin declined 230 bps to 18.3%. Our Medtronic Operating Income Comparison dashboard has more details (Note that LTM figures in this dashboard don’t take into account the Q4 numbers released last week). Medtronic reported adjusted earnings of $1.57 on a per share and adjusted basis, up 5% y-o-y, and it compares with our forecast of $1.56.
Although Medtronic posted upbeat Q4 results, its fiscal 2024 earnings outlook was lower than anticipated. It expects its earnings to be between $5.00 and $5.10 on a per-share and adjusted basis, compared to expected EPS of around $5.20. At the mid-point of the provided range, this reflects a 5% cut from its $5.29 figure reported in fiscal 2023. This did not sit well with the investors, evident from the recent stock price decline. Medtronic has also announced its plans to acquire South Korea-based insulin patch maker EOFlow for $738 million.
We have updated our model to reflect the latest results. We forecast the company’s sales to rise 4% to $32.3 billion in fiscal 2024 and its earnings to be around the higher end of the guidance at $5.11. Looking at the stock price, we estimate Medtronic’s Valuation to be $93 per share, about 15% above the current market price of $81. At its current levels, Medtronic stock is trading at 16x its expected forward earnings of $5.11 on a per share and adjusted basis for fiscal 2024, compared to the last three-year average of around 21x. We have assigned a slightly lower multiple for Medtronic compared to its historical average, considering the expected cut in earnings in the near term. Furthermore, the recent uncertainty in the financial sector has raised concerns about a potential recession, which may impact Medtronic’s business.
What if you’re looking for a high-performance portfolio with a low downside instead? Here’s a reinforced value portfolio that has beaten the market consistently while limiting losses during periods of sharp market declines.
Returns May 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
MDT Return -10% 5% 14%
S&P 500 Return 1% 10% 88%
Trefis Multi-Strategy Portfolio 1% 10% 245%
[1] Month-to-date and year-to-date as of 5/30/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtronic has also announced its plans to acquire South Korea-based insulin patch maker EOFlow for $738 million. At its current levels, Medtronic stock is trading at 16x its expected forward earnings of $5.11 on a per share and adjusted basis for fiscal 2024, compared to the last three-year average of around 21x. We have assigned a slightly lower multiple for Medtronic compared to its historical average, considering the expected cut in earnings in the near term. | Although the company posted upbeat Q1 results last week, the stock has declined due to lower-than-expected guidance for fiscal 2024. On a reported basis, the operating margin declined 230 bps to 18.3%. Total [2] MDT Return -10% 5% 14% S&P 500 Return 1% 10% 88% Trefis Multi-Strategy Portfolio 1% 10% 245% [1] Month-to-date and year-to-date as of 5/30/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Medtronic reported adjusted earnings of $1.57 on a per share and adjusted basis, up 5% y-o-y, and it compares with our forecast of $1.56. At its current levels, Medtronic stock is trading at 16x its expected forward earnings of $5.11 on a per share and adjusted basis for fiscal 2024, compared to the last three-year average of around 21x. Total [2] MDT Return -10% 5% 14% S&P 500 Return 1% 10% 88% Trefis Multi-Strategy Portfolio 1% 10% 245% [1] Month-to-date and year-to-date as of 5/30/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Although the company posted upbeat Q1 results last week, the stock has declined due to lower-than-expected guidance for fiscal 2024. Medtronic reported adjusted earnings of $1.57 on a per share and adjusted basis, up 5% y-o-y, and it compares with our forecast of $1.56. Looking at the stock price, we estimate Medtronic’s Valuation to be $93 per share, about 15% above the current market price of $81. |
30981.0 | 2023-05-31 00:00:00 UTC | Abbott (ABT) Gains As Market Dips: What You Should Know | ABT | https://www.nasdaq.com/articles/abbott-abt-gains-as-market-dips%3A-what-you-should-know-10 | nan | nan | Abbott (ABT) closed the most recent trading day at $102, moving +0.29% from the previous trading session. This change outpaced the S&P 500's 0.61% loss on the day. At the same time, the Dow lost 0.41%, and the tech-heavy Nasdaq gained 10.45%.
Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 8.78% over the past month. This has lagged the Medical sector's loss of 4.16% and the S&P 500's gain of 1.05% in that time.
Wall Street will be looking for positivity from Abbott as it approaches its next earnings report date. The company is expected to report EPS of $1.04, down 27.27% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $9.67 billion, down 14.08% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $4.38 per share and revenue of $39.38 billion. These totals would mark changes of -17.98% and -9.8%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Abbott. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.07% higher within the past month. Abbott is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Abbott's current valuation metrics, including its Forward P/E ratio of 23.21. Its industry sports an average Forward P/E of 22.11, so we one might conclude that Abbott is trading at a premium comparatively.
We can also see that ABT currently has a PEG ratio of 4.56. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.44 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 52, putting it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABT in the coming trading sessions, be sure to utilize Zacks.com.
Just Released: Free Report Reveals Little-Known Strategies to Help Profit from the $30 Trillion Metaverse Boom
It's undeniable. The metaverse is gaining steam every day. Just follow the money. Google. Microsoft. Adobe. Nike. Facebook even rebranded itself as Meta because Mark Zuckerberg believes the metaverse is the next iteration of the internet. The inevitable result? Many investors will get rich as the metaverse evolves. What do they know that you don't? They’re aware of the companies best poised to grow as the metaverse does. And in a new FREE report, Zacks is revealing those stocks to you. This week, you can download, The Metaverse - What is it? And How to Profit with These 5 Pioneering Stocks. It reveals specific stocks set to skyrocket as this emerging technology develops and expands. Don't miss your chance to access it for free with no obligation.
>>Show me how I could profit from the metaverse!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott (ABT) closed the most recent trading day at $102, moving +0.29% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.56. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com. | Abbott (ABT) closed the most recent trading day at $102, moving +0.29% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.56. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott (ABT) closed the most recent trading day at $102, moving +0.29% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.56. | Abbott (ABT) closed the most recent trading day at $102, moving +0.29% from the previous trading session. We can also see that ABT currently has a PEG ratio of 4.56. To follow ABT in the coming trading sessions, be sure to utilize Zacks.com. |
30982.0 | 2023-05-31 00:00:00 UTC | Peter Lynch Detailed Fundamental Analysis - ABT | ABT | https://www.nasdaq.com/articles/peter-lynch-detailed-fundamental-analysis-abt | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top NASDAQ 100 Stocks
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30983.0 | 2023-05-30 00:00:00 UTC | Abbott (ABT) Reports Upbeat Cardiomems Sensor Study Result | ABT | https://www.nasdaq.com/articles/abbott-abt-reports-upbeat-cardiomems-sensor-study-result | nan | nan | Abbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study — MONITOR-HF. The study revealed that Abbott's CardioMEMS HF System led to a significant improvement in quality-of-life scores in patients with indicated heart failures as early as three months. The MONITOR-HF results were announced recently at a late-breaking presentation at the European Society of Cardiology's annual meeting of the Heart Failure Association in Prague.
The recent development will fortify Abbott’s Heart Failure business.
More on MONITOR-HF Trial
A prospective, randomized trial called MONITOR-HF has 348 patients registered in 25 centres across the Netherlands. Patients had heart failure classified as Class III by the New York Heart Association (NYHA), undergoing an urgent care visit that required IV diuretics. Patients were randomized to receive either GDMT, the gold standard for treating heart failure or hemodynamic monitoring using the Abbott CardioMEMS.
MONITOR-HF was conducted by the Erasmus University Medical Center in Rotterdam, Netherlands. The MONITOR-HF is the third randomized, controlled trial globally that will provide health benefits to indicated heart failure patients.
Study Outcome
The MONITOR-HF trial met its primary endpoint, finding that heart failure participants who received a CardioMEMS sensor reported a clinically meaningful improvement in quality of life, measured by a 7-point mean increase on the Kansas City Cardiomyopathy Questionnaire (KCCQ). The score was higher compared with patients in the control group, whose scores declined. The KCCQ is a clinical standard assessment in heart failure that has been recommended to record and measure patient-reported quality of treatment.
Image Source: Zacks Investment Research
The paperclip-sized CardioMEMS sensor monitors for pressure changes that signify worsening heart failure after being inserted into the pulmonary artery during a minimally-invasive surgery. It helps patients and their care teams to manage a patient's status from anywhere by wirelessly transmitting daily readings to the patient's clinical team.
Significance of the Study
Per management, the MONITOR-HF results are more significant given that patients who were already receiving a high-quality care experienced considerable increases in their quality of life, while utilizing the CardioMEMS monitoring system.
Heart failure is a serious health issue that affects patients all over the world and has a high rate of morbidity and mortality. These findings confirm that, compared with medication alone, a proactive, remote-centered strategy employing pressure monitoring with CardioMEMS results in better health outcomes and increased patient satisfaction across a variety of health indices.
Industry Prospects
Per a report by Precedence Research, the global cardiac monitoring market size was estimated at $8.24 billion in 2022 and is expected to reach $20.23 billion by 2032 at a CAGR of 8.51%. Rising incidence of cardiovascular disorders, treatment costs of cardiac diseases, increasing use of ambulatory and home services, favorable government regulation and technological advancement are the factors driving the market.
Recent Developments
In May 2023, Abbott presented a favorable outcome on its leadless pacemaker. The company unveiled late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device Exemption (IDE) study. The study demonstrated that AVEIR DR leadless pacemaker met its three prespecified primary endpoints for safety and performance. The data also noted that this device could provide new benefits for people with slower-than-normal heart rhythms.
The same month, Abbott announced the receipt of the FDA approval for its Assert-IQTM insertable cardiac monitor (ICM), giving doctors a new choice for the diagnostic assessment and ongoing monitoring of patients with irregular heartbeats. This approval adds to Abbott's line-up of remote patient management and treatment tools that can support doctors more effectively.
Price Performance
In the past year, Abbott’s shares have declined 10.8% compared with the industry’s fall of 32.8%.
Zacks Rank & Key Picks
Abbott currently carries Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Merit Medical Systems MMSI, West Pharmaceutical Services WST and Perrigo PRGO, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical Systems has an estimated long-term growth rate of 11%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 20.22%.
So far this year, MMSI’s shares have risen 18.9% compared with the industry’s 8.7% growth.
West Pharmaceutical Services has an estimated long-term growth rate of 6.3%. Its earnings surpassed estimates in three of the trailing four quarters and missed the same once, the average surprise being 13.61%.
So far this year, WST’s shares have gained 49.1% compared with the industry’s 8.7% growth.
Perrigo’s earnings are expected to improve 24.2% in 2023. The strong momentum is likely to continue in 2024 as well. PRGO’s earnings surpassed estimates in two of the trailing four quarters and missed the same twice, the average negative surprise being 0.79%.
The company has lost 1.9% so far this year against the industry’s 4.8% growth.
This Little-Known Semiconductor Stock Could Be Your Portfolio’s Hedge Against Inflation
Everyone uses semiconductors. But only a small number of people know what they are and what they do. If you use a smartphone, computer, microwave, digital camera or refrigerator (and that’s just the tip of the iceberg), you have a need for semiconductors. That’s why their importance can’t be overstated and their disruption in the supply chain has such a global effect. But every cloud has a silver lining. Shockwaves to the international supply chain from the global pandemic have unearthed a tremendous opportunity for investors. And today, Zacks' leading stock strategist is revealing the one semiconductor stock that stands to gain the most in a new FREE report. It's yours at no cost and with no obligation.
>>Yes, I Want to Help Protect My Portfolio During the Recession
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
Perrigo Company plc (PRGO) : Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study — MONITOR-HF. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here. Study Outcome The MONITOR-HF trial met its primary endpoint, finding that heart failure participants who received a CardioMEMS sensor reported a clinically meaningful improvement in quality of life, measured by a 7-point mean increase on the Kansas City Cardiomyopathy Questionnaire (KCCQ). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study — MONITOR-HF. Study Outcome The MONITOR-HF trial met its primary endpoint, finding that heart failure participants who received a CardioMEMS sensor reported a clinically meaningful improvement in quality of life, measured by a 7-point mean increase on the Kansas City Cardiomyopathy Questionnaire (KCCQ). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study — MONITOR-HF. The study revealed that Abbott's CardioMEMS HF System led to a significant improvement in quality-of-life scores in patients with indicated heart failures as early as three months. | Abbott Laboratories, Inc. ABT presented new data from an investigator-sponsored European study — MONITOR-HF. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report To read this article on Zacks.com click here. The MONITOR-HF results were announced recently at a late-breaking presentation at the European Society of Cardiology's annual meeting of the Heart Failure Association in Prague. |
30984.0 | 2023-05-30 00:00:00 UTC | Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs | ABT | https://www.nasdaq.com/articles/intuitive-surgical-gives-buying-opportunity-off-its-52-week-highs | nan | nan | Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Da Vinci is turning 23 years old this year, with over 10 million surgeries worldwide performed since its launch in 1995. The company has continued to innovate and grow its installed base to 7,779, which still grew revenues by 14.3% in Q1 2023. Each installed robotic system sets the Intuitive Surgical ecosystem in place as the healthcare company continues to generate revenues from surgeries, equipment, training, and support. It’s continuing to expand its digital services.
Recovering from the Pandemic
The pandemic disrupted elective and non-emergency surgeries put on hold to make room for COVID-19 patients. Normalization has returned for surgeries. China lifted its COVID-19 restrictions which should be a tailwind for the company after January 2023. The company has dominated the robot-assisted surgery market for over two decades and remained king of the hill despite any competition from other medical device makers like Microbot Medical Inc. (NASDAQ: MBOT), Boston Scientific Co. (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Stryker Co. (NYSE: SYK), Becton Dickinson& Co. (NYSE: BDX), and Medtronic plc (NYSE: MDT).
Use Cases
The da Vinci systems have evolved through many generations and expanded to many models enabling minimally invasive surgeries in general surgery and specialties, including cardiothoracic, urologic, gynecologic, and head and neck. It has the highest worldwide procedures in general surgery, hernia repair, cholecystectomy and bariatric procedures.
FDA Approval for Prostatectomy
On April 28, 2023, it received FDA approval for simple and radical transvesical prostatectomy, a surgical approach through the urinary bladder. Simple prostatectomy is a surgical procedure for removing part of the prostate gland for conditions like benign prostate hyperplasia (BPH), which can cause blockage of urine flow and bladder issues. It also approved the da Vinci SP system for radical prostatectomy, which is the procedure to remove the entire prostate. This is done in cases of prostate cancer.
Back in Growth Mode
On April 18, 2023, Intuitive Surgical released its fiscal first-quarter 2023 results for the quarter ending March 2023. The company reported an earnings-per-share (EPS) profit of $1.23 versus consensus analyst estimates of $1.20, beating estimates by $0.03. Revenues grew by 14.3% year-over-year (YoY) to $1.70 billion, beating analyst estimates for $1.53 billion. Global da Vinci procedures grew 26% YoY. The quarter reflected continued COVID-19 disruptions in China, hurting January volumes. Intuitive Surgical placed 213 da Vinci Surgical Systems in the quarter, compared to 311 in the year-ago period. It grew its installed base to 7,779 systems, up 12% YoY. Instruments and accessory revenues, which include Ion catheters and multi-port accessories, rose 22% to $986 million compared to $810 million in the year-ago period.
The CEO’s Take
Intuitive Surgical CEO Gary Guthart commented, “For 2023, our priorities are as follows: First, we are focused on increased adoption for our priority procedures in countries through outstanding training, commercial and market access execution. Second, we are pursuing expanded indications and launches for our new platforms. Third, we are focused on excellence and continuity of supply, product quality and services provision as we emerge from pandemic stresses."
Analyst Actions Sink Shares
After the Q1 2023 earnings report, 11 analysts reiterated their Outperform, Overweight, and Buy ratings and price target increases. Notable names include JP Morgan reiterating its Overweight rating with a raised price target of $335 from $250. Bank of America reiterated its Buy rating raising its price target to $315 from $300. Evercore ISI has an In-Line rating raising its price target to $270 from $240 while shares were trading in the $300s. Most of the price targets were at or below where ISRG was trading, which is likely one of the reasons for the pullback after hitting 52-week highs.
Intuitive Surgical analyst ratings and price targets can be found at MarketBeat.
Weekly Cup Awaiting Handle
The weekly candlestick chart on ISRG illustrates the year-long cup formation that commenced on the cup lip line peak at $308.97 commencing in April 2022. ISRG fell to a low of $180.07 by October 2022 before staging a rally to $285.09 in December 2023. Shares formed a market structure high (MSH) sell trigger on the breakdown under $257.46, sending ISRG to a low of $222.65 in March 2023. Incidentally, the weekly market structure low (MSL) buys triggered at the same level as the MSH sell trigger on a breakout of $257.46. This caused a rally to re-test the cup lip line at $308.97 and complete the cup.
ISRG continued to peak at the new 52-week high of $317.81. Shares peaked out to form another MSH sell trigger under $297.93. The weekly stochastic is peaking at the 95-band. Pullback support levels are $285.09, $275.28, $257.46 MSH/MSL trigger and $244.49.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company has dominated the robot-assisted surgery market for over two decades and remained king of the hill despite any competition from other medical device makers like Microbot Medical Inc. (NASDAQ: MBOT), Boston Scientific Co. (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Stryker Co. (NYSE: SYK), Becton Dickinson& Co. (NYSE: BDX), and Medtronic plc (NYSE: MDT). Each installed robotic system sets the Intuitive Surgical ecosystem in place as the healthcare company continues to generate revenues from surgeries, equipment, training, and support. Back in Growth Mode On April 18, 2023, Intuitive Surgical released its fiscal first-quarter 2023 results for the quarter ending March 2023. | The company has dominated the robot-assisted surgery market for over two decades and remained king of the hill despite any competition from other medical device makers like Microbot Medical Inc. (NASDAQ: MBOT), Boston Scientific Co. (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Stryker Co. (NYSE: SYK), Becton Dickinson& Co. (NYSE: BDX), and Medtronic plc (NYSE: MDT). Intuitive Surgical placed 213 da Vinci Surgical Systems in the quarter, compared to 311 in the year-ago period. Shares formed a market structure high (MSH) sell trigger on the breakdown under $257.46, sending ISRG to a low of $222.65 in March 2023. | The company has dominated the robot-assisted surgery market for over two decades and remained king of the hill despite any competition from other medical device makers like Microbot Medical Inc. (NASDAQ: MBOT), Boston Scientific Co. (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Stryker Co. (NYSE: SYK), Becton Dickinson& Co. (NYSE: BDX), and Medtronic plc (NYSE: MDT). Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Each installed robotic system sets the Intuitive Surgical ecosystem in place as the healthcare company continues to generate revenues from surgeries, equipment, training, and support. | The company has dominated the robot-assisted surgery market for over two decades and remained king of the hill despite any competition from other medical device makers like Microbot Medical Inc. (NASDAQ: MBOT), Boston Scientific Co. (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Stryker Co. (NYSE: SYK), Becton Dickinson& Co. (NYSE: BDX), and Medtronic plc (NYSE: MDT). It also approved the da Vinci SP system for radical prostatectomy, which is the procedure to remove the entire prostate. Intuitive Surgical placed 213 da Vinci Surgical Systems in the quarter, compared to 311 in the year-ago period. |
30985.0 | 2023-05-27 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-21 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30986.0 | 2023-05-26 00:00:00 UTC | Should You Invest in the iShares U.S. Medical Devices ETF (IHI)? | ABT | https://www.nasdaq.com/articles/should-you-invest-in-the-ishares-u.s.-medical-devices-etf-ihi-6 | nan | nan | Looking for broad exposure to the Healthcare - Medical Devices segment of the equity market? You should consider the iShares U.S. Medical Devices ETF (IHI), a passively managed exchange traded fund launched on 05/01/2006.
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Medical Devices is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 6, placing it in top 38%.
Index Details
The fund is sponsored by Blackrock. It has amassed assets over $5.92 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Medical Devices segment of the equity market. IHI seeks to match the performance of the Dow Jones U.S. Select Medical Equipment Index before fees and expenses.
The Dow Jones U.S. Select Medical Equipment Index measures the performance of the medical equipment sector of the U.S. equity market.
Costs
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.
Annual operating expenses for this ETF are 0.39%, making it one of the cheaper products in the space.
It has a 12-month trailing dividend yield of 0.47%.
Sector Exposure and Top Holdings
While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.
Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.24% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT).
The top 10 holdings account for about 70.60% of total assets under management.
Performance and Risk
The ETF has gained about 1.01% so far this year and it's up approximately 0.28% in the last one year (as of 05/26/2023). In that past 52-week period, it has traded between $47.07 and $57.17.
The ETF has a beta of 0.85 and standard deviation of 20.61% for the trailing three-year period, making it a medium risk choice in the space. With about 70 holdings, it effectively diversifies company-specific risk.
Alternatives
IShares U.S. Medical Devices ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, IHI is a great option for investors seeking exposure to the Health Care ETFs segment of the market. There are other additional ETFs in the space that investors could consider as well.
First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. First Trust Indxx Medical Devices ETF has $1.99 million in assets, SPDR S&P Health Care Equipment ETF has $533.20 million. MDEV has an expense ratio of 0.70% and XHE charges 0.35%.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.
Get it free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
iShares U.S. Medical Devices ETF (IHI): ETF Research Reports
Abbott Laboratories (ABT) : Free Stock Analysis Report
Medtronic PLC (MDT) : Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports
First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.24% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.24% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.24% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). First Trust Indxx Medical Devices ETF (MDEV) tracks INDXX GLOBAL MEDICAL EQUIPMENT INDEX and the SPDR S&P Health Care Equipment ETF (XHE) tracks S&P Health Care Equipment Select Industry Index. | Looking at individual holdings, Thermo Fisher Scientific Inc (TMO) accounts for about 17.24% of total assets, followed by Abbott Laboratories (ABT) and Medtronic Plc (MDT). Click to get this free report iShares U.S. Medical Devices ETF (IHI): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report SPDR S&P Health Care Equipment ETF (XHE): ETF Research Reports First Trust Indxx Medical Devices ETF (MDEV): ETF Research Reports To read this article on Zacks.com click here. Additionally, sector ETFs offer convenient ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. |
30987.0 | 2023-05-26 00:00:00 UTC | Is Illumina Stock A Better Pick Over TMO? | ABT | https://www.nasdaq.com/articles/is-illumina-stock-a-better-pick-over-tmo | nan | nan | We believe Illumina stock (NASDAQ: ILMN) and its industry peer Thermo Fisher Scientific stock (NYSE: TMO) are good buying opportunities and will likely offer similar returns in the next three years. ILMN trades at a higher valuation of 7.3x trailing revenues, compared to 4.6x for TMO, partly due to its financial position. However, Thermo Fisher Scientific has seen better revenue growth in recent years and is more profitable, as discussed below.
Looking at stock returns, ILMN has fared slightly better with 1% returns this year vs. -5% returns for TMO. However, both have underperformed the broader S&P500 index, up 8%. There is more to the comparison, and in the sections below, we discuss why we believe that both ILMN and TMO stock will offer good returns in the next three years. We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Illumina vs. Thermo Fisher Scientific: Which Stock Is A Better Bet? Parts of the analysis are summarized below.
1. Thermo Fisher Scientific’s Revenue Growth Is Better
Thermo Fisher Scientific’s revenue growth has been much better, with a 20.8% average annual growth rate in the last three years, compared to 10.8% for Illumina.
Illumina’s sales have been rising due to the booming demand for gene sequencing. The company’s cancer screening and population genomics testing are driving its revenue growth. Also, gains from Covid-19 surveillance programs have contributed to the top-line expansion.
Illumina has a recurring revenue model from consumables and services, accounting for 84% of the company’s total sales in 2022.
Thermo Fisher Scientific manufactures analytical laboratory instruments used in various tests, and the pandemic has increased demand for these instruments. Its sales growth is buoyed by continued market share gains for its instruments.
Thermo Fisher Scientific has seen a good 15% growth in 2022, primarily driven by its Laboratory Products & Biopharma Services segment, which saw a substantial 51% y-o-y growth. This can be attributed to its December 2021 acquisition of PPD Inc. – a clinical research services provider to the biopharma and biotech industry – for $17.4 billion. The PPD business contributed $7.1 billion to the company’s top line in 2022.
Our Illumina Revenue Comparison and Thermo Fisher Scientific Revenue Comparison dashboards provide more insight into the companies’ sales.
Looking forward, Thermo Fisher Scientific’s revenue is expected to grow marginally faster than Illumina’s over the next three years. The table below summarizes our revenue expectations for the two companies over the next three years. It points to a CAGR of 9.4% for Illumina, compared to a 10.6% CAGR for Thermo Fisher Scientific, based on Trefis Machine Learning analysis.
Note that we have different methodologies for companies negatively impacted by Covid and those not impacted or positively impacted by Covid while forecasting future revenues. For companies negatively affected by Covid, we consider the quarterly revenue recovery trajectory to predict recovery to the pre-Covid revenue run rate. Beyond the recovery point, we apply the average annual growth observed three years before Covid to simulate a return to normal conditions. For companies registering positive revenue growth during Covid, we consider yearly average growth before Covid with a certain weight to growth during Covid and the last twelve months.
Thermo Fisher Scientific Is More Profitable But Comes With Higher Risk
Illumina’s operating margin has slid from 29.3% in 2019 to -90.6% in 2022, while Thermo Fisher Scientific’s operating margin declined marginally from 20.6% to 20.3% over this period.
Looking at the last twelve-month period, Thermo Fisher Scientific’s operating margin of 18.3% fares much better than -99.3% for Illumina.
This sharp decline for Illumina can be attributed to an impairment charge of $3.9 billion on goodwill and a legal contingency of $458 million in potential fines from the European Commission related to the Grail acquisition.
Note that Illumina acquired Grail in 2021 despite regulatory concerns, and it is likely to face a fine of 10% of its global annual turnover as a penalty for closing the deal without EU antitrust approval.
Our Illumina Operating Income Comparison and Thermo Fisher Scientific Operating Income Comparison dashboards have more details.
Thermo Fisher Scientific’s free cash flow margin of 17.5% is higher than 5.2% for Illumina.
Looking at financial risk, Illumina fares better with its 6.9% debt as a percentage of equity lower than 17.4% for Thermo Fisher Scientific and its 12.9% cash as a percentage of assets higher than 3.7% for the latter, implying that Illumina has a better debt position and more cash cushion.
3. The Net of It All
We see that Thermo Fisher Scientific has demonstrated better revenue growth, is more profitable, and is available at a comparatively lower valuation multiple. On the other hand, Illumina has a better debt position and cash cushion.
Now, looking at prospects, using P/S as a base, due to high fluctuations in P/E and P/EBIT, we believe Thermo Fisher Scientific is the better choice of the two, given its lower valuation and better prospects. That said, even Illumina stock is expected to give similar returns.
If we compare the current valuation multiples to the historical averages, Illumina fares better, with its stock currently trading at 7.1x trailing revenues vs. the last five-year average of 15.0x. In contrast, Thermo Fisher Scientific stock trades at 4.6x trailing revenues vs. the last five-year average of 5.9x.
Our Illumina (ILMN) Valuation Ratios Comparison and Thermo Fisher Scientific (TMO) Valuation Ratios Comparison have more details.
The table below summarizes our revenue and return expectations for Illumina and Thermo Fisher Scientific over the next three years and points to an expected return of 31% for ILMN over this period vs. a 36% expected return for TMO, based on Trefis Machine Learning analysis – Illumina vs. Thermo Fisher Scientific – which also provides more details on how we arrive at these numbers.
While ILMN and TMO may offer good returns in the next three years, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Abbott vs. Amerco.
What if you’re looking for a high-performance portfolio with a low downside instead? Here’s a reinforced value portfolio that has beaten the market consistently while limiting losses during periods of sharp market declines.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We compare a slew of factors, such as historical revenue growth, returns, and valuation, in an interactive dashboard analysis of Illumina vs. Thermo Fisher Scientific: Which Stock Is A Better Bet? This sharp decline for Illumina can be attributed to an impairment charge of $3.9 billion on goodwill and a legal contingency of $458 million in potential fines from the European Commission related to the Grail acquisition. Note that Illumina acquired Grail in 2021 despite regulatory concerns, and it is likely to face a fine of 10% of its global annual turnover as a penalty for closing the deal without EU antitrust approval. | Our Illumina Operating Income Comparison and Thermo Fisher Scientific Operating Income Comparison dashboards have more details. Our Illumina (ILMN) Valuation Ratios Comparison and Thermo Fisher Scientific (TMO) Valuation Ratios Comparison have more details. The table below summarizes our revenue and return expectations for Illumina and Thermo Fisher Scientific over the next three years and points to an expected return of 31% for ILMN over this period vs. a 36% expected return for TMO, based on Trefis Machine Learning analysis – Illumina vs. Thermo Fisher Scientific – which also provides more details on how we arrive at these numbers. | Thermo Fisher Scientific’s Revenue Growth Is Better Thermo Fisher Scientific’s revenue growth has been much better, with a 20.8% average annual growth rate in the last three years, compared to 10.8% for Illumina. Thermo Fisher Scientific Is More Profitable But Comes With Higher Risk Illumina’s operating margin has slid from 29.3% in 2019 to -90.6% in 2022, while Thermo Fisher Scientific’s operating margin declined marginally from 20.6% to 20.3% over this period. The table below summarizes our revenue and return expectations for Illumina and Thermo Fisher Scientific over the next three years and points to an expected return of 31% for ILMN over this period vs. a 36% expected return for TMO, based on Trefis Machine Learning analysis – Illumina vs. Thermo Fisher Scientific – which also provides more details on how we arrive at these numbers. | ILMN trades at a higher valuation of 7.3x trailing revenues, compared to 4.6x for TMO, partly due to its financial position. Thermo Fisher Scientific’s Revenue Growth Is Better Thermo Fisher Scientific’s revenue growth has been much better, with a 20.8% average annual growth rate in the last three years, compared to 10.8% for Illumina. The table below summarizes our revenue and return expectations for Illumina and Thermo Fisher Scientific over the next three years and points to an expected return of 31% for ILMN over this period vs. a 36% expected return for TMO, based on Trefis Machine Learning analysis – Illumina vs. Thermo Fisher Scientific – which also provides more details on how we arrive at these numbers. |
30988.0 | 2023-05-26 00:00:00 UTC | ESGU, PEG, GIS, ABT: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/esgu-peg-gis-abt%3A-large-outflows-detected-at-etf | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares ESG Aware MSCI USA ETF (Symbol: ESGU) where we have detected an approximate $73.0 million dollar outflow -- that's a 0.5% decrease week over week (from 147,450,000 to 146,650,000). Among the largest underlying components of ESGU, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is off about 0.5%, General Mills Inc (Symbol: GIS) is up about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.3%. For a complete list of holdings, visit the ESGU Holdings page » The chart below shows the one year price performance of ESGU, versus its 200 day moving average:
Looking at the chart above, ESGU's low point in its 52 week range is $77.2839 per share, with $96.41 as the 52 week high point — that compares with a last trade of $92.24. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
Also see:
ETFs Holding PRTK
NXG Videos
MVIN Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of ESGU, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is off about 0.5%, General Mills Inc (Symbol: GIS) is up about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.3%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. | Among the largest underlying components of ESGU, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is off about 0.5%, General Mills Inc (Symbol: GIS) is up about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.3%. For a complete list of holdings, visit the ESGU Holdings page » The chart below shows the one year price performance of ESGU, versus its 200 day moving average: Looking at the chart above, ESGU's low point in its 52 week range is $77.2839 per share, with $96.41 as the 52 week high point — that compares with a last trade of $92.24. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of ESGU, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is off about 0.5%, General Mills Inc (Symbol: GIS) is up about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares ESG Aware MSCI USA ETF (Symbol: ESGU) where we have detected an approximate $73.0 million dollar outflow -- that's a 0.5% decrease week over week (from 147,450,000 to 146,650,000). For a complete list of holdings, visit the ESGU Holdings page » The chart below shows the one year price performance of ESGU, versus its 200 day moving average: Looking at the chart above, ESGU's low point in its 52 week range is $77.2839 per share, with $96.41 as the 52 week high point — that compares with a last trade of $92.24. | Among the largest underlying components of ESGU, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is off about 0.5%, General Mills Inc (Symbol: GIS) is up about 0.1%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares ESG Aware MSCI USA ETF (Symbol: ESGU) where we have detected an approximate $73.0 million dollar outflow -- that's a 0.5% decrease week over week (from 147,450,000 to 146,650,000). For a complete list of holdings, visit the ESGU Holdings page » The chart below shows the one year price performance of ESGU, versus its 200 day moving average: Looking at the chart above, ESGU's low point in its 52 week range is $77.2839 per share, with $96.41 as the 52 week high point — that compares with a last trade of $92.24. |
30989.0 | 2023-05-25 00:00:00 UTC | Abbott Laboratories (ABT) Shares Cross 2% Yield Mark | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-shares-cross-2-yield-mark | nan | nan | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.34 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF (SPY) back on 12/31/1999 — you would have paid $146.88 per share. Fast forward to 12/31/2012 and each share was worth $142.41 on that date, a decrease of $4.67/share over all those years. But now consider that you collected a whopping $25.98 per share in dividends over the same period, for a positive total return of 23.36%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.6%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield.
ABT has been growing its dividend for more than 20 years consecutively. For more dividend growth stocks view our Dividend Aristocrats List on Dividend Channel.
Click here to find out which 9 other dividend stocks just recently went on sale »
Also see:
High-Yield Canadian Real Estate Stocks
FMI shares outstanding history
Morgan Stanley 13F Filers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.34 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.34 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.34 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $2.04), with the stock changing hands as low as $101.34 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. |
30990.0 | 2023-05-24 00:00:00 UTC | Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker | ABT | https://www.nasdaq.com/articles/abbott-abt-unveils-late-breaking-data-on-leadless-pacemaker | nan | nan | Abbott ABT announced a favorable outcome on its leadless pacemaker. The company unveiled late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device Exemption (IDE) study.
The study demonstrated that AVEIR DR leadless pacemaker met its three prespecified primary endpoints for safety and performance. The data also noted that this device could provide new benefits for people with slower-than-normal heart rhythms.
This favorable outcome has been sent to the FDA as part of Abbott's submission for approval of the AVEIR DR device.
More on the News
The results were presented during a late-breaking clinical trial session at the Heart Rhythm Society's (HRS) 44th annual meeting from May 19-21, 2023. The study has also been published in The New England Journal of Medicine.
Abbott noted that in the study, primary safety and efficacy endpoints were analyzed in the first 300 people enrolled across 55 centers in the United States, Canada and Europe. Its three-month post-implant results showed that physicians demonstrated a 98.3% implant success rate. Further, the safety endpoint evaluating freedom from device or procedure complications was achieved. The company also noted that more than 97% of people had successful atrio-ventricular (AV) synchrony.
Added to this, in each of the seven different postures and walking speeds, the average AV synchrony was more than 95%. This, according to Abbott, implies that the system will function appropriately during everyday life activities.
Image Source: Zacks Investment Research
Here's How AVEIR DR is Better
According to Abbott, unlike traditional pacemakers, leadless pacemakers are implanted directly into the heart through a minimally invasive, catheter-based procedure. This eliminates the need for cardiac leads and a pulse generator under the skin.
The company stated that many people require pacing and sensing in both the right atrium and the right ventricle. However, the currently available leadless pacing options are limited to single-chamber ventricular devices. This is because seamless, wireless synchronization of two leadless pacemakers has been a significant technological challenge.
For the vast majority of people, a dual-chamber pacemaker like AVEIR DR will be of great benefit.
Industry Prospects
Per a report by Grand View Research, the global arrhythmia monitoring devices market size is expected to reach $8.41 billion in 2025, with a CAGR of 6.8%. Continuous R&D activities in the field of cardiac monitoring are driving the market.
Latest Development
Abbott’s last-reported first quarter of 2023 organic sales, excluding COVID testing, increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals Division (EPD) and Nutrition. Within EPD, sales increased 11% in the quarter led by strong performance in Brazil, China, and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management.
Within Nutrition, sales increased more than 10%. In the United States, pediatric nutrition growth of more than 35% was driven by favorable year-over-year comparisons (lower sales in the first quarter of 2022 were due to a voluntary recall of certain infant formula products).
Within Diagnostics, excluding COVID testing, organic sales growth was led by mid-to-high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. Despite dull sales in China, Core Lab Diagnostics sales showed year-over-year improvement, driven by strong performance in the United States and Europe.
Within Medical Devices, sales grew 12.5% globally on an organic basis, including mid-teens growth in the United States and double-digit growth internationally. In Diabetes Care, sales of FreeStyle Libre grew more than 25% on an organic basis in the quarter, including approximately 50% growth in the United States and mid-teens growth internationally.
Share Price Performance
Over the past year, Abbott has been outperforming the industry it belongs to. The stock has lost 5.3% compared with the industry’s 29.6% fall.
Zacks Rank & Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Zimmer Biomet ZBH, Penumbra PEN and Hologic, Inc. HOLX.
Zimmer Biomet, sporting a Zacks Rank #1 (Strong Buy) at present, has an earnings yield of 5.42% compared to the industry’s -1.86%. Zimmer Biomet’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 7.38%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Zimmer Biomet shares have risen 11.9% against the industry’s 29.6% decline in the past year.
Penumbra, sporting a Zacks Rank #1 at present, has an estimated growth rate of 64.1% for 2024. Penumbra shares have risen 123.7% compared with the industry’s 2.3% increase over the past year.
PEN’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 109.4%.
Hologic, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 4.68% compared to the industry’s -7.62%. Shares of HOLX have risen 3.6% compared with the industry’s 2.4% growth over the past year.
Hologic’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 27.3%.
Free Report: Must-See Hydrogen Stocks
Hydrogen fuel cells are already used to provide efficient, ultra-clean energy to buses, ships and even hospitals. This technology is on the verge of a massive breakthrough, one that could make hydrogen a major source of America's power. It could even totally revolutionize the EV industry.
Zacks has released a special report revealing the 4 stocks experts believe will deliver the biggest gains.
Download Cashing In on Cleaner Energy today, absolutely free.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Hologic, Inc. (HOLX) : Free Stock Analysis Report
Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ABT announced a favorable outcome on its leadless pacemaker. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Latest Development Abbott’s last-reported first quarter of 2023 organic sales, excluding COVID testing, increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals Division (EPD) and Nutrition. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT announced a favorable outcome on its leadless pacemaker. Despite dull sales in China, Core Lab Diagnostics sales showed year-over-year improvement, driven by strong performance in the United States and Europe. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott ABT announced a favorable outcome on its leadless pacemaker. Image Source: Zacks Investment Research Here's How AVEIR DR is Better According to Abbott, unlike traditional pacemakers, leadless pacemakers are implanted directly into the heart through a minimally invasive, catheter-based procedure. | Abbott ABT announced a favorable outcome on its leadless pacemaker. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report To read this article on Zacks.com click here. The study demonstrated that AVEIR DR leadless pacemaker met its three prespecified primary endpoints for safety and performance. |
30991.0 | 2023-05-24 00:00:00 UTC | Abbott, other formula makers face FTC investigation for collusion - WSJ | ABT | https://www.nasdaq.com/articles/abbott-other-formula-makers-face-ftc-investigation-for-collusion-wsj-0 | nan | nan | Adds details from WSJ report and background
May 24 (Reuters) - The U.S. Federal Trade Commission is investigating whether baby-formula makers colluded on bids for attractive state contracts, the Wall Street Journal reported on Wednesday.
The FTC is looking into whether Abbott Laboratories ABT.N and other formula manufacturers have "engaged in collusion or coordination with any other market participant regarding the bidding", the WSJ report said, citing documents posted to FTC's website.
The FTC has sought information from Nestle NESN.S, which makes the Good Start line of infant formulas, a company spokeswoman told the Journal, adding that the Swiss manufacturer has responded to the FTC.
FTC, Abbott, and Nestle did not immediately respond to Reuters requests for comment.
In February, Abbott said it received a civil investigative demand from the FTC related to a probe of the companies participating in bids for WIC formula contracts.
(Reporting by Rahat Sandhu and Maria Ponnezhath in Bengaluru; Editing by Shailesh Kuber)
((Rahat.Sandhu@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The FTC is looking into whether Abbott Laboratories ABT.N and other formula manufacturers have "engaged in collusion or coordination with any other market participant regarding the bidding", the WSJ report said, citing documents posted to FTC's website. Adds details from WSJ report and background May 24 (Reuters) - The U.S. Federal Trade Commission is investigating whether baby-formula makers colluded on bids for attractive state contracts, the Wall Street Journal reported on Wednesday. FTC, Abbott, and Nestle did not immediately respond to Reuters requests for comment. | The FTC is looking into whether Abbott Laboratories ABT.N and other formula manufacturers have "engaged in collusion or coordination with any other market participant regarding the bidding", the WSJ report said, citing documents posted to FTC's website. FTC, Abbott, and Nestle did not immediately respond to Reuters requests for comment. In February, Abbott said it received a civil investigative demand from the FTC related to a probe of the companies participating in bids for WIC formula contracts. | The FTC is looking into whether Abbott Laboratories ABT.N and other formula manufacturers have "engaged in collusion or coordination with any other market participant regarding the bidding", the WSJ report said, citing documents posted to FTC's website. Adds details from WSJ report and background May 24 (Reuters) - The U.S. Federal Trade Commission is investigating whether baby-formula makers colluded on bids for attractive state contracts, the Wall Street Journal reported on Wednesday. The FTC has sought information from Nestle NESN.S, which makes the Good Start line of infant formulas, a company spokeswoman told the Journal, adding that the Swiss manufacturer has responded to the FTC. | The FTC is looking into whether Abbott Laboratories ABT.N and other formula manufacturers have "engaged in collusion or coordination with any other market participant regarding the bidding", the WSJ report said, citing documents posted to FTC's website. Adds details from WSJ report and background May 24 (Reuters) - The U.S. Federal Trade Commission is investigating whether baby-formula makers colluded on bids for attractive state contracts, the Wall Street Journal reported on Wednesday. The FTC has sought information from Nestle NESN.S, which makes the Good Start line of infant formulas, a company spokeswoman told the Journal, adding that the Swiss manufacturer has responded to the FTC. |
30992.0 | 2023-05-24 00:00:00 UTC | Abbott: MONITOR-HF Trial With CardioMEMS Sensor Meets Primary Endpoint | ABT | https://www.nasdaq.com/articles/abbott%3A-monitor-hf-trial-with-cardiomems-sensor-meets-primary-endpoint | nan | nan | (RTTNews) - Abbott (ABT) said data from an investigator-sponsored European trial found managing indicated heart failure patients with CardioMEMS HF System resulted in a significant improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial is the third randomized, controlled trial globally, funded by the Dutch Ministry of Health with clinical research organization costs paid by Abbott.
The MONITOR-HF trial also resulted in a significant 44% reduction in heart failure-related hospitalizations among chronic heart failure patients who used guideline-directed medical therapy.
The CardioMEMS sensor, once placed in the pulmonary artery during a minimally invasive procedure, monitors for pressure changes that indicate worsening heart failure. It first received approval from the FDA in 2014.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (RTTNews) - Abbott (ABT) said data from an investigator-sponsored European trial found managing indicated heart failure patients with CardioMEMS HF System resulted in a significant improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial is the third randomized, controlled trial globally, funded by the Dutch Ministry of Health with clinical research organization costs paid by Abbott. The CardioMEMS sensor, once placed in the pulmonary artery during a minimally invasive procedure, monitors for pressure changes that indicate worsening heart failure. | (RTTNews) - Abbott (ABT) said data from an investigator-sponsored European trial found managing indicated heart failure patients with CardioMEMS HF System resulted in a significant improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial is the third randomized, controlled trial globally, funded by the Dutch Ministry of Health with clinical research organization costs paid by Abbott. The MONITOR-HF trial also resulted in a significant 44% reduction in heart failure-related hospitalizations among chronic heart failure patients who used guideline-directed medical therapy. | (RTTNews) - Abbott (ABT) said data from an investigator-sponsored European trial found managing indicated heart failure patients with CardioMEMS HF System resulted in a significant improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial is the third randomized, controlled trial globally, funded by the Dutch Ministry of Health with clinical research organization costs paid by Abbott. The MONITOR-HF trial also resulted in a significant 44% reduction in heart failure-related hospitalizations among chronic heart failure patients who used guideline-directed medical therapy. | (RTTNews) - Abbott (ABT) said data from an investigator-sponsored European trial found managing indicated heart failure patients with CardioMEMS HF System resulted in a significant improvement in patient-reported quality-of-life scores as early as three months after use with the remote monitoring sensor. The MONITOR-HF trial is the third randomized, controlled trial globally, funded by the Dutch Ministry of Health with clinical research organization costs paid by Abbott. It first received approval from the FDA in 2014. |
30993.0 | 2023-05-24 00:00:00 UTC | ABT Makes Notable Cross Below Critical Moving Average | ABT | https://www.nasdaq.com/articles/abt-makes-notable-cross-below-critical-moving-average-1 | nan | nan | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $105.29, changing hands as low as $104.60 per share. Abbott Laboratories shares are currently trading off about 0.9% on the day. The chart below shows the one year performance of ABT shares, versus its 200 day moving average:
Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $118.23 as the 52 week high point — that compares with a last trade of $104.84. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com
Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average »
Also see:
WBT Options Chain
Institutional Holders of ESDI
MANT Options Chain
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $105.29, changing hands as low as $104.60 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $118.23 as the 52 week high point — that compares with a last trade of $104.84. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: WBT Options Chain Institutional Holders of ESDI MANT Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $105.29, changing hands as low as $104.60 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $118.23 as the 52 week high point — that compares with a last trade of $104.84. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: WBT Options Chain Institutional Holders of ESDI MANT Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $105.29, changing hands as low as $104.60 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $118.23 as the 52 week high point — that compares with a last trade of $104.84. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: WBT Options Chain Institutional Holders of ESDI MANT Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $105.29, changing hands as low as $104.60 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $93.25 per share, with $118.23 as the 52 week high point — that compares with a last trade of $104.84. The ABT DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other dividend stocks recently crossed below their 200 day moving average » Also see: WBT Options Chain Institutional Holders of ESDI MANT Options Chain The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
30994.0 | 2023-05-24 00:00:00 UTC | What To Expect From Medtronic's Q4? | ABT | https://www.nasdaq.com/articles/what-to-expect-from-medtronics-q4 | nan | nan | Medtronic (NYSE: MDT) is scheduled to report its fiscal 2023 fourth-quarter results on Thursday, May 25. We expect Medtronic stock to trade sideways post-Q4 results announcement, with its revenues and earnings expected to align with the street estimates. The company should continue to benefit from its new products and a better pricing environment. Although we expect Medtronic to report in-line results, we believe its stock has little room for growth, as discussed below. Our interactive dashboard analysis of Medtronic’s Earnings Preview has additional details.
(1) Better Pricing To Aid Sales
Trefis estimates Medtronic’s Q4 fiscal 2023 total revenues to be around $8.2 billion, reflecting a low single-digit y-o-y rise but marginally below the $8.3 billion consensus estimate.
The company should benefit from its new products, including the Micra AV pacemaker and Onyx Frontier drug-eluting stent. It should also see continued strength in cardiac products.
However, the Medical Surgical segment may see lower sales due to a continued decline in ventilator demand.
Forex headwinds may also weigh on the overall top-line growth. Medtronic expects around 4.5% to 5% organic revenue growth in Q4.
Looking at the last quarter, Medtronic’s revenue was flat y-o-y to $7.7 billion, as a 5% rise in the Neuroscience portfolio and a 1% gain in the Cardiovascular portfolio was offset by a 7% decline in the Medical Surgical segment.
Our dashboard on Medtronic Revenues provides more details on the company’s segments.
(2) EPS expected to align with the consensus estimates
Medtronic’s Q4 fiscal 2023 earnings per share (EPS) is expected to be $1.56 per Trefis analysis, in line with the consensus estimate.
Medtronic’s net income of $1.7 billion in Q3 reflected a 6% fall y-o-y, as the company’s adjusted operating margins fell over 200 bps to 25.9%.
Looking at the full fiscal 2023, we expect EPS to be lower at $5.29, compared to the $5.55 seen in fiscal 2022.
(3) MDT stock has little room for growth
We estimate Medtronic’s Valuation to be $97 per share, reflecting only an 8% upside from its current market price of around $90.
This represents a little over an 18x P/E multiple, aligning with the levels seen in late 2021.
If the company reports upbeat Q4 results and the 2024 guidance is better than the street estimates, it is likely that the P/E multiple will be revised upward, resulting in higher levels for MDT stock.
may have moved, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you'll be surprised how counter-intuitive the stock valuation is for Pfizer vs Merck. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While MDT stock may see higher levels, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. For example, you’ll be surprised at how counter-intuitive the stock valuation is for Becton Dickinson vs. Amerco.
What if you’re looking for a high-performance portfolio with a low downside instead? Here’s a reinforced value portfolio that has beaten the market consistently while limiting losses during periods of sharp market declines.
Returns May 2023
MTD [1] 2023
YTD [1] 2017-23
Total [2]
MDT Return -4% 12% 22%
S&P 500 Return -1% 8% 85%
Trefis Multi-Strategy Portfolio 0% 9% 243%
[1] Month-to-date and year-to-date as of 5/24/2023
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company should benefit from its new products, including the Micra AV pacemaker and Onyx Frontier drug-eluting stent. Medtronic’s net income of $1.7 billion in Q3 reflected a 6% fall y-o-y, as the company’s adjusted operating margins fell over 200 bps to 25.9%. (3) MDT stock has little room for growth We estimate Medtronic’s Valuation to be $97 per share, reflecting only an 8% upside from its current market price of around $90. | (1) Better Pricing To Aid Sales Trefis estimates Medtronic’s Q4 fiscal 2023 total revenues to be around $8.2 billion, reflecting a low single-digit y-o-y rise but marginally below the $8.3 billion consensus estimate. (2) EPS expected to align with the consensus estimates Medtronic’s Q4 fiscal 2023 earnings per share (EPS) is expected to be $1.56 per Trefis analysis, in line with the consensus estimate. \n\nBased on article theme, variations to \"While may have moved\" can be (a) While may be overvalued (or undervalued) (b) While can move (c) Although may not be attractive (d) While is worth considering"}" data-sheets-userformat="{"2":1049345,"3":{"1":0},"11":4,"12":0,"23":1}" data-sheets-textstyleruns="{"1":0}{"1":210,"2":{"2":{"1":2,"2":1136076},"5":1,"9":1}}{"1":225}{"1":229,"2":{"4":8}}{"1":267,"2":{"4":8,"6":1}}{"1":299,"2":{"4":8}}" data-sheets-hyperlinkruns="{"1":210,"2":"https://dashboards.trefis.com/data/companies/PFE/no-login-required/HMIwIvym/Pfizer-vs-Merck-PFE-stock-s-similar-valuation-vs-MRK-stock-is-counter-intuitive"}{"1":225}">While MDT stock may see higher levels, the Covid-19 crisis has created many pricing discontinuities, which can offer attractive trading opportunities. | (1) Better Pricing To Aid Sales Trefis estimates Medtronic’s Q4 fiscal 2023 total revenues to be around $8.2 billion, reflecting a low single-digit y-o-y rise but marginally below the $8.3 billion consensus estimate. (2) EPS expected to align with the consensus estimates Medtronic’s Q4 fiscal 2023 earnings per share (EPS) is expected to be $1.56 per Trefis analysis, in line with the consensus estimate. Total [2] MDT Return -4% 12% 22% S&P 500 Return -1% 8% 85% Trefis Multi-Strategy Portfolio 0% 9% 243% [1] Month-to-date and year-to-date as of 5/24/2023 [2] Cumulative total returns since the end of 2016 Invest with Trefis Market-Beating Portfolios See all Trefis Price Estimates The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (1) Better Pricing To Aid Sales Trefis estimates Medtronic’s Q4 fiscal 2023 total revenues to be around $8.2 billion, reflecting a low single-digit y-o-y rise but marginally below the $8.3 billion consensus estimate. Looking at the last quarter, Medtronic’s revenue was flat y-o-y to $7.7 billion, as a 5% rise in the Neuroscience portfolio and a 1% gain in the Cardiovascular portfolio was offset by a 7% decline in the Medical Surgical segment. (3) MDT stock has little room for growth We estimate Medtronic’s Valuation to be $97 per share, reflecting only an 8% upside from its current market price of around $90. |
30995.0 | 2023-05-24 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-20 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
30996.0 | 2023-05-22 00:00:00 UTC | Judge tosses out some claims in Abbott baby formula litigation | ABT | https://www.nasdaq.com/articles/judge-tosses-out-some-claims-in-abbott-baby-formula-litigation | nan | nan | By Jonathan Stempel
May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula.
In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination.
The parents said they would not have bought or would have paid less for formula but for the Abbott Park, Illinois-based company's claims that it was safe.
But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.
"In short, the plaintiffs received exactly what they say they bargained for: safe infant formula," Kennelly wrote.
The judge also issued decisions that narrowed but did not dismiss two related lawsuits against Abbott.
In one, 28 plaintiffs brought personal injury claims alleging that Abbott's formula caused salmonella contamination, bacterial meningitis and other health problems.
The other lawsuit by eight plaintiffs alleged that Similac products contained heavy metals and were manufactured in unsanitary decisions.
The litigation followed Abbott's February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula.
Last May, Food and Drug Administration Commissioner Robert Califf told Congress that conditions in the plant were "egregiously unsanitary." The plant reopened in July.
In a statement, Abbott said it believed the lawsuits were without merit. It also said no "sealed, distributed product" from the Michigan plant had tested positive for salmonella or for Cronobacter sakazakii, a bacteria that can cause meningitis.
Sam Geisler, a lawyer at Aylstock, Witkin, Kreis, & Overholtz co-leading the litigation, said the plaintiffs were reviewing their next steps.
"The end goal has been, is now, and will continue to be holding Abbott accountable for putting the lives of the most vulnerable at risk," Geisler said in an email.
Separate nationwide litigation before a different Chicago judge involves claims that Abbott's formula caused a deadly illness in preterm infants. Abbott has denied those claims.
The cases are: In re Recalled Abbott Infant Formula Products Liability Litigation, U.S. District Court, Northern District of Illinois, No. 22-04148; and Willoughby et al v. Abbott Laboratories in the same court, Nos. 22-01322 and 23-00338.
(Reporting by Jonathan Stempel in New York; Editing by Marguerita Choy and Himani Sarkar)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In one, 28 plaintiffs brought personal injury claims alleging that Abbott's formula caused salmonella contamination, bacterial meningitis and other health problems. Separate nationwide litigation before a different Chicago judge involves claims that Abbott's formula caused a deadly illness in preterm infants. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In one, 28 plaintiffs brought personal injury claims alleging that Abbott's formula caused salmonella contamination, bacterial meningitis and other health problems. The cases are: In re Recalled Abbott Infant Formula Products Liability Litigation, U.S. District Court, Northern District of Illinois, No. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. The litigation followed Abbott's February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. The judge also issued decisions that narrowed but did not dismiss two related lawsuits against Abbott. |
30997.0 | 2023-05-22 00:00:00 UTC | Judge tosses some claims in Abbott baby formula litigation | ABT | https://www.nasdaq.com/articles/judge-tosses-some-claims-in-abbott-baby-formula-litigation | nan | nan | By Jonathan Stempel
May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula.
In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination.
The parents said they would not have bought or would have paid less for formula but for the Abbott Park, Illinois-based company's claims that it was safe.
But the judge said the parents lacked standing to sue, saying they did not show which Abbott products or lots were contaminated, or that their children experienced symptoms.
"In short, the plaintiffs received exactly what they say they bargained for: safe infant formula," Kennelly wrote.
The judge also narrowed but did not dismiss two related lawsuits against Abbott.
In one, 28 plaintiffs brought personal injury claims alleging that Abbott's formula caused salmonella contamination, bacterial meningitis and other health problems.
The other lawsuit by eight plaintiffs alleged that Similac products contained heavy metals and were manufactured in unsanitary decisions.
Abbott did not immediately respond to requests for comment.
The litigation followed Abbott's February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula.
Last May, Food and Drug Administration Commissioner Robert Califf told Congress that conditions in the plant were "egregiously unsanitary." The plant reopened in July.
Sam Geisler, a lawyer at Aylstock, Witkin, Kreis, & Overholtz co-leading the litigation, said the plaintiffs are reviewing their next steps.
"The end goal has been, is now, and will continue to be holding Abbott accountable for putting the lives of the most vulnerable at risk," Geisler said in an email.
Separate nationwide litigation before a different Chicago judge involves claims that Abbott's formula caused a deadly illness in preterm infants. Abbott has denied those claims.
The cases are: In re Recalled Abbott Infant Formula Products Liability Litigation, U.S. District Court, Northern District of Illinois, No. 22-04148; and Willoughby et al v. Abbott Laboratories in the same court, Nos. 22-01322 and 23-00338.
(Reporting by Jonathan Stempel in New York Editing by Marguerita Choy)
((jon.stempel@thomsonreuters.com; +1 646 223 6317; Reuters Messaging: jon.stempel.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In one, 28 plaintiffs brought personal injury claims alleging that Abbott's formula caused salmonella contamination, bacterial meningitis and other health problems. Separate nationwide litigation before a different Chicago judge involves claims that Abbott's formula caused a deadly illness in preterm infants. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. The cases are: In re Recalled Abbott Infant Formula Products Liability Litigation, U.S. District Court, Northern District of Illinois, No. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. The litigation followed Abbott's February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula. Separate nationwide litigation before a different Chicago judge involves claims that Abbott's formula caused a deadly illness in preterm infants. | By Jonathan Stempel May 22 (Reuters) - Abbott Laboratories ABT.N persuaded a federal judge to dismiss some claims in nationwide litigation over recalled baby formula. In a decision on Monday, U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Similac and other formula that they said had a "substantial risk" of bacteria contamination. The litigation followed Abbott's February 2022 closure of a baby formula plant in Sturgis, Michigan and subsequent recalls, which together caused a nationwide shortage of formula. |
30998.0 | 2023-05-22 00:00:00 UTC | Abbott (ABT) Expands in Electrophysiology With New FDA Nod | ABT | https://www.nasdaq.com/articles/abbott-abt-expands-in-electrophysiology-with-new-fda-nod | nan | nan | Abbott's ABT catheter line of products advanced after it received regulatory approval. The company announced that its TactiFlex Ablation Catheter, Sensor Enabled has received FDA approval for treating people with abnormal heart rhythms like atrial fibrillation (AFib). The company claims this catheter to be the world’s first ablation catheter with a flexible tip and contact force technology.
The latest approval broadens the company’s electrophysiology business line.
In February, the company had received European CE Mark for TactiFlex Ablation Catheter, Sensor Enabled. This catheter is also approved for use in Japan, Africa and Australia.
More on the News
Patients with AFib often feel dizziness, chest pain and heart palpitations. AFib can even lead to stroke if left untreated. From a medical perspective, it is always better to address the issue as fast as possible.
AFib is currently claimed to be the most common abnormal heart rhythm.
Abbott noted that using TactiFlex catheters can reduce procedure times and provide better safety compared to the company's previous-generation catheters.
The TactiFlex catheter is designed to be used together with Abbott's EnSite X EP System. EnSite X is the company’s advanced heart mapping system enabling physicians to view and precisely identify areas in the heart that require ablation.
How TactiFlex is Superior to Other Catheters
According to Abbott, unlike other available catheters, the TactiFlex catheter is facilitated by a tip design with a laser-cut pattern. It flexes when in contact with the heart wall. This helps in directing fluid to the treated tissue, allowing more accurate positioning of the catheter. This in turn provides up to two-times higher stability in a beating heart, crucial for consistent therapy delivery.
In this regard, the company noted that the TactiFlex catheter generated strong clinical outcomes in the TactiFlex AF IDE study with more than 99% acute procedural success.
Image Source: Zacks Investment Research
Huge Market Prospect for TactiFlex
Per data provided by Abbott, over 37 million people globally live with AFib and this figure is expected to more than double by 2050. Further, an additional five million cases are diagnosed every year, indicating a growing health challenge requiring cutting-edge solutions.
In such a situation, we believe the latest regulatory approval in the United States is well-timed and strategic.
Latest Development
Abbott’s last-reported first quarter of 2023 organic sales growth, excluding COVID testing, increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals Division (EPD) and Nutrition. Within EPD, sales increased 11% in the quarter led by strong performance in Brazil, China, and Southeast Asia and across several therapeutic areas, including cardiometabolic, gastroenterology, CNS and pain management.
Within Nutrition, sales increased more than 10%. In the United States, pediatric nutrition growth of more than 35% was driven by favorable year-over-year comparisons (lower sales in the first quarter of 2022 were due to a voluntary recall of certain infant formula products).
Within Diagnostics, excluding COVID testing, organic sales growth was led by mid to high single-digit growth in Core Lab, Rapid and Point of Care Diagnostics. Despite dull sales in China, Core Lab Diagnostics sales showed year-over-year improvement led by strong performance in the United States and Europe.
Within Medical Devices, sales grew 12.5% globally on an organic basis, including mid-teens growth in the United States and double-digit growth internationally. In Diabetes Care, sales of FreeStyle Libre grew more than 25% on an organic basis in the quarter, including approximately 50% growth in the United States and mid-teens growth internationally.
Share Price Performance
Over the past year, Abbott has been outperforming the industry it belongs to. The stock has lost 5.3% compared with the industry’s 29.6% fall.
Zacks Rank & Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Addus Homecare Corporation ADUS, Merit Medical Systems, Inc. MMSI and Davita Inc DVA.
The Zacks Consensus Estimate for Addus Homecare’s 2023 earnings indicates 10.9% year-over-year growth. The Zacks Consensus Estimate for ADUS’s 2023 earnings has moved 0.5% north in the past 30 days.
Addus Homecare has a long-term estimated growth rate of 11.8%.It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical reported first-quarter 2023 adjusted EPS of 64 cents, beating the Zacks Consensus Estimate by 16.4%. Revenues of $297.6 million surpassed the Zacks Consensus Estimate by 5.9%. It currently carries a Zacks Rank #2.
Merit Medical has a long-term estimated growth rate of 11%. MMSI’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 20.2%.
DaVita, carrying a Zacks Rank #2 at present, has a long-term estimated growth rate of 14.6%. DVA’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 17.3%.
DaVita has lost 1.9% compared with the industry’s 18% decline over the past year.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report
Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott's ABT catheter line of products advanced after it received regulatory approval. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. The company announced that its TactiFlex Ablation Catheter, Sensor Enabled has received FDA approval for treating people with abnormal heart rhythms like atrial fibrillation (AFib). | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott's ABT catheter line of products advanced after it received regulatory approval. Latest Development Abbott’s last-reported first quarter of 2023 organic sales growth, excluding COVID testing, increased 10%, led by double-digit growth in Medical Devices, Established Pharmaceuticals Division (EPD) and Nutrition. | Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. Abbott's ABT catheter line of products advanced after it received regulatory approval. How TactiFlex is Superior to Other Catheters According to Abbott, unlike other available catheters, the TactiFlex catheter is facilitated by a tip design with a laser-cut pattern. | Abbott's ABT catheter line of products advanced after it received regulatory approval. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Merit Medical Systems, Inc. (MMSI) : Free Stock Analysis Report Addus HomeCare Corporation (ADUS) : Free Stock Analysis Report To read this article on Zacks.com click here. The company announced that its TactiFlex Ablation Catheter, Sensor Enabled has received FDA approval for treating people with abnormal heart rhythms like atrial fibrillation (AFib). |
30999.0 | 2023-05-20 00:00:00 UTC | Guru Fundamental Report for ABT - Peter Lynch | ABT | https://www.nasdaq.com/articles/guru-fundamental-report-for-abt-peter-lynch-19 | nan | nan | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: PASS
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of ABBOTT LABORATORIES
ABT Guru Analysis
ABT Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of ABBOTT LABORATORIES ABT Guru Analysis ABT Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). | Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. ABBOTT LABORATORIES (ABT) is a large-cap growth stock in the Medical Equipment & Supplies industry. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.